

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Prevalence and Its Predictors of Drug-Related Hospitalizations among Patients Visited Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054778
Article Type:	Original research
Date Submitted by the Author:	23-Jun-2021
Complete List of Authors:	Demessie, Mulate ; Addis Ababa University Berha, Alemseged; Addis Ababa University, Pharmacology and Clinical Pharmacy
Keywords:	Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Prevalence and Its Predictors of Drug-Related Hospitalizations among Patients Visited Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

Mulate Belete Demessie¹, Alemseged Beyene Berha^{1*}

* Corresponding author: alembeyene98@gmail.com

ABSTRACT

Objectives: The aim of this study was to determine the prevalence, categories and its predictors of drug related hospitalizations (DRHs) among patients visited at emergency departments of Addis Ababa city hospitals in Ethiopia.

Design: A multicenter prospective observational study was conducted through patients interview and review their medical chart.

Settings: The study was undertaken in three tertiary care hospitals, Addis Ababa, Ethiopia.

Participants: A total of 423 patients who fulfilled the inclusion criteria were recruited.

Outcome measures Prevalence and preventability of drug related hospitalizations, categories of drug related problems causing drug related hospitalizations, medications and diseases involved in drug related hospitalizations and factors independently associated with them.

Result: 423 participants who fulfilled the inclusion criteria were enrolled in the study. Of those, more than half of them (216, 51.1%) were females. The mean age (SD) of the study participants was 47.50 (\pm 17.21) years. The mean length of hospital stay (SD) was 10.29(\pm 8.99) days. Among the included participants, near to three-fifth (245, 57.9%) of patients were hospitalized due to drug related problems, of which 87.8% were preventable. Of those, more than half (130, 53%) of them were noted from failure to receive drugs followed by untreated indications (94, 37.8%). Factors associated with DRHs were age \geq 65 years (Adjusted Odds Ratio [AOR]=7.451,95%CI: 1.889-

29.397), tertiary educational level (AOR=0.360, 95%CI: 0.141-0.923), participants who did not have any occupation (AOR=3.409, 95%CI: 1.120-10.374), presence of co-morbid conditions (AOR=2.004, 95%CI: 1.095-3.668), and hospital stay > 7 days (AOR=2.186, 95%CI: 1.412-3.382).

Conclusion: Nearly 90% of DRHs were deemed to be preventable in the study settings. Older age, lower educational level, unemployment, presence of co-morbid condition and staying > 7 days in hospital as an inpatient were predictors of DRHs.

Strength and limitations of the study

- As to our knowledge, this study is the first study in Africa continent.
- The strength of this study is the study design that is a prospective observational study which is specifically tailored to evaluate direct impact of drug related problems on treatment or preventive measures on disease. This study was a multicenter, therefore, representativeness of the finding is more accepted and convinced.
- And also, the sample size was sufficiently large to estimate the incidence and predictors of DRHs.
- One of the main limitations of this study was there are no standardized procedures for immediate recording and reporting DRHs which may result in to limit the real estimation of the prevalence of DRHs. This problem was mitigated by using clinical pharmacists who have an ability to identify and resolve drug related problems at emergency department.
- A factor limiting the scope of this study concerned patients admitted to an emergency ward. Hence, considerable numbers of patients with DRPs from other major departments have been missed.

INTRODUCTION

Though drugs can be ordered for the intention of achieving desired health outcomes that improve the patient's quality of life, any symptom and sign of the disease causing drug related hospitalizations (DRHs) as a result of drug related problems (DRPs) can be appeared.¹⁻³ DRP was defined according to Helper and strand as 'an undesired event or circumstance due to drug therapy that actually or potentially interferes with desired health outcomes'.⁴

In the globe, medications use has been becoming increased because of the presence of large numbers of diseases which in turn contributed to the production of medications in advances from pharmaceutical industries. Therefore, advances in drug therapies led to an apparent increase in the incidence of DRPs leading hospitalization. Hospitalization can be defined as drug related if it is straightforwardly linked to one of eight predefined Helper's and Strand's classifications of DRPs: adverse drug reaction (ADR), drug interaction, improper drug selection, untreated indication, sub-therapeutic dosage, supra-therapeutic dosage, failure to receive drugs, and drug use without indication.⁵⁻¹¹ Those DRPs can arise when a medicine is prescribed aptly and used correctly (e.g., ADR), due to errors involving prescribing (including inappropriate or over-treatment, and failure to prescribe the indicated treatment or under-treatment), dispensing, administering, reconciling, or monitoring of medicines and from patient poor adherence.^{2 12 13} According to the World Health Organization (WHO), an ADR is any harmful, undesired and inadvertent drug effect that occurs at doses used in human for therapy, diagnosis or prophylaxis.¹⁴

Over the past decades, DRHs have been stated as prevailing. In the United States, 17 million emergency department (ED) visits and 8.7 million hospital admissions accounted from DRPs annually.¹⁵ It increases morbidity and mortality rates, health care cost, decreases income and household productivity and reduced quality of life.^{2 16 17}

1
2
3 The studies carried out in different study areas of the globe manifested the extent of DRHs have
4 been estimated to be between 16% to 41.3%. Of those, 50% to 95% were preventable. Among
5 DRHs; suprathereapeutic dosage (10.3%-12.7%), non-compliance (10.6%-65.8%), ADRs (10.7%-
6 45.5%) and untreated indications (10.7-13.3% were frequently identified.^{5 8 16 18-20}

7
8
9
10
11
12
13 DRPs resulting DRHs were defined as preventable if the patient failed to take a drug that is known
14 to reduce or prevent the symptoms according to the prescribed directions, took a drug for which a
15 patient had a known allergy, drug treatment was obviously improper, dosage differed from
16 accepted recommendations, took a drug that was not indicated, and if there was a failure to monitor
17 by a physician at reasonable time intervals and inadequate monitoring due to inability to see a
18 physician e.g., financial difficulties whilst if there was no reasonable actions to prevent DRPs
19 which is termed as non-preventable.^{18 21}

20
21
22
23
24
25
26
27
28
29
30
31 In many studies, patients with DRHs had mainly cardiovascular diseases and diabetes. In those
32 diseases, cardiovascular drugs and hypoglycemic medications were involved in DRHs.^{5 9 10 16 18 19}
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22 23 Studies previously investigated that polypharmacy, advanced age and comorbid conditions
were factors that favor the occurrence of DRHs.^{3 5 18 19}

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

It is important to determine DRHs prevalence to improve treatment outcomes and prevent unnecessary preventable admissions. So, to the best of our knowledge there are no studies about DRHs in Ethiopia. Therefore, the present study aimed to determine the prevalence, categories and its predictors of DRHs among patients admitted to an emergency ward (EW) of the three selected hospitals in Addis Ababa City, Ethiopia.

METHODS

Study Settings

The study was carried out in EW of Tikur Anbessa Specialized Hospital (TASH), Zewditu Memorial Hospital (ZMH) and Yekatit 12 Hospital Medical College (Y12HMC), Addis Ababa city, Ethiopia. TASH was inaugurated in 1972. It has 700 beds and it is a tertiary care teaching hospital of Addis Ababa University. In TASH, outpatient, inpatient and emergency services are delivered. The ED provided services to about 13,920 patients per year. Y12HMC was established in 1923. It is also a tertiary care level referral and teaching hospital in Addis Ababa that provides both inpatient and outpatient treatment for a large number of people from the Addis Ababa city and different nation parts. The hospital has total of three ED rooms. The adult medical ED is collocated with adult surgical ED. It served around 10,560 patients per year in ED. The third hospital where in this study was carried out is ZMH which was built and owned by the Seventh day Adventist Church, but was nationalized during the Derg regime in 1976 and it is one of a teaching and general referral hospitals in Ethiopia and it served for about 10,560 patients per year at ED.

Patient involvement

Patients did not participate in the initial conception and design of the study. However, based on the comments of the pretest (5% of the sample size) participating patients, we have made a correction on the patient approach and timing for an interview during data collection. Patients played the central role in this study in determining the level of medication use, adherence and medical history.

Study design and population

A prospective observational study design was used and the data were collected from August to September, 2020 using a structured questionnaire which was developed from related articles that were rigorously evaluated. All patients who admitted at EW of the three selected hospitals during the study period and those who fulfilled the inclusion criteria were recruited.

Inclusion and exclusion criteria

Patients who had medical history with completed data and patients greater than and equal to 14 years old were included. Whereas, Patients who had incomplete or no medical records, patients who were refuse to participate, patients presented with trauma and injuries associated with accidents (e.g. road traffic accidents, beaten by stick, stabbing and bulleting) and who were poisoned/intoxicated (for instance snake bite, alcohol intoxication or use of pesticide) were excluded.

Sample size determination and techniques

Since there was no study done on DRHs in Ethiopia, the sample size was estimated using the general formula for single population proportion.

$$n = [(Z \alpha/2)^2 \times p (1-p)] \div d^2 = [(1.96)^2 \times 0.5 \times 0.5] / 0.05^2 = 384$$

(Hence; n = required sample size, Z $\alpha/2$ = critical value for normal distribution at 95% confidence interval which equals 1.96 (Z value at alpha = 0.05), P = Proportion of drug related hospitalization = 0.5, d = margin of error of 5%=0.05. The calculated sample size using this formula was 384. Adding 10% contingency (for non-response rate), it makes the final sample size to be 423. Therefore, this research was being conducted in three hospitals, 169 participants were included from TASH, 127 participants from ZMH and other 127 participants from Y12MHC. This was

1
2
3 computed according to the three hospitals patients per year services proportion in EW as it is
4 mentioned in the section of study settings.
5
6

7 **Data collection procedures**

8
9
10 Structured data collection tools were used by three pharmacists to obtain the necessary data
11 including the patient's demographic details and clinical information related to numbers of
12 medications being taken prior to admission by interviewing the patients. Furthermore, patient's
13 medical records were reviewed by data collectors to identify clinical information (disease history,
14 allergic status, admission diagnosis, length of hospital stay during admission, number of
15 medications being taken prior to admission, data on laboratory investigations) and supplementary
16 information and clarifications on some patient's medical information were obtained through
17 discussion with the residents and interns. By applying those data gathering approach, different
18 categories of DRPs resulting hospitalization with their possible independent associated factors
19 were determined. Data collectors who were three pharmacists who had basic knowledge on
20 pharmaceutical care services and also received training on how to collect data from patient's
21 medication charts and on how to approach the patients and health care professionals and ways of
22 using updated references such as Medscape, UpToDate, 2018 and Micromedex in order to
23 determine the presence of DRPs brought DRHs. Once DRPs resulting DRHs were identified, they
24 were recorded and classified using DRPs registration format according to Helper's and Strand's
25 classification.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Data collection management**

47
48 Pretest was performed on 5% patients in TASH prior to the actual data collection period and
49 amendment was made accordingly. The data collection process was supervised, and data
50 abstraction formats were reviewed and checked for their completeness every day to ensure its
51 quality. Urgent correction was made, if any errors were identified.
52
53
54
55
56
57
58
59

Data analysis

The data were entered and analyzed using Statistical Package for Social Science (SPSS) version 26. Mean and standard deviation for continuous variables and frequency and percentage for categorical variables were computed by using descriptive statistics in SPSS to summarize socio-demographic and relevant clinical characteristics of the study participants. Tables and charts were used to present the results. Furthermore, univariate and multiple binary logistic regressions were performed to analyze factors that predict drug related hospitalizations; and variables whose p-values < 0.2 in the univariate analysis were included in the multiple binary logistic regressions to control the effect of confounders. The level of significance was chosen at p-value \leq 0.05 and results were reported as odds ratios (OR) with 95% confidence intervals.

RESULTS

Socio-demographic and clinical characteristics of the study participants

From 2655 study participants enrolled in this study. A total of 423 study participants were included for analysis. Of them, 169 participants were from TASH, 127 from ZMH and 127 from Y12HMC (Figure 1).

As socio-demographic and clinical characteristics of the participants depicted in

Table 1: Socio-demographic and clinical characteristics of the participants in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Gender			
Male	119(48.6)	88(49.4)	207(48.9)
Female	126(51.4)	90(50.6)	216(51.1)
Age (in years)			
Mean± SD	48.23±17.85		
14 - 24	24(9.8)	14(7.9)	38(8.98)
25- 39	51(20.8)	59(33.1)	110(26)

40 - 64	100(40.8)	74(41.6)	174(41.1)
>64	70(28.6)	31(17.4)	101(23.9)
Marital status			
Single	64(26.1)	34(19.1)	98(23.2)
Married	129(48.6)	105(59)	234(55.3)
widowed	20(8.2)	9(5.1)	29(6.7)
Divorced	42(17.1)	31(16.9)	73(17.3)
Education level			
No formal education	116(47.3)	72(40.4)	188(44.4)
Elementary	66(26.9)	47(26.4)	113(26.7)
Secondary	31(12.7)	35(19.7)	66(15.6)
Tertiary	32(13.1)	24(13.5)	56(13.2)
Residence			
Addis Ababa	177(72.2)	127(71.3)	304(71.9)
Out of Addis Ababa	68(27.8)	51(28.7)	119(28.1)
Religion			
Orthodox	186(76)	136(76)	322(76.1)
Muslim	42(17.1)	31(17.4)	73(17.3)
Catholic	1(0.4)	1(0.6)	2(0.5)
Protestant	16(6.5)	10(6)	26(6.1)

DRHs, drug related hospitalizations; non-DRHs, non-drug related hospitalizations; SD, standard deviation

Table 1 ... Continued

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Employment			
Employed	25(10.2)	25(14)	50(11.8)
Unemployed	0.0	1(0.6)	1(0.24)
House wife	30(12.2)	33(18.5)	63(14.9)
Merchant	13(5.3)	14(7.9)	27(6.4)
Student	18(7.3)	7(3.9)	25(5.9)
Laborer	51(20.8)	32(18)	83(19.6)
Retired	57(23.3)	40(22.5)	97(22.9)
Others	29(11.8)	14(7.9)	43(10.2)
Farmer	22(9)	12(6.7)	34(8)

Social habit (smoking cigarette)			
Yes	29(11.8)	15(8.4)	44(10.4)
No	216(88.2)	163(91.6)	379(89.6)
Social habit (dining alcohol)			
Yes	71(29)	57(32)	128(30.3)
No	174(71)	121(68)	295(69.7)
Physical activity(walk)			
Yes	165(39)	127(71.3)	292(69)
No	80(32.7)	51(28.7)	131(31)
Physical activity (regular physical exercise)			
Yes	5(2)	5(2.8)	10(2.4)
No	240(98)	173(97.2)	413(97.6)

²Others: participants who did not have any occupation rather they were dependent to live with other people.

DRH, drug related hospitalization; Non-DRH, Non-drug related hospitalization; n, number; SD, standard deviation

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Other Drugs (including OTC, herbals)			
Yes	3(1.2)	0(0)	3(0.7)
No	242(98.8)	178(100)	420(99.3)
Number of medications taken per patient			
Mean± SD	3.39±2.35		
0	24(9.8)	12(6.7)	36(8.5)
1	41(16.7)	26(14.6)	67(15.8)
2	35(14.3)	40(22.5)	75(17.7)
3-5	98(40)	75(42.1)	173(40.9)
>5	47(19.2)	25(14)	72(17)
Polypharmacy			
Yes	84(34.3)	43(24.2)	127(30)
No	161(65.7)	135(75.8)	296(70)
Co morbid condition			
Yes	137(55.9)	76(42.7)	213(50.4)
No	108(44.1)	102(57.3)	210(49.6)

Co morbid condition (Hypertension)			
Yes	68(27.8)	40(22.5)	108(25.5)
Co morbid condition (Diabetes mellitus)			
Yes	31(12.7)	22(12.4)	53(12.5)
Co morbid condition (Cardiac diseases)			
	38(15.5)	21(11.8)	59(13.9)
Length of Hospital stay (Days)			
1–7	101(41.2)	112(62.9)	213(50.4)
>7	144(58.8)	66(37.1)	210(49.6)
Mean± SD	11.4±9.27		
Median	9		
Range	2-96		

, more than half of the participants (216, 51.1%) were females. The mean (SD) age of the participants was 47.5 (\pm 17.21) years and nearly two third (275, 65%) of the patients were age \geq to 40 years. More than 70 % (301, 71.1%) of the total participants' level of education was below secondary school. Nearly three fourth of them (304, 71.9%) resided in Addis Ababa city. Out of the total study participants, (245, 57.9%) of them were taking \geq three drugs prior to admission and (127, 30%) of the participants were taking \geq five drugs which is termed as polypharmacy. Above half of the participants (213, 50.4%) had co-morbid diseases which have been hypertension (108, 22.5%), cardiac diseases (59, 13.5%) and diabetes mellitus (53, 12.5%) were predominant. The total length of hospital stay was 4352 days with a mean (SD) of 10.28 \pm 8.99 days and ranges from 2 to 96 days.

Table 1: Socio-demographic and clinical characteristics of the participants in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)

Variables	¹ DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Gender			
Male	119(48.6)	88(49.4)	207(48.9)
Female	126(51.4)	90(50.6)	216(51.1)

1				
2				
3	Age (in years)			
4	Mean± SD	48.23±17.85		
5	14 - 24	24(9.8)	14(7.9)	38(8.98)
6	25- 39	51(20.8)	59(33.1)	110(26)
7	40 - 64	100(40.8)	74(41.6)	174(41.1)
8	>64	70(28.6)	31(17.4)	101(23.9)
9				
10	Marital status			
11	Single	64(26.1)	34(19.1)	98(23.2)
12	Married	129(48.6)	105(59)	234(55.3)
13	widowed	20(8.2)	9(5.1)	29(6.7)
14	Divorced	42(17.1)	31(16.9)	73(17.3)
15				
16	Education level			
17	No formal education	116(47.3)	72(40.4)	188(44.4)
18	Elementary	66(26.9)	47(26.4)	113(26.7)
19	Secondary	31(12.7)	35(19.7)	66(15.6)
20	Tertiary	32(13.1)	24(13.5)	56(13.2)
21				
22	Residence			
23	Addis Ababa	177(72.2)	127(71.3)	304(71.9)
24	Out of Addis Ababa	68(27.8)	51(28.7)	119(28.1)
25				
26	Religion			
27	Orthodox	186(76)	136(76)	322(76.1)
28	Muslim	42(17.1)	31(17.4)	73(17.3)
29	Catholic	1(0.4)	1(0.6)	2(0.5)
30	Protestant	16(6.5)	10(6)	26(6.1)
31				
32				
33				
34				

DRHs, drug related hospitalizations; non-DRHs, non-drug related hospitalizations; SD, standard deviation

Table 1 ... Continued

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Employment			
Employed	25(10.2)	25(14)	50(11.8)
Unemployed	0.0	1(0.6)	1(0.24)
House wife	30(12.2)	33(18.5)	63(14.9)
Merchant	13(5.3)	14(7.9)	27(6.4)
Student	18(7.3)	7(3.9)	25(5.9)
Laborer	51(20.8)	32(18)	83(19.6)

Retired	57(23.3)	40(22.5)	97(22.9)
Others ²	29(11.8)	14(7.9)	43(10.2)
Farmer	22(9)	12(6.7)	34(8)
Social habit (smoking cigarette)			
Yes	29(11.8)	15(8.4)	44(10.4)
No	216(88.2)	163(91.6)	379(89.6)
Social habit (dining alcohol)			
Yes	71(29)	57(32)	128(30.3)
No	174(71)	121(68)	295(69.7)
Physical activity(walk)			
Yes	165(39)	127(71.3)	292(69)
No	80(32.7)	51(28.7)	131(31)
Physical activity (regular physical exercise)			
Yes	5(2)	5(2.8)	10(2.4)
No	240(98)	173(97.2)	413(97.6)

²Others: participants who did not have any occupation rather they were dependent to live with other people.

DRH, drug related hospitalization; Non-DRH, Non-drug related hospitalization; n, number; SD, standard deviation

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Other Drugs (including OTC, herbals)			
Yes	3(1.2)	0(0)	3(0.7)
No	242(98.8)	178(100)	420(99.3)
Number of medications taken per patient			
Mean± SD	3.39±2.35		
0	24(9.8)	12(6.7)	36(8.5)
1	41(16.7)	26(14.6)	67(15.8)
2	35(14.3)	40(22.5)	75(17.7)
3-5	98(40)	75(42.1)	173(40.9)
>5	47(19.2)	25(14)	72(17)

Table 1 continued

Polypharmacy			
Yes	84(34.3)	43(24.2)	127(30)
No	161(65.7)	135(75.8)	296(70)
Co morbid condition			
Yes	137(55.9)	76(42.7)	213(50.4)
No	108(44.1)	102(57.3)	210(49.6)
Co morbid condition (Hypertension)			
Yes	68(27.8)	40(22.5)	108(25.5)
Co morbid condition (Diabetes mellitus)			
Yes	31(12.7)	22(12.4)	53(12.5)
Co morbid condition (Cardiac diseases ³)			
38(15.5)	21(11.8)	59(13.9)	
Length of Hospital stay (Days)			
1–7	101(41.2)	112(62.9)	213(50.4)
>7	144(58.8)	66(37.1)	210(49.6)
Mean± SD	11.4±9.27		
Median	9		
Range	2-96		

Prevalence and categories of drug related hospitalizations

Of the 423 enrolled patients, drug related hospitalizations were identified in 245 (57.9%) participants, of which 87.8% were deemed preventable. A total of 322 DRPs leading to DRHs were observed in 245 participants, representing 1.31 DRPs per patient, since 55(22.4%) patients presented two DRPs (**Figure 2**). Out of 245 drug related hospitalized patients, more than half (130, 53%) of them were noted from failure to receive drugs followed by untreated indication (94, 37.8%) and then sub-therapeutic dosage (30, 12.2%). The main reasons for failure to receive drugs were due to patients prefer not to take the medication (43, 33.1%); fear of adverse events (18, 13.8%); and drug product not available (17, 13.1%) (**Error! Reference source not found.**).

Table 2: Categories of drugs related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Untreated indications	Untreated medical condition is existed	34(36.2)
	Synergistic/ potentiating drug needed	42(44.7)
	Preventive/ prophylactic drug needed	18(19%)
	Improper Drug Selection	16(6.5)
	More effective alternative drug is available	6(37.5)
	Condition is already refractory to drug	2(12.5)
	The drug is not effective for condition	6(37.5)
	Others ⁴	2(12.5)

⁴ Others; patients who were using expired drugs like insulin and albuterol.

Table 2 Continued.....

Error! Reference source not found. Continued.....

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Sub therapeutic Dosage	Wrong dose (too small) of the drug	30(12.2)
	Frequency is inappropriate (long)	24(80)
	Duration of drug use is too short	5(16.7)
Supra therapeutic Dosage	Duration of drug use is too short	1(3.3)
	Wrong dose (too high) of the drug	13(5.3)
Adverse drug reaction	Wrong dose (too high) of the drug	11(84.6)
	Frequency is inappropriate (short)	2(15.4)
	Adverse drug reaction	38(15.5)
	Undesired effect from the drug is found	34(89.5)
	Unsafe drug for patient is existed	1(2.6)
Drug Interactions	Dosage is administered too rapidly	1(2.6)
	Allergic reactions is found/reported	2(5.3)
	Drug Interactions	1(0.4)
	There is (are) major drug interaction	1(100)

⁵Others; patients who were using expired drugs like insulin and albuterol.

Table 2 Continued.....

Error! Reference source not found. Continued.....

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Failure to receive drugs.		130(53.5)
	Does not understand instructions	6(4.6)
	Patients prefer not to take	43(33.1)
	Patients forget to take	3(2.3)
	Drug product not available	17(13.1)
	Cost of medication too expensive	16(12.3)
	Disbelieves on the drug effectiveness	1(0.8)
	Patients felt better	17(13.1)
	Patients felt worse	1(0.8)
	Fear of adverse events	18(13.8)
	Failure to follow-up due to Covid-19	8(6.2)
Total number of DRPs leading DRHs		322
Total number of participants with DRHs		245
Average number DRPs per patients with DRHs		1.31
Preventability of DRHs		215(87.8)

Medications and diseases involved in drug related hospitalizations

From the total 245 drug related hospitalized patients, nearly one third of them had the cardiovascular diseases (80,32.6%),of which heart failure accounted for (59, 24%) followed by endocrine disease(47,19.2%) with the prominent disease of diabetes mellitus(44,18%) and cerebrovascular disease which was stroke(26,10.6%).Patients who had HIV(15, 6.1%) and asthma (14, 5.7%) also accounted for more than 10% of DRHs as presented in Table 3 .

Table 3: Diseases that associated with drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Disease's categories(n)	Name of specific disease	n,(%)
	PAD	6(2.4)
	Hypertension	9(3.7)
Cardiovascular diseases (n=80, 32.6%)	Heart failure	59(24)
	DVT	5(2)
	Ischemic heart disease	1(0.4)
	Schizophrenia	2(0.8)
CNS diseases (n=8, 3.2%)	Epilepsy	6(2.4)
Cerebrovascular disease (n=26, 10.6%)	Stroke	26(10.6)
Infectious diseases (n=21, 8.5%)	Tuberculosis	6(2.4)
	HIV	15(6.1)
Endocrine system diseases (n=47, 19.2%)	Thyroid storm	1(0.4)
	Diabetes mellitus	44(18)
	Hypoglycemia	2(0.8)

PAD, Peripheral arterial disease; DVT, Deep venous thromboembolism; HIV, Human immunodeficiency virus; AML, acute myeloid leukemia; NHL, non-hodking lymphoma; MDS, myelodysplastic syndrome; HL, hodkin lymphoma; CLL, chronic lymphoid leukemia

Table 3 Continued

Table 3 Continued.....

Disease's categories(n)	Name of specific disease	n,(%)
Diseases of cancer (n=25, 10.1%)	Colonic Cancer	2(0.8)
	Hematological malignancy	2(0.8)
	Melanoma	1(0.4)
	AML	3(1.2)
	NHL	3(1.2)
	Gastric Cancer	1(0.4)
	Lung cancer	2(0.8)
	MDS	1(0.4)
	HL	1(0.4)
	CLL	1(0.4)
	Hair cell leukemia	1(0.4)
	Breast cancer	3(1.2)
	Cervical cancer	2(0.8)
	⁵ ALL	1(0.4)
	Myelofibrosis	1(0.4)
Diseases of the respiratory system (n=21, 8.5%)	COPD	3(1.2)
	Bronchoectiasis	3(1.2)
	Asthma	14(5.7)
	Corpulmonal	1(0.4)
GI diseases (n=10, 4%)	Dyspepsia	5(2)
	CLD	5(2)
	TEN	1(0.4)
Others (n=7, 2.8%)	Anemia	2(0.8)
	CKD	2(0.8)
	SLE and hemophilia	1 for each (0.8)

ALL, acute lymphoid leukemia; COPD, chronic obstructive pulmonary disease; CLD, chronic liver disease; TEN, toxic epidermal necrosis; CKD, chronic kidney disease; SLE, systemic lupus erythematous

Total 245(100)

A total of 497 numbers of drugs were pertained to 245 patients DRHs. This entails that 2.03 drugs per patient were involved in DRHs. Of these, cardiovascular, chemotherapeutic and endocrine drug classes were the most frequently involved drugs which contributed to hospital admissions. Among cardiovascular drugs; furosemide (59,24.1%), angiotensin converting enzyme inhibitors (ACEIs) (48,19.1%), and antiplatelets and anticoagulants (44,18%) were most frequently mentioned followed by drugs act on the endocrine system; oral hypoglycemic agents (37, 15.1%) and insulin (24, 9.8%). And also, the chemotherapeutic drugs such as antibiotics (25 ,10%), anticancer drugs (23 ,9%), and combination antiretroviral therapy (15, 6.1%) were associated to the patients for DRHs. Medication classes and specific drugs reported in DRHs depicted in Table 4.

Table 4: Medication classes and specific drugs implicated in drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Drugs class	Specific drugs	n (%)
Cardiovascular drugs		
	Atorvastatin	31(12.7)
	Antiplatelets (aspirin,clopidogril)	24(9.8)
	Furosemide	59(24.1)
	Spironolactone	33(13.5)
	Anticoagulants (Warfarin, heparin)	20(8.2)
	Beta blockers (metoprolol,atenolol)	21(8.6)
	Digoxin	15(6.1)
	Angiotensin converting enzyme inhibitors (enalapril/lisinopril)	48(19.6)
	Calcium channel blockers (nifedipine, amlodipine)	34(13.9)
	Hydrochlorothiazide	11(4.5)

Table 4 Continued.....

Table 4 continued.....

Drugs class	Specific drugs	n (%)
Drugs act on the respiratory system	Long-acting beta blockers	15(6.1)
	bronchodilator	10(4.1)
Central nervous system drugs	Antiepileptics	5(2)
	antipsychotic	5(2)
	Amitriptylin	2(0.8)
Chemotherapeutic drugs	Antibiotics (piperacillin/tazobactam, meropenem, amoxicillin, amoxicillin/clavunic acid, ceftriaxone, benzathine penicillin)	25(10.2)
	Combination antiretroviral therapy	15(6.1)
	Anti-tuberculosis	13(5.3)
	Anticancer drugs	23(9.4)
Immuno-suppressants	Mycophenolate	1(.4)
	corticosteroids (prednisolone,budesonide)	9(3.7)
Endocrine drugs	Oral hypoglycemic drugs(metformin,glibenclamide)	37(15.1)
	Insulin	24(9.8)
	Propylthiouracil	4(1.6)
Gastrointestinal drug	Proton pump inhibitors	7(2.9)
Others	Potassium chloride	1(0.4)
	Non-steroidal anti-inflammatory drugs	3(1.2)

Opioid 1(0.4)

Table 4 Continued.....

Table 4 Continued

Drugs class	Specific drugs	n (%)
Others		
	Ferrous sulphate	1(0.4)
Total number of medications involved in DRHs		497
Total number of participants with DRHs		245(57.9)
Average number medications per patients with DRHs		2.03

Factors associated with the occurrence of drug related hospitalizations

According to the multivariate logistic regression analysis, five variables such as age, employment, presence of co morbid disease, length of hospital stay and education level were significantly associated with the occurrence of DRHs (See in Table 5). Age > 64 years (Adjusted Odds Ratio (AOR)=7.451, 95%CI: 1.889-29.397, P=0.004) which indicated that an increased age would make to develop DRHs. Tertiary educational level (AOR=0.360, 95%CI: 0.141-0.923, P=0.033) which indicates that being literate protect the participants from DRHs by 64% as compared to participants who had no formal education.

Among the employment participants who did not have any occupation (AOR=3.409, 95%CI:1.120-10.374, P=0.031) were 3.4 times more likely to be hospitalized due to drug related morbidity than non-drug related while compared to the employed one. Moreover, the students were more than 6 times high likely to had DRHs than non-DRHs while compared to the employed participants (AOR=6.33 ,95%CI:1.375-29.153, P=0.018).

Participants with two or more diseases (co-morbid conditions) were 2 times high likely to contract DRHs than non-DRHs as compared to participants without co-morbid diseases (AOR=2.004,95%CI: 1.095-3.668, P=0.024), and regarding patients' hospital stay, participants stayed > 7 days were 2.2 times more likely with DRHs than non-DRHs while compared to < 7 days of length of hospital stay (AOR=2.186,95%CI: 1.412-3.382, P=0).

Table 5: Predictors that involved in drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Variables	Causes of Patients hospitalization			Odds Ratios		P-value
	DRH (245)	Non-DRH (178)	Total (423)	COR (95% CI)	AOR(95% CI)	
	n (%)	n (%)	n (%)			
Age (Years)						
Mean ±SD	48.24±17.86		47.50±17.21			
14 - 24	24(9.8)	14(7.9)	38(8.98)	1.000	1.000	0.006
25- 39	51(20.8)	59(33.1)	110(26)	0.759(0.35-1.66)	1.55(0.51-4.66)	0.435
40 - 64	100(40.8)	74(41.6)	174(41.1)	0.38(0.22-0.67)	2.567(0.82-8.06)	0.106
>64	70(28.6)	31(17.4)	101(23.9)	0.60(0.36-1.00)	7.45(1.89-29.40)	0.004

¹⁰ DRH, drug related hospitalization; non-DRH, non-drug related hospitalization; COR, crude odds ratio; AOR, adjusted odds ratio; CI, confidence interval

Table 5 Continued

Table 5 Continued

Variables	Causes of Patients hospitalization			Odds Ratios		P-value
	DRH(245) n (%)	Non-DRH(178) n (%)	Total(423) n (%)	COR(95% CI)	AOR(95% CI)	
Marital status						
Single	64(26.1)	34(19.1)	98(23.2)	1.000	1.00	0.300
Married	129(48.6)	105(59)	234(55.3)	0.60(0.37-0.99)	0.60(0.29-1.23)	0.160
Widowed	20(8.2)	9(5.1)	29(6.7)	0.74(0.40-1.39)	0.49(0.20-1.18)	0.109
Divorced	42(17.1)	31(16.9)	73(17.3)	1.18(0.49-2.87)	0.35(0.19-0.75)	0.983
Education level						
No formal education						
Elementary	66(26.9)	47(26.4)	113(26.7)	0.87(0.54-1.40)	0.57(0.23-1.43)	0.229
Secondary	31(12.7)	35(19.7)	66(15.6)	0.55(0.31-0.97)	0.57(0.23-1.39)	0.215
Tertiary	32(13.1)	24(13.5)	56(13.2)	0.83(0.45-1.52)	0.36(0.14-0.92)	0.033
Employment						
Employed	25(10.2)	25(14)	50(11.8)	1.00	1.00	0.156
Unemployed	0	1(0.6)	1(0.24)	0.48(0.21-1.12)	0.29(0.09-0.89)	1.000
house wife	30(12.2)	33(18.5)	63(14.9)	1.80(0.65-4.98)	1.81(0.56-5.89)	0.259
merchant	13(5.3)	14(7.9)	27(6.4)	0.44(0.19-0.98)	1.81(0.56-5.89)	0.325
Student	18(7.3)	7(3.9)	25(5.9)	0.45(0.17-1.20)	6.33(1.38-29.15)	0.018
Day laborer	51(20.8)	32(18)	83(19.6)	0.89(0.34-2.29)	2.64(0.99-7.023)	0.051
Retired	57(23.3)	40(22.5)	97(22.9)	0.77(0.35-1.67)	0.98(0.35-2.79)	0.973
farmer	22(9)	12(6.7)	34(8)	1.24(0.42-3.66)	2.89(0.89-9.36)	0.077
Others*	29(11.8)	14(7.9)	43(10.2)	0.69(0.32-1.46)	3.41(1.12-10.37)	0.031
Polypharmacy						
Yes	84(34.3)	43(24.2)	127(30)	1.64(1.06-2.53)	1.48(0.72-3.04)	0.284
No	161(65.7)	135(75.8)	296(70)	1.00	1.00	

*Others: participants who did not have any occupation

Table 5 Continued

Table 5 Continued

Variables	Causes of Patients hospitalization			Odds Ratios		P-value
	DRH(245) n (%)	Non-DRH(178) n (%)	Total(423) n (%)	COR(95% CI)	AOR(95% CI)	
Co morbid condition						
Yes	137(55.9)	76(42.7)	213(50.4)	1.70(1.15-2.51)	2.00(1.09-3.67)	0.024
No	108(44.1)	102(57.3)	210(49.6)	1.00	1.00	
Hospital stays (days)						
1–7	101(41.2)	112(62.9)	213(50.4)	1.00	1.00	
>7	144(58.8)	66(37.1)	210(49.6)	2.42(1.63-3.60)	2.19(1.41-3.38)	0.000

DISCUSSION

The aim of optimizing pharmacotherapy is to achieve the desired therapeutic outcomes in the absence of morbidity and mortality associated with the drug. To the best of our knowledge, this study is the first to explore the prevalence, categories and rate of preventability of DRHs in ED at three selected hospitals in Ethiopia.

The occurrence of DRHs was high (245,57.9%) and is substantially utmost from other studies conducted in America (16.2%), Brasil(31.6%), Denmark (10.8%), Norway(38%), Sewdin (41.3%), Greece(12.8%) %, India(17.2%), and Malaysia (39%).^{3 5 6 16-18 24 25} The high prevalence in the current study could be explained by numbers of reasons:(1) The categories of DRPs causing DRHs investigated in the present study were comprehensive, whilst other studies only investigated particular types of DRPs resulted DRHs such as therapeutic failure²⁵ and ADR^{2 24 26 27}; (2) the prospective design of this study helps to ensure that all information required to accurately classify

1
2
3 the events were gathered;(3)detailed histories of drug therapy obtained by clinical pharmacists
4 may improve detection of DRHs ;and(4) use of the Helper's and Strand's comprehensive
5 classification system has likely boosted the probability that all possible drug-related causes of
6 hospitalization to be identified. Largely, the wide variability in the rate of DRHs may be attributed
7 to the variations in the extent of study population, inclusion criteria, study settings, participant's
8 level of education and awareness, level of health professional expertise, methods of evaluating
9 DRHs attributed to DRPs, study designs (prospective vs. retrospective) and the study duration.
10 These variations of reasons also reported by other studies.^{2 9 10 26 27}

11
12 In this study, 87.8 % of DRHs were deemed to be preventable which is agreed with other
13 international studies in which preventability of DRHs has been by far greater than fifty percent.⁹⁻
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11 16 19 20 27 28 In the present study, the reasons why DRHs preventability has been high due to they
have not been appeared, if possible, measurements could be taken prior to drug related diseases.
For instance, the principal categories of DRHs in our study were failure to receive drugs
(130,53.5%) and untreated indication (94, 38.5%). Hence, both DRHs attributed to DRPs could be
avoided by providing awareness for patients about their drugs use, applying good prescribing and
dispensing practice, and providing appropriate pharmaceutical care plan.

The majority of DRHs were most commonly seen among female patients, which is concordant
with what has been done in the previous study.²⁹ However, in study done in Saudi Arabia, DRHs
were largely found in male patients.^{2 20} Elderly patients developed more DRPs leading to DRHs
than patients in other age groups which also in line with other studies.^{5 25 30} The main reasons
could be as patient's age is becoming advanced; physiologic functions are being deteriorated and
presence of likelihood of co morbid conditions which may predispose them to taking of multiple
drugs concomitantly which ultimately basis for the patients to contract medication side effects,
interactions (drug-drug or drug-food) thereby failure to receive drugs will occur owing to patients

non-adherence to their regimens, fear of drugs side effect, unavailability and expensiveness of the drugs.

In this study, patients whose education level being elementary and below were more prone in developing DRHs than having education high school or above which was consistent with studies done previously.^{3 16} This could be related to high level education might be useful to understand about appropriate medications use. More than half of DRHs also accounted from patients whose occupations were day laborer, retired and patients lived in dependency stated as others in

Table 1: Socio-demographic and clinical characteristics of the participants in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Gender			
Male	119(48.6)	88(49.4)	207(48.9)
Female	126(51.4)	90(50.6)	216(51.1)
Age (in years)			
Mean± SD	48.23±17.85		
14 - 24	24(9.8)	14(7.9)	38(8.98)
25- 39	51(20.8)	59(33.1)	110(26)
40 - 64	100(40.8)	74(41.6)	174(41.1)
>64	70(28.6)	31(17.4)	101(23.9)
Marital status			
Single	64(26.1)	34(19.1)	98(23.2)
Married	129(48.6)	105(59)	234(55.3)
widowed	20(8.2)	9(5.1)	29(6.7)
Divorced	42(17.1)	31(16.9)	73(17.3)
Education level			
No formal education	116(47.3)	72(40.4)	188(44.4)
Elementary	66(26.9)	47(26.4)	113(26.7)
Secondary	31(12.7)	35(19.7)	66(15.6)
Tertiary	32(13.1)	24(13.5)	56(13.2)
Residence			
Addis Ababa	177(72.2)	127(71.3)	304(71.9)
Out of Addis Ababa	68(27.8)	51(28.7)	119(28.1)
Religion			

Orthodox	186(76)	136(76)	322(76.1)
Muslim	42(17.1)	31(17.4)	73(17.3)
Catholic	1(0.4)	1(0.6)	2(0.5)
Protestant	16(6.5)	10(6)	26(6.1)

DRHs, drug related hospitalizations; non-DRHs, non-drug related hospitalizations; SD, standard deviation

Table 1 ... Continued

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Employment			
Employed	25(10.2)	25(14)	50(11.8)
Unemployed	0.0	1(0.6)	1(0.24)
House wife	30(12.2)	33(18.5)	63(14.9)
Merchant	13(5.3)	14(7.9)	27(6.4)
Student	18(7.3)	7(3.9)	25(5.9)
Laborer	51(20.8)	32(18)	83(19.6)
Retired	57(23.3)	40(22.5)	97(22.9)
Others	29(11.8)	14(7.9)	43(10.2)
Farmer	22(9)	12(6.7)	34(8)
Social habit (smoking cigarette)			
Yes	29(11.8)	15(8.4)	44(10.4)
No	216(88.2)	163(91.6)	379(89.6)
Social habit (dining alcohol)			
Yes	71(29)	57(32)	128(30.3)
No	174(71)	121(68)	295(69.7)
Physical activity(walk)			
Yes	165(39)	127(71.3)	292(69)
No	80(32.7)	51(28.7)	131(31)
Physical activity (regular physical exercise)			
Yes	5(2)	5(2.8)	10(2.4)
No	240(98)	173(97.2)	413(97.6)

²Others: participants who did not have any occupation rather they were dependent to live with other people.

DRH, drug related hospitalization; Non-DRH, Non-drug related hospitalization; n, number; SD, standard deviation

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Other Drugs (including OTC, herbals)			
Yes	3(1.2)	0(0)	3(0.7)
No	242(98.8)	178(100)	420(99.3)
Number of medications taken per patient			
Mean± SD	3.39±2.35		
0	24(9.8)	12(6.7)	36(8.5)
1	41(16.7)	26(14.6)	67(15.8)
2	35(14.3)	40(22.5)	75(17.7)
3-5	98(40)	75(42.1)	173(40.9)
>5	47(19.2)	25(14)	72(17)
Polypharmacy			
Yes	84(34.3)	43(24.2)	127(30)
No	161(65.7)	135(75.8)	296(70)
Co morbid condition			
Yes	137(55.9)	76(42.7)	213(50.4)
No	108(44.1)	102(57.3)	210(49.6)
Co morbid condition (Hypertension)			
Yes	68(27.8)	40(22.5)	108(25.5)
Co morbid condition (Diabetes mellitus)			
Yes	31(12.7)	22(12.4)	53(12.5)
Co morbid condition (Cardiac diseases)			
38(15.5)	21(11.8)	59(13.9)	
Length of Hospital stay (Days)			
1–7	101(41.2)	112(62.9)	213(50.4)
>7	144(58.8)	66(37.1)	210(49.6)
Mean± SD	11.4±9.27		
Median	9		
Range	2-96		

1
2
3 .It could be associated with that of they could not afford their drugs and cultural issue.
4
5

6 Of the 245 patients with DRHs, the foremost category of DRHs in this study was failure to receive
7 drugs (130,53.5%) followed by untreated indication (94,38.5%),adverse drug reaction(38,15.5%)
8 and sub therapeutic dosage (30,12.2%).The findings were reported by other studies.^{11 16 18-20 23 25 28}

9
10
11
12
13 ³¹The major reasons for failure to receive drugs in present study were patients prefer not to take
14 the drugs rather they preferred others cultural and religious therapy activities, drug products were
15 not available, cost of medications was too expensive, fear of adverse events, failure to follow-up
16 due to Covid-19, and they felt better and near to half of patients with DRHs were illiterate.
17
18 Therefore, inability to recall the regimen were other important reasons associated with increased
19 risk of a hospitalization related to failure to receive drugs which was mentioned in the past studies.
20
21
22
23
24
25

26
27 ^{3 10 19}

28
29
30 The second frequent category of DRHs was untreated indication (94, 38.5%) as it was reported in
31 other studies.^{8 20} Reasons were patients remained untreated; prophylaxis and synergistic
32 medications were not indicated. This might be due to incorrect diagnosis; patients didn't come to
33 health setting timely and treating physicians did not follow the management guidelines/protocols.
34
35 For example, patients having moderate persistent asthma were being treated with albuterol
36 inhalation alone and statins have not been indicated for patients with atherosclerotic cardiovascular
37 disease (ASCVDs) like peripheral arterial disease, stroke, ischemic heart disease and whose age \geq
38 40 years with diabetes mellitus and high low density lipoprotein level. In addition, some
39 compelling indication like hypertension remains untreated and subsequently results in DRHs
40 owing to stroke and others cardiovascular diseases. Furthermore, since only cancer diagnosis and
41 management are carried out in one of this research setting hospital which is TASH, patients come
42 from different Ethiopia places were remained untreated and predisposed to various empirical
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 therapies that also lead to improper drug selection until they treat with anti-cancer drugs in TASH.

1
2
3 ADRs (38, 15.5%) were also commonly reported as the common classifications of DRHs which
4 is also mentioned with other studies.^{10 17-19 27 28 32} This might be associated numerous numbers of
5 cardiac and diabetic patients in our study population and poor awareness of patients with regard to
6 cardiac medications untoward effects such as diuretics inducing electrolytes disturbance and
7 hypoglycemic symptoms of antidiabetics, respectively might be plausible explanations for
8 increased ADRs. Some ADRs could be resulted from disobeying of direction for use of the
9 medications. For example, diabetes mellitus patient who was on metformin experienced epigastric
10 burning sensation pain and vomiting after metformin was being taken without meal. Overall, the
11 plausible explanations for DRHs might be the absence of pharmaceutical care services in many
12 health institutions including those wards of the study settings that is very important to optimize
13 drug therapy and patient safety and also there were a poor collaboration among patients, clinical
14 pharmacists and physicians about patient's medications use process involving medications use,
15 their side effects, adherence issue and consequences if they will not take their medication properly.
16 Therefore, the better opportunity for clinical pharmacists to add value in patient care roles is
17 through ensuring medication management services according to evidence-based guidelines. Both
18 failure to receive drugs and untreated indication for which need additional drug therapy were
19 mentioned in the present study as a main categories of DRPs resulted DRHs were supported by
20 other study.^{6 8 16}

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46 In this study finding, medication classes that were frequently reported as causing of DRHs were
47 cardiovascular medicines, chemotherapeutic drugs, endocrine drugs, respiratory medicines and
48 central nervous system drugs. Among these classes of drugs, cardiovascular drug were
49 predominantly involved in DRHs which was in line with other studies.^{3 5 19 23 25 31} Cardiovascular
50 drugs, antidiabetics, and antiasthmatics were most commonly associated with DRHs was
51 supported in the previous studies.^{2 22 24 25} The most common drugs associated with DRHs
52
53
54
55
56
57
58
59

1
2
3 mentioned in this study finding were furosemide, ACEIs, insulins, oral hypoglycemic agents,
4 warfarin, spironolactone, aspirin and central nervous system agent and those were implicated in
5 the previous studies.^{6 9 19 20 22 27 31} The main reason might be connected with the common diseases
6 of the study area which were heart failure, diabetes mellitus, stroke, human immunodeficiency
7 virus and asthma. For those diseases, the above-mentioned drugs have been participated.
8
9

10
11
12 Moreover, the most common organ system involved in DRHs was the cardiovascular system (80,
13 32.6%), with the most common specific disease of heart failure (55, 22.5%) which is consistent
14 with the previous studies.^{5 23} Moreover, hypertension was mentioned for DRHs which was
15 implicated in the previous study.^{20 25 31} This is due to cardiovascular diseases require multiple
16 medicine regimens and this contributed to DRPs. Among hospitalized patients attributed to
17 endocrine systems were due to hypoglycemia, hyperglycemia and diabetic ketoacidosis which
18 was also cited in the other study.^{20 25} It might be due to the patients poor awareness about the
19 hypoglycemic symptoms of anti-hypoglycemic agents, poor monitoring control and patients
20 prefer not to take the medications.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37
38 In this study, age, educational level, length of hospital stays and presence of co morbid disease had
39 statistically significant correlation with the occurrence of DRHs. The findings are consistent with
40 other studies.^{16 18 28 29}
41
42
43
44

45
46 In multiple binary logistic regression analysis, patients with ≥ 65 years of age were 7.45 times
47 more likely to be hospitalized due to drug related morbidity than non-drug related as compared to
48 age between 14 and 24 years. This might be owing to age-related physiological changes, larger
49 number of coexisting disease conditions which require multiple medications have been associated
50 with an increased risk of DRHs.
51
52
53
54
55
56
57
58
59
60

1
2
3 From employment factor, students were 6.3 folds high likely exposed to DRHs than non-drug
4 related as compared to the employed. This might be explained by the nature of the disease they
5 had which means students in this finding have majorly contracted heart failure disease secondary
6 to chronic rheumatoid valvular heart disease. Consequently, it needs lifelong and multiple
7 medications treatment and then they faced various DRPs leading hospitalizations. Moreover,
8 participants who did not have any occupation rather they lived with others in depending situation
9 were 3.4 times high likely to be hospitalized owing to drug related diseases than non-drug related
10 as compared to employed.
11
12
13
14
15
16
17
18
19
20
21

22 The other factor was education level in which patients with tertiary education level were 64% less
23 likely to be hospitalized with drug related hospitalizations as compared to participants who did not
24 have formal education. This could be related to high level education might be useful to understand
25 about appropriate medications use. This was supported by the studies conducted at Brasil.^{3 10 16}
26 Patients with co morbid disease were also 2 folds high likely to be drug related hospitalized than
27 non-drug related as compared to patients without co morbid disease. As implicated in the previous
28 studies,^{16 28 29} co- morbidity increases the vulnerability towards DRPs. These results clearly
29 indicate the necessity of managing DRHs in multimorbid patients.
30
31
32
33
34
35
36
37
38
39
40
41

42 For patients who stayed > 7dasy in hospital due to admission were 2.4 times more likely to develop
43 DRHs compared to patients who admitted due to non-DRHs with estimated to < 7 days of length
44 of hospital stay. In terms of drug related hospital stay, the overall length of the hospital stay in the
45 present study was 2788 days with the average length of hospital stay 11.4±9.27 days, which is
46 longer than what has been reported in other study¹¹. This was might be owing to the data in the
47 previous study is in a single hospital and for a relatively short period of time (28 days) while in this
48 finding, the study was carried out at three tertiary care hospitals for the periods of 60 days.
49
50
51
52
53
54
55
56
57
58
59
60

Therefore, avoiding preventable DRHs is also a very cost-effective tool for health care systems and could reduce the problem of bed crisis in hospitals.

Among factors which have not demonstrated an association in multivariate analysis, polypharmacy was mentioned. This agree with what have been reported in other studies^{19 23}. In contrast, polypharmacy has been reported having positive association with the occurrence of DRHs in the previous literatures^{3 5 10 19 20 28}. This insignificance could be resulted from variations in numbers of used medications and identified DRPs for causing DRHs. In this study, around two third of the patients with DRHs were used from none to four drugs per patient. Accordingly, to say polypharmacy; \geq five drugs should be concomitantly taken. Furthermore, the identified DRPs causing DRHs were failure to receive drugs and untreated indication. So, both categories reveal not taking medications and the patients might not use polypharmacy. Additionally; marital status did not illustrate significant association with DRHs.

This study has some limitations. One of the main limitations of this study was there are no standardized protocols for immediately recording and reporting DRHs which may limit the estimation of real drug related hospitalized cases and leads to discrepancy of actual DRHs. This problem was mitigated by using clinical pharmacists who have an ability to identify and resolve DRPs. A factor limiting the scope of this study concerned patients admitted to an EW. Hence, considerable numbers of patients with DRPs from other major departments have been missed. Though, during the data collection period, patients brought to health institutions were decreased owing to covid-19 epidemic, being this study multicenter has been able to obtain large sample size.

Conclusion

The prevalence of DRHs was relatively high among emergency ward patients in the study settings. Failure to receive drugs and untreated indication were the most frequently reported categories of

1
2
3 DRHs. Of drugs, cardiovascular drugs and drugs acting on the endocrine system have been the
4 most frequently implicated drugs in patients with DRHs. Amid factors; Age, educational level,
5 participants who did not have any occupation, presence of co-morbid condition and hospital stay
6 have had significant association with DRHs. Hence, researches regarding DRHs should be
7 conducted in different Ethiopian hospitals to demonstrate its impact. Categories DRHs in patients'
8 medical chart should be appropriately recorded and to improve quality health services, clinical
9 pharmacy services should be delivered in different wards of the hospitals. Medication use
10 counseling and education are needed for chronic disease patients. Therefore, patients,
11 caregivers/families, nurses, physicians and pharmacists should be collaborating more closely to
12 provide and reinforce pharmaceutical care and monitor patients to prevent drug related emergency
13 department visits and subsequent morbidity and mortality.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Author affiliations**

31
32 ¹Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health
33 Science, Addis Ababa University, Addis Ababa, Ethiopia
34
35
36
37
38

39 **Acknowledgment**

40
41 We would like to thank the study participants who gave their time and provided the necessary
42 information. We also express our gratitude for data collectors and staffs who were assigned in EW
43 of study settings for their cooperation.
44
45
46
47
48
49

50 **Contributors**

51
52 ABB and MBD contributed to conceptualization, design, analysis and write up. MBD organized
53 the collection of data for analysis and write up the draft manuscript. ABB and MBD supervised
54 the collection data and overall research work including interpretation of results, reviewed and
55
56
57
58
59

revised critically the manuscript. Both authors approved the final version to be submitted for publication.

Funding This study was done with the financial support of Addis Ababa University. The funder had no role in the study design, data collection, analysis, preparation of the manuscript, or decision to publish.

Competing interests There are no conflicts of interest.

Patient consent for publication Not required

Ethics approval Prior to study initiation, letter of ethical approval (Ref No;ERB/SOP/172/08/2020) was obtained from ethical review committee, School of Pharmacy, College of Health Sciences , Addis Ababa University.

Data availability statement Data are accessed upon reasonable request of the corresponding author. All relevant data are within the manuscript and Supporting Information files.

Provenance and peer review Not commissioned; externally peer reviewed.

Supporting information

S 1 File:[Data collection tool.docx](#)

ORCID iDs

Mulate Belete Demessie : <https://orcid.org/0000-0002-1517-7293>

Alemseged Beyene Berha : <https://orcid.org/0000-0003-3825-2863>

REFERENCES

1. Al Hamid A, Ghaleb M, Aljadhey H, et al. A systematic review of hospitalization resulting from medicine-related problems in adult patients. *British journal of clinical pharmacology* 2014;78(2):202-17. doi: 10.1111/bcp.12293

2. Alayed N, Alkhalifah B, Alharbi M, et al. Adverse Drug Reaction (ADR) as a Cause of Hospitalization at a Government Hospital in Saudi Arabia: A Prospective Observational Study. *Current drug safety* 2019;14(3):192-98. doi: 10.2174/1574886314666190520105330
3. Andreazza RS, Silveira De Castro M, Sippel Koche P, et al. Causes of drug-related problems in the emergency room of a hospital in southern Brazil. *Gaceta sanitaria* 2011;25(6):501-6. doi: 10.1016/j.gaceta.2011.05.016
4. STRAND HA. Opportunities and responsibilities in pharmaceutical care. *American journal of hospital pharmacy* 1990;47:533-43.
5. Gustafsson M, Sjolander M, Pfister B, et al. Drug-related hospital admissions among old people with dementia. *European journal of clinical pharmacology* 2016;72(9):1143-53. doi: 10.1007/s00228-016-2084-3
6. Lea M, Mowe M, Mathiesen L, et al. Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. *PloS one* 2019;14(7):e0220071. doi: 10.1371/journal.pone.0220071
7. Pattanaik S, Dhamija P, Malhotra S, et al. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. *British journal of clinical pharmacology* 2009;67(3):363-9. doi: 10.1111/j.1365-2125.2008.03346.x
8. Pellegrin KL, Lee E, Uyeno R, et al. Potentially preventable medication-related hospitalizations: A clinical pharmacist approach to assessment, categorization, and quality improvement. *Journal of the American Pharmacists Association : JAPhA* 2017;57(6):711-16. doi: 10.1016/j.japh.2017.06.019
9. R L Howard AJA, P D Howard, M Partridge. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study *Qual Saf Health Care* 2003;125:280–85.
10. Singh H, Kumar BN, Sinha T, et al. The incidence and nature of drug-related hospital admission: A 6-month observational study in a tertiary health care hospital. *Journal of pharmacology & pharmacotherapeutics* 2011;2(1):17-20. doi: 10.4103/0976-500X.77095
11. Yosef H. Al-Olah KMAT. Admissions through the emergency department due to drug-related problems. *Ann Saudi Med* 2008;28 (6):426-29.
12. Centre WMR. Medicines-related admissions. *WeMeReC Bulletin* February,2015

13. Robert J. Cipolle LS, Peter Morley Pharmaceutical Care Practice: The PatientCentered Approach to Medication Management Services, 3e >. *McGraw-Hill Medical* 2012
14. WHO. International drug monitoring. 1969(425)
15. Johnson JA, Boatman LI. Drug-Related Morbidity and Mortality:
A Cost-of-Illness Model. *Journal of Managed Care Pharmacy* 1996;2(1):39-45.
16. Dammalapati SG, Challa SR, Challa P, et al. Incidence and Factors Associated with Drug Related Hospital Admissions in a South Indian Tertiary Care Hospital. *Indian Journal of Pharmacy Practice* 2018;11(1):37-43. doi: 10.5530/ijopp.11.1.7
17. J. HALLAS BH, L. F. GRAM, E. GRODUM, K. BRBSEN, T. HAGHFELTt & N. DAMSBOS. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. *Journal of Internal Medicine* 1990; 2280: 83-90.
18. Kent M. Nelson aRLT. Drug-Related Hospital Admissions. *Pharmacotherapy* 1996;16(4): 70 1-707.
19. Leslie Jo Samoy PJZ, Robert M. Balen, Riyad B. Abu-Laban, and Mark Roberts. Drug-Related Hospitalizations in a Tertiary Care Internal Medicine Service of a Canadian Hospital:
A Prospective Study. *Pharmacotherapy* 2006;26(11):1578–86.
20. Mohamed Al-Arifi HA-H, Mohamed Al-Meziny , Ragab Said ,, Aljadhey H. Emergency department visits and admissions due to drug related problems at Riyadh military hospital (RMH), Saudi Arabia. *Saudi Pharmaceutical Journal* 2013(22):17–25. doi: 10.1016/j.jsps.2013.01.001
21. Almut G Winterstein BCS, Charles D Hepler, and Charles Poole. Preventable Drug-Related Hospital Admissions. *Ann Pharmacother* 2002;36:1238-48. doi: 10.1345/aph.1A225
22. Daniel S. Budnitz MCL, Nadine Shehab, and Chesley L. Richards. Emergency Hospitalizations for Adverse Drug Events in Older Americans. *The new england journal o f medicine* 2011;365:2002-12.
23. Marcum ZA, Pugh MJ, Amuan ME, et al. Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. *The journals of gerontology Series A, Biological sciences and medical sciences* 2012;67(8):867-74. doi: 10.1093/gerona/gls001
24. Alexopoulou A, Dourakis SP, Mantzoukis D, et al. Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. *European journal of internal medicine* 2008;19(7):505-10. doi: 10.1016/j.ejim.2007.06.030

25. Karuppannan M, Nee T, Thong W, et al. The prevalence of adverse drug event-related admissions at a local hospital in Malaysia. *Archives of Pharmacy Practice* 2013;4(4):160. doi: 10.4103/2045-080x.123224
26. Geer MI, Koul PA, Tanki SA, et al. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. *Journal of pharmacological and toxicological methods* 2016;81:323-34. doi: 10.1016/j.vascn.2016.04.011
27. Parameswaran Nair N, Chalmers L, Connolly M, et al. Prediction of Hospitalization due to Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC Score). *PloS one* 2016;11(10):e0165757. doi: 10.1371/journal.pone.0165757
28. Peter J. Zed EAF, Stacy Ackroyd-Stolarz, Nancy G. Murphy, Neil J. MacKinnon, Doug Sinclair. Medication-Related Emergency Department Visits in Pediatrics: a Prospective Observational Study. *American Academy of Pediatrics* 2015;135(3) doi: DOI: 10.1542/peds.2014-1827
29. Nivya K, Sri Sai Kiran V, Ragoo N, et al. Systemic review on drug related hospital admissions - A pubmed based search. *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society* 2015;23(1):1-8. doi: 10.1016/j.jsps.2013.05.006
30. Linkens AEMJH, Milosevic V, van der Kuy PHM, et al. Medication-related hospital admissions and readmissions in older patients: an overview of literature. *International Journal of Clinical Pharmacy* 2020;42(5):1243-51. doi: 10.1007/s11096-020-01040-1
31. Ayalew MB, HGT, OAA. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures. *Bulletin of emergency and trauma* 2019;7(4):339-46.
32. Hohl CM, Nosyk B, Kuramoto L, et al. Outcomes of emergency department patients presenting with adverse drug events. *Annals of emergency medicine* 2011;58(3):270-79 e4. doi: 10.1016/j.annemergmed.2011.01.003

Figure 1: Patient's inclusion information flow chart in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)

Figure 2: Numbers of drug related problems occurrence per patient leading hospitalization in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1




Figure 1

review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data abstraction formats

Annex 1: Patient’s demographic and clinical data

IC card.....DOA.....Date of discharge.....

Part I: Socio-Demographic Characteristics					
1. Age (in years)		2. Sex Male <input type="checkbox"/> Female <input type="checkbox"/>			
3. Marital status		Single <input type="checkbox"/>	Married <input type="checkbox"/>	Divorced <input type="checkbox"/>	Widowed <input type="checkbox"/>
4. Religion		Orthodox	Muslim	Catholic <input type="checkbox"/>	protestant <input type="checkbox"/> others <input type="checkbox"/>
5. Educational status		No formal <input type="checkbox"/>	Grade 9-10 <input type="checkbox"/>	College diploma <input type="checkbox"/>	
		Grade 1-8 <input type="checkbox"/>	Grade 10-12 <input type="checkbox"/>	University degree and above <input type="checkbox"/>	
6. Residence (current)		Addis Ababa <input type="checkbox"/>	Out of Addis Ababa <input type="checkbox"/>		
7. Job type		Employed <input type="checkbox"/>	Unemployed <input type="checkbox"/>	house wife <input type="checkbox"/>	merchant <input type="checkbox"/> Student <input type="checkbox"/> daily laborer <input type="checkbox"/>
		<input type="checkbox"/> farmer	Others-----		
8. Social habits	Cigarette Smoker	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Alcohol Drinker	Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Physical activity	Walk	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Sport	Yes <input type="checkbox"/> No <input type="checkbox"/>
Part II: Clinical characteristics					
1. Chief complaint					
2. Name of the disease					
3. Other Drugs (including OTC, herbals)		No <input type="checkbox"/>	Yes <input type="checkbox"/>	If yes list them and their purpose of use (indications)	
4. Comorbid condition		No <input type="checkbox"/>	Yes <input type="checkbox"/>	If yes list here	
5. Length of hospital stay (LOS).....		6. Average patient service cost/day.....			

BMJ Open: first published as 10.1136/bmjopen-2021-024778 on 9 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

Part III: Data abstraction formats on taken patient histories, laboratory investigations, physical examinations and diagnostic imaging techniques

Weight (kg) _____ Height (cm) _____ Body mass index (BMI) [kg/m²] _____

1. Past medical conditions and medications

Indication	Drug product (Generic Name)	Full Dosage regimen	Date (dd/mm/yy)		Response Effectiveness/ profile	safety
			Started	Stopped		

2. Past medical history (hospitalizations, surgical procedures, injuries, pregnancies and so on)

PMH: _____

PSH: _____

Injuries: _____

3. Physical Examination (PE)/vital signs: Consecutive record of visits

Date(dd/mm/yy)	First visit				Second Visit				Third visit				
	BP	PR	RR	T ⁰	BP	PR	RR	T ⁰	BP	PR	RR	T ⁰	
SaO ₂													

Any Pertinent physical examination and/or Review of systems findings:

4. Pertinent laboratory and imaging series results (Findings for three consecutive results).

Lab Investigations		Date(dd/mm/yy)	Date(dd/mm/yy)	Date(dd/mm/yy)
Parameters				
Blood glucose level	HbA1c (%):			
	FBS(mg/dL):			
	RBS(mg/dL):			
Lipid panels	TC: mg/dl			
	LDL: mg/dl			
	TG: mg/dl			
	HDL: mg/dl			
RFTs	BUN/Scr			
	eGFR			
LFTs	AST			
	ALT			
	ALP			
	Bil/Alb			
Coagulation profile	PT			
	INR			
	PTT			
Serum electrolyte	Na ⁺ /Cl ⁻			
	Mg ²⁺ /K ⁺			
	Ca ²⁺ /Po ₄ ³⁻			
CBC	WBC/N/L			
	RBC/Hgb/Hct			
	MCV/MCH			
	Plt			
Others				
Any diagnostic tools/Imaging techniques/modalities with findings				
Technique	Date(dd/mm/yy)	Date(dd/mm/yy)	Date(dd/mm/yy)	Date(dd/mm/yy)

Annex 2: Categories of potentially Preventable Drugs-Related Admission Categories

DTPs Categories	Common Cause of Drug therapy problem
1. Unnecessary drug therapy	<input type="checkbox"/> No medical indication of the drug is found <input type="checkbox"/> Duplication of drug therapy is existed <input type="checkbox"/> Non drug therapy should be indicated <input type="checkbox"/> Drug is used in treating avoidable ADR <input type="checkbox"/> Others ,specify_____
2. Needs additional drug therapy	<input type="checkbox"/> Untreated medical condition is existed <input type="checkbox"/> Preventive/ prophylactic drug needed <input type="checkbox"/> Synergistic/ potentiating drug needed <input type="checkbox"/> Others, specify_____
3. Ineffective drug product/ Improper Drug Selection	<input type="checkbox"/> More effective alternative drug is available <input type="checkbox"/> Condition is already refractory to drug <input type="checkbox"/> Dosage form is inappropriate <input type="checkbox"/> The drug is not effective for condition <input type="checkbox"/> Others, specify_____
4. Sub therapeutic Dosage.	<input type="checkbox"/> Wrong dose (too small) of the drug <input type="checkbox"/> Frequency is inappropriate (long) <input type="checkbox"/> Duration of drug use is too short
5. Over dosage	<input type="checkbox"/> Wrong dose (too high) of the drug <input type="checkbox"/> Frequency is inappropriate (short) <input type="checkbox"/> Duration of drug use is too long <input type="checkbox"/> Others, specify_____
6. Adverse drug reaction	<input type="checkbox"/> Undesired effect from the drug is found <input type="checkbox"/> Unsafe drug for patient is existed <input type="checkbox"/> Dosage is administered or changed too rapidly <input type="checkbox"/> Allergic reactions is found/reported <input type="checkbox"/> Contraindication to the drug is present <input type="checkbox"/> Administered too rapidly
7. Drug Interactions	<input type="checkbox"/> There is (are) Major drug interaction (s)
8. Failure to Receive Drugs.	<input type="checkbox"/> Does not understand instructions: the patient does not understand how to properly take or use the drug product and dosage regimen. <input type="checkbox"/> Patient prefers not to take <input type="checkbox"/> Patient forgets to take <input type="checkbox"/> Drug product not available <input type="checkbox"/> Cost of medication too expensive <input type="checkbox"/> Cannot swallow/administer drug <input type="checkbox"/> No willingness to take the drug <input type="checkbox"/> Unavailability of medication <input type="checkbox"/> Disbelieves on the drug effectiveness <input type="checkbox"/> Patient felt better or worse <input type="checkbox"/> Fear of adverse events <input type="checkbox"/> Regimen complexity

Medication classes	Individual drugs	Types of DRPs

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Prevalence and Predictors of Drug-Related Hospitalizations among Patients Visited Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054778.R1
Article Type:	Original research
Date Submitted by the Author:	20-Nov-2021
Complete List of Authors:	Demessie, Mulate ; Addis Ababa University Berha, Alemseged; Addis Ababa University, Pharmacology and Clinical Pharmacy
Primary Subject Heading:	Emergency medicine
Secondary Subject Heading:	Patient-centred medicine, Pharmacology and therapeutics, Health services research
Keywords:	Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Prevalence and Predictors of Drug-Related Hospitalizations among Patients Visited Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

Mulate Belete Demessie¹, Alemseged Beyene Berha^{1*}

*Corresponding author: alembeyene98@gmail.com

ABSTRACT

Objectives: This study aimed to determine the prevalence, categories and predictors of drug related hospitalizations (DRHs) among patients visited emergency departments of Addis Ababa city hospitals, Ethiopia.

Design: A multicenter prospective observational study was conducted through patients interview and chart review.

Settings: The study was undertaken in three tertiary care hospitals, Addis Ababa, Ethiopia.

Participants: A total of 423 patients fulfilling the inclusion criteria were included.

Outcome measures: Prevalence and preventability of DRHs, categories of drug related problems causing DRHs, medications and diseases involved in DRHs and factors significantly associated with DRHs.

Result: More than half of the patients (216, 51.1%) were females. The mean age (SD) was 47.50 (± 17.21) years. The mean length of hospital stay (SD) was 10.29 (± 8.99) days. Nearly, 60% (249) of them were hospitalized due to drug related problems, of which 87.8% were preventable. The cause for hospitalization for more than half (130, 53%) of them was failure to receive drugs and 37.85 (94) patients were categorized as untreated indications. Age ≥ 65 years (Adjusted Odds Ratio [AOR]=7.451, 95%CI: 1.889-29.397), tertiary educational level (AOR=0.360, 95%CI: 0.141-0.923), participants who did not have any occupation (AOR=3.409, 95%CI: 1.120-10.374)

1
2
3 presence of co-morbid conditions (AOR=2.004, 95%CI: 1.095-3.668) and hospital stay > 7 days
4
5 (AOR=2.186, 95%CI: 1.412-3.382) were predictors of DRHs.
6

7 **Conclusion:** Nearly 90% of DRHs were deemed to be preventable in the study settings. Older
8
9 age, lower educational level, unemployment, presence of co-morbid condition and staying >7 days
10
11 in hospital as an inpatient were predictors of DRHs.
12
13

14 **Strength and limitations of the study**

- 15
16
17 ➤ To the best of our knowledge this is the first study in the African continent.
18
19 ➤ The strength of this study is the study design which is a prospective observational study.
20
21 ➤ This is a multicenter study with sufficient sample size, increasing representativeness the
22
23 findings.
24
25 ➤ The main limitation of this study is lack of standardized procedures for immediate recording
26
27 and reporting of DRHs.
28
29 ➤ Patients who visited other than the emergency ward were excluded from participation can also
30
31 be considered as a limitation of the study.
32
33
34
35

36 **INTRODUCTION**

37
38
39 Though drugs can be ordered for the intention of achieving desired health outcomes that improve
40
41 patients quality of life, symptoms and signs of diseases causing drug related hospitalizations
42
43 (DRHs) as a result of drug related problems (DRPs) could be apparent.¹⁻³ DRP is defined according
44
45 to Helper and strand as ‘an undesired event or circumstance due to drug therapy that actually or
46
47 potentially interferes with desired health outcomes’.⁴
48
49
50

51 Medication’s use has been increasing across the globe due to the presence of large number of
52
53 treatable diseases and this has contributed to production of more advanced medications by the
54
55 pharmaceutical industries. Therefore, advances in drug therapies could lead to an apparent increase
56
57 in the incidence of DRPs, which in turn lead to hospitalization⁵. Hospitalization can be defined as
58
59

1
2
3 drug related if it is straightforwardly linked to one of the eight predefined Helper's and Strand's
4 classifications of DRPs: adverse drug reaction (ADR), drug interaction, improper drug selection,
5 untreated indication, sub-therapeutic dosage, supra-therapeutic dosage, failure to receive drugs,
6 and drug use without indication.⁶⁻¹² Those DRPs can arise when a medicine is prescribed aptly and
7 used correctly (e.g., ADR), due to errors involving prescribing (including inappropriate or over-
8 treatment, and failure to prescribe the indicated treatment or under-treatment), dispensing,
9 administering, reconciling, or monitoring of medicines as well as from poor patient adherence.^{2 13}

10
11
12
13
14
15
16
17
18
19 ¹⁴ According to the World Health Organization (WHO), an ADR is any harmful, undesired and
20 inadvertent drug effect that occurs at doses used in human for therapy, diagnosis or prophylaxis.¹⁵

21
22
23
24
25 Over the past decades, DRHs have been considered as wide spreading¹⁶. In the United States, DRPs
26 accounted for 17 million emergency department (ED) visits and 8.7 hospitalizations annually.¹⁷ It
27 increases morbidity and mortality rates, health care cost, decreases income and household
28 productivity and reduced quality of life.^{2 18 19}

29
30
31
32
33
34
35 Studies carried out in different areas of the globe estimated the extent of DRHs to be between 16%
36 to 41.3%. Of these, 50% to 95% were preventable. Supratherapeutic dosage (10.3%-12.7%), non-
37 compliance (10.6%-65.8%), ADRs (10.7%-45.5%) and untreated indications (10.7-13.3%) were
38 frequently identified as the causes of DRHs.^{6 9 18 20-22}

39
40
41
42
43
44
45 DRPs resulting DRHs were defined as preventable if the patient failed to take a drug that is known
46 to reduce or prevent symptoms according to the prescribed directions, took a drug for which a
47 patient had a known allergy, drug treatment was obviously improper, dosage differed from
48 accepted recommendations, took a drug that was not indicated, and if there was a failure to monitor
49 by a physician at reasonable time intervals due to financial difficulty. If there was, however, no
50 reasonable actions to prevent DRPs, it is then termed as non-preventable.^{20 23}

1
2
3 In many studies, patients with DRHs had mainly cardiovascular diseases and diabetes, suggesting
4 that cardiovascular and hypoglycemic medications were involved in DRHs.^{6 10 11 18 20 21 24 25}

7 Previous studies also identified polypharmacy, advanced age and comorbid conditions as factors
8 that favor the occurrence of DRHs.^{3 6 20 21}

11
12
13 It is thus important to determine DRHs prevalence to improve treatment outcomes and prevent
14 unnecessary admissions. To the best of our knowledge, there are no studies conducted about DRHs
15 in Ethiopia. The present study therefore aimed to determine the prevalence, categories and
16 predictors of DRHs among patients admitted to an ED of three selected hospitals in Addis Ababa,
17 the capital of Ethiopia.
18
19
20
21
22
23
24

25 **METHODS**

26 **Study Settings**

27
28
29 The study was carried out in the ED of Tikur Anbessa Specialized Hospital (TASH), Zewditu
30 Memorial Hospital (ZMH), and Yekatit 12 Hospital Medical College (Y12HMC), Addis Ababa,
31 Ethiopia. TASH has 700 beds and it is a tertiary care teaching hospital affiliated with Addis Ababa
32 University. In TASH, outpatient, inpatient, and emergency services are delivered. The ED provides
33 services for about 13,920 patients per year. Y12HMC is also a tertiary care level referral and
34 teaching hospital that provides both inpatient and outpatient treatment for a large number of people
35 coming from Addis Ababa as well as other places of the country. The hospital has a total of three
36 ED rooms. The adult medical ED is collocated with adult surgical ED. It serves around 10,560
37 patients per year. The third hospital is ZMH, which is one of the teaching and general referral
38 hospitals in Ethiopia and the ED serves about 10,560 patients per year.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient involvement

Patients did not participate in the initial conception and design of the study. However, based on the participating patients' comments during the pretest (5% of the sample size), we made a correction on the patient approach and timing for an interview at ED during data collection. Patients who participated actively in this study determined the medication use, level of adherence, and medical history.

Study design and population

A prospective observational study design was used to collect data from August to September, 2020. All patients admitted to the ED of the three selected hospitals during the study period and fulfilled the inclusion criteria were included.

Inclusion and exclusion criteria

Patients having a medical history with completed data and ≥ 14 years old were included. Patients with incomplete or no medical records, refused to participate, presented with trauma and injuries associated with accidents (e.g. road traffic accidents, beaten by stick, stabbing and bulleting) and poisoned/intoxicated (for instance snake bite, alcohol intoxication or use of pesticide) were excluded. During data collection periods, about 2655 patients were being admitted to the ED, out of which 423 participants fulfilled the inclusion criteria

Sample size determination and techniques

Since there was no study done on DRHs in Ethiopia, the sample size was estimated using the general formula for single population proportion.

$$n = [(Z \alpha/2)^2 \times p (1-p)] / d^2 = [(1.96)^2 \times 0.5 \times 0.5] / 0.05^2 = 384$$

(Hence; n = required sample size, $Z\alpha/2$ = critical value for normal distribution at 95% confidence interval, which equals 1.96 (Z value at $\alpha = 0.05$), P = Proportion of DRH = 0.5, d = margin of

1
2
3 error of 5%=0.05. The calculated sample size using this formula was 384. Adding 10%
4 contingency (for non-response rate) to compensate participants who could refuse to participate,
5 brought the final sample size to 423. The sample size was distributed to the three hospitals based
6 on the patient load of hospital's ED per annum as mentioned in the Study settings. Accordingly,
7
8 169 participants were included from TASH, 127 participants from ZMH and 127 participants from
9
10 Y12MHC.
11
12
13
14
15

16 17 **Data collection procedures** 18

19
20 A structured questionnaire was developed from carefully evaluated published articles in the
21 literature. For instance, categories of DRPs that leads to hospitalization and factors having
22 association with DRH (e.g. socio-demographic and clinical characteristics) were extracted from
23 literatures. All the necessary data including patients' demographic details (age, sex, marital status,
24 education level, employment), and clinical information like the number of medications being taken
25 prior to admission were collected and documented using a data collection tools through
26 interviewing the patients. Furthermore, patient's medical records were reviewed by data collectors
27 to obtain clinical information (disease history, allergic status, admission diagnosis, length of
28 hospital stay during admission, number of medications being taken prior to admission, data on
29 laboratory investigations). Supplementary information and clarifications on some patient's
30 medical information were obtained through discussion with the treating physicians and residents.
31 By applying those data gathering approach, different categories of DRPs resulting hospitalization
32 with their possible causes were determined.
33
34
35
36
37
38
39
40
41
42
43

44 Data were collected by three pharmacists having Master of Science degrees in Clinical Pharmacy.
45 They had basic knowledge and skill in pharmaceutical care services and also received training on
46 how to obtain data from patients' medication charts and approach the patients and health care
47 professionals. Updated Ethiopian Standard Treatment Guidelines for Hospitals, third edition,
48 2014, Ethiopian Antiretroviral Therapy and Tuberculosis Guidelines, Cancer Treatment Protocols
49 prepared by TASH Oncologists, Pharmacotherapy textbooks, Medscape, UpToDate were used as
50 a guide for diseases management. Micromedex online database was used to check drug
51
52
53
54
55
56
57
58
59

1
2
3 interactions. Furthermore, updated guidelines released from American Cardiology Center,
4 American Heart Association, European Cardiology Society, American Diabetic Association were
5 used as a guide to treat different diseases. Clinical pharmacists along with physicians determined
6 subtherapeutic and suprathereapeutic dosage outcomes using medical charts, laboratory tests,
7 clinical outcomes, medication dose and frequency. Participant's hospitalization attributed to
8 failure to receive drugs was decided using physician's recording documentation, clinical
9 pharmacists' knowledge and patients reporting evidence. Untreated indications and improper drug
10 selection were evaluated and interpreted using treatment guidelines. For instance, if patients
11 presented with untreated or improperly treated cardiac diseases, treatment was initiated and
12 optimized using the American Heart Association guidelines, and UpToDate latest version. To
13 minimize bias, the three pharmacists at each hospital independently evaluated the identified DRPs
14 resulted hospitalizations. Decision was then reached by reaching consensus after a series of
15 meetings and discussions as well consultations with physicians and residents. Once DRPs resulting
16 DRHs were identified, they were recorded and classified using DRPs registration format according
17 to Helper's and Strand's classification.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Data collection management**

39
40 Pretest was performed on 5% patients in TASH prior to the actual data collection period and
41 amendment was made accordingly. The data collection process was supervised, and the
42 information gathered via data abstraction formats were reviewed and checked for their
43 completeness every day to ensure quality. Urgent correction was made, if any errors were
44 identified.
45
46
47
48
49
50
51
52

53 **Data analysis**

54
55 The data were entered and analyzed using Statistical Package for Social Sciences (SPSS) version
56 26. Mean and standard deviation for continuous variables and frequency and percentage for
57
58
59
60

categorical variables were computed by using descriptive statistics in SPSS to summarize socio-demographic and relevant clinical characteristics of the study participants. Tables and charts were used to present the results. Furthermore, univariate and multiple binary logistic regressions were performed to analyze factors that predict DRHs. Variables with p-values < 0.2 in the binary univariate analysis were included in the multiple binary logistic regressions to control the effect of confounders. The level of significance was set at p-value ≤ 0.05 and results were reported as odds ratios (OR) with 95% confidence intervals.

RESULTS

Socio-demographic and clinical characteristics

From 2655 participants enrolled in the study, a total of 423 study participants were included for analysis. Of them, 169 participants from TASH, 127 from ZMH and another 127 from Y12HMC were included (*Figure 1*).

Socio-demographic and clinical characteristics of the participants is depicted in

Table 1: Socio-demographic and clinical characteristics of the participants in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Gender			
Male	119(48.6)	88(49.4)	207(48.9)
Female	126(51.4)	90(50.6)	216(51.1)
Age* (in years)			
Mean \pm SD	48.23 \pm 17.85	46.5 \pm 16.3	47.5 \pm 17.2
14 - 24	24(9.8)	14(7.9)	38(8.98)
25- 39	51(20.8)	59(33.1)	110(26)
40 - 64	100(40.8)	74(41.6)	174(41.1)
>64	70(28.6)	31(17.4)	101(23.9)
Marital status*			
Single	64(26.1)	34(19.1)	98(23.2)
Married	129(48.6)	105(59)	234(55.3)

widowed	20(8.2)	9(5.1)	29(6.7)
Divorced	42(17.1)	31(16.9)	73(17.3)
Education level*			
No formal education	116(47.3)	72(40.4)	188(44.4)
Elementary	66(26.9)	47(26.4)	113(26.7)
Secondary	31(12.7)	35(19.7)	66(15.6)
Tertiary	32(13.1)	24(13.5)	56(13.2)
Residence			
Addis Ababa	177(72.2)	127(71.3)	304(71.9)
Out of Addis Ababa	68(27.8)	51(28.7)	119(28.1)
Religion			
Orthodox	186(76)	136(76)	322(76.1)
Muslim	42(17.1)	31(17.4)	73(17.3)
Catholic	1(0.4)	1(0.6)	2(0.5)
Protestant	16(6.5)	10(6)	26(6.1)

DRHs, drug related hospitalizations; non-DRHs, non-drug related hospitalizations; SD, standard deviation;

* Represent variables having significant bivariate associations.

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Employment status*			
Salaried worker	111(45.3)	83(46.6)	194(45.9)
Unemployed	87(35.5)	74(41.6)	161(38.1)
Student	18(7.3)	7(3.9)	25(5.9)
Other	29(11.8)	14(7.9)	43(10.2)
Social habit (smoking cigarette)			
Yes	29(11.8)	15(8.4)	44(10.4)
No	216(88.2)	163(91.6)	379(89.6)
Social habit (drinking alcohol)			
Yes	71(29)	57(32)	128(30.3)
No	174(71)	121(68)	295(69.7)
Any physical activity			
Yes	170(69.4)	132(74.1)	302(71.4)
No	70(30.6)	46(25.9)	106(28.6)

² Others: participants who did not have any occupation rather they were lived as dependent with other people. DRH, drug related hospitalization; Non-DRH, Non-drug related hospitalization; n, number; SD, standard deviation

* Represent variables having significant bivariate associations.

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Home remedies (herbals)			
Yes	3(1.2)	0(0)	3(0.7)
No	242(98.8)	178(100)	420(99.3)
Number of medications taken per patient *			
Mean± SD	3.4±2.4	3.2±2.1	3.3±2.3
0	24(9.8)	12(6.7)	36(8.5)
1	41(16.7)	26(14.6)	67(15.8)
2	35(14.3)	40(22.5)	75(17.7)
3-4	61(24.9)	57(32)	118(27.9)
≥5	84(34.3)	43(24.2)	127(30)
Polypharmacy			
Yes	84(34.3)	43(24.2)	127(30)
No	161(65.7)	135(75.8)	296(70)
Co morbid condition*			
Yes	137(55.9)	76(42.7)	213(50.4)
No	108(44.1)	102(57.3)	210(49.6)
Co morbid condition (Hypertension)			
Yes	68(27.8)	40(22.5)	108(25.5)
Co morbid condition(Diabetes mellitus)			
Yes	31(12.7)	22(12.4)	53(12.5)
Co morbid condition (Cardiac diseases)			
Yes	38(15.5)	21(11.8)	59(13.9)
Length of Hospital stay (Days) *			
1-7	101(41.2)	112(62.9)	213(50.4)
>7	144(58.8)	66(37.1)	210(49.6)

. More than half of the participants (216, 51.1%) were females. The mean (SD) age of the participants was 47.5 (\pm 17.21) years and nearly two third (275, 65%) were \geq 40 years of age. More than 70 % (301, 71.1%) of the total participants' level of education was below secondary school. Nearly three-quarter of them (304, 71.9%) resided in Addis Ababa city. Out of the total study participants, 58% (245) of them were taking \geq 3 and 30% (127) \geq five drugs prior to admission, which is termed as polypharmacy. Above half of the participants (213, 50.4%) had co-morbid diseases, including hypertension (108, 22.5%), cardiac diseases (59, 13.5%) and diabetes mellitus (53, 12.5%). The total length of hospital stay was 4352 days with a mean (SD) of 10.28 \pm 8.99 days and ranges from 2 to 96 days.

Table 1: Socio-demographic and clinical characteristics of the participants in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)

Variables	¹ DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Gender			
Male	119(48.6)	88(49.4)	207(48.9)
Female	126(51.4)	90(50.6)	216(51.1)
Age* (in years)			
Mean \pm SD	48.23 \pm 17.85	46.5 \pm 16.3	47.5 \pm 17.2
14 - 24	24(9.8)	14(7.9)	38(8.98)
25- 39	51(20.8)	59(33.1)	110(26)
40 - 64	100(40.8)	74(41.6)	174(41.1)
>64	70(28.6)	31(17.4)	101(23.9)
Marital status*			
Single	64(26.1)	34(19.1)	98(23.2)
Married	129(48.6)	105(59)	234(55.3)
widowed	20(8.2)	9(5.1)	29(6.7)
Divorced	42(17.1)	31(16.9)	73(17.3)
Education level*			
No formal education	116(47.3)	72(40.4)	188(44.4)
Elementary	66(26.9)	47(26.4)	113(26.7)
Secondary	31(12.7)	35(19.7)	66(15.6)
Tertiary	32(13.1)	24(13.5)	56(13.2)
Residence			

Addis Ababa	177(72.2)	127(71.3)	304(71.9)
Out of Addis Ababa	68(27.8)	51(28.7)	119(28.1)
Religion			
Orthodox	186(76)	136(76)	322(76.1)
Muslim	42(17.1)	31(17.4)	73(17.3)
Catholic	1(0.4)	1(0.6)	2(0.5)
Protestant	16(6.5)	10(6)	26(6.1)

DRHs, drug related hospitalizations; non-DRHs, non-drug related hospitalizations; SD, standard deviation;

* Represent variables having significant bivariate associations.

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Employment status*			
Salaried worker	111(45.3)	83(46.6)	194(45.9)
Unemployed	87(35.5)	74(41.6)	161(38.1)
Student	18(7.3)	7(3.9)	25(5.9)
Other ²	29(11.8)	14(7.9)	43(10.2)
Social habit (smoking cigarette)			
Yes	29(11.8)	15(8.4)	44(10.4)
No	216(88.2)	163(91.6)	379(89.6)
Social habit (drinking alcohol)			
Yes	71(29)	57(32)	128(30.3)
No	174(71)	121(68)	295(69.7)
Any physical activity			
Yes	170(69.4)	132(74.1)	302(71.4)
No	70(30.6)	46(25.9)	106(28.6)

Table 1 continued

² Others: participants who did not have any occupation rather they were lived as dependent with other people. DRH, drug related hospitalization; Non-DRH, Non-drug related hospitalization; n, number; SD, standard deviation

* Represent variables having significant bivariate associations.

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Home remedies (herbals)			
Yes	3(1.2)	0(0)	3(0.7)
No	242(98.8)	178(100)	420(99.3)
Number of medications taken per patient *			
Mean± SD	3.4±2.4	3.2±2.1	3.3±2.3
0	24(9.8)	12(6.7)	36(8.5)
1	41(16.7)	26(14.6)	67(15.8)
2	35(14.3)	40(22.5)	75(17.7)
3-4	61(24.9)	57(32)	118(27.9)
≥5	84(34.3)	43(24.2)	127(30)
Polypharmacy			
Yes	84(34.3)	43(24.2)	127(30)
No	161(65.7)	135(75.8)	296(70)
Co morbid condition*			
Yes	137(55.9)	76(42.7)	213(50.4)
No	108(44.1)	102(57.3)	210(49.6)
Co morbid condition (Hypertension)			
Yes	68(27.8)	40(22.5)	108(25.5)
Co morbid condition(Diabetes mellitus)			
Yes	31(12.7)	22(12.4)	53(12.5)
Co morbid condition (Cardiac diseases ³)			
Yes	38(15.5)	21(11.8)	59(13.9)
Length of Hospital stay (Days) *			

1—7	101(41.2)	112(62.9)	213(50.4)
>7	144(58.8)	66(37.1)	210(49.6)

* Represent variables having significant bivariate associations.

Prevalence and categories of drug related hospitalizations

From a total of 423 enrolled patients, DRHs were identified in 245 (57.9%) participants, of which 87.8% were deemed preventable. A total of 322 DRPs rendering DRHs were observed in 245 participants, representing 1.31 DRPs per patient (**Figure 2**). Out of 245 drug related hospitalized patients, more than half (130, 53%) of them were due to failure to receive drugs followed by untreated indication (94, 37.8%) and sub-therapeutic dosage (30, 12.2%). The main reasons for failure to receive drugs included patients preferred not to take the medication (43, 33.1%); feared adverse events (18, 13.8%); and drug products were not available (17, 13.1%)**Error! Reference source not found.**

Table 2:Categories of drugs related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Untreated indications	Untreated medical condition is existed	34(36.2)
	Synergistic/ potentiating drug needed	42(44.7)
	Preventive/ prophylactic drug needed	18(19%)
Improper Drug Selection	More effective alternative drug is available	6(37.5)
	Condition is already refractory to drug	2(12.5)
	The drug is not effective for condition	6(37.5)
	Others ⁴	2(12.5)

⁴ Others; patients who were using expired drugs like insulin and albuterol.

Table 2Continued.....

Error! Reference source not found. Continued.....

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Sub therapeutic Dosage		30(12.2)
	Wrong dose (too small) of the drug	24(80)
	Frequency is inappropriate (long)	5(16.7)
	Duration of drug use is too short	1(3.3)
Supra therapeutic Dosage		13(5.3)
	Wrong dose (too high) of the drug	11(84.6)
	Frequency is inappropriate (short)	2(15.4)
Adverse drug reaction		38(15.5)
	Undesired effect from the drug is found	34(89.5)
	Unsafe drug for patient is existed	1(2.6)
	Dosage is administered too rapidly	1(2.6)
	Allergic reactions is found/reported	2(5.3)
Drug Interactions		1(0.4)
	There is (are) major drug interaction	1(100)

⁵Others; patients who were using expired drugs like insulin and albuterol.

Table 2 Continued.....

Error! Reference source not found. Continued.....

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Failure to receive drugs.		130(53.5)
	Does not understand instructions	6(4.6)
	Patients prefer not to take	43(33.1)
	Patients forget to take	3(2.3)

Drug product not available	17(13.1)
Cost of medication too expensive	16(12.3)
Disbelieves on the drug effectiveness	1(0.8)
Patients felt better	17(13.1)
Patients felt worse	1(0.8)
Fear of adverse events	18(13.8)
Failure to follow-up due to Covid-19	8(6.2)
Total number of DRPs leading DRHs	322
Total number of participants with DRHs	245
Average number DRPs per patients with DRHs	1.31
Preventability of DRHs	215(87.8)

Medications and diseases involved in drug related hospitalizations

Out of a total of 245 drug related hospitalized patients, nearly one -third of them had cardiovascular diseases (80, 32.6%) followed by endocrine disorders (47, 19.2%) and cerebrovascular disease (26, 10.6%).

Table 3: Diseases that associated with drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Disease's categories	n(%)
Cardiovascular diseases	80 (32.6%)
CNS diseases	8 (3.2%)
Cerebrovascular disease	26(10.6%)
Infectious diseases	21 (8.5%)
Endocrine system diseases	47 (19.2%)
Diseases of cancer	25 (10.1%)
Diseases of the respiratory system	21 (8.5%)
GI diseases	10 (4%)
Others*	7 (2.8%)

*Includes anemia, chronic kidney disease, systemic lupus erythematosus and hemophilia

Medication classes and specific drugs implicated in DRHs are depicted in Table 4.

A total of 497 drugs were implicated in 245 drug-related hospitalized patients, providing an encounter of 2.03 drugs per drug-related hospitalized patient. Cardiovascular, antimicrobial, antineoplastic and endocrine drug classes were the most frequently involved drugs in the hospital admissions. Among cardiovascular drugs; furosemide (59,24.1%), angiotensin converting enzyme inhibitors (ACEIs) (48,19.1%), and antiplatelets & anticoagulants (44,18%) were the most frequently mentioned followed by drugs acting on the endocrine system like oral hypoglycemic agents (37, 15.1%) and insulin (24, 9.8%). Antibiotics (25 ,10%), anticancer drugs (23 ,9%), and combination antiretroviral therapy (15, 6.1%) had also contributed to admission to varied extent.

Table 4: Medication classes and specific drugs implicated in drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Drugs class	Specific drugs	n (%)
Cardiovascular drugs		
	Atorvastatin	31(12.7)
	Antiplatelets(aspirin,clopidogril)	24(9.8)
	Furosemide	59(24.1)
	Spironolactone	33(13.5)
	Anticoagulants (Warfarin, heparin)	20(8.2)
	Beta blockers (metoprolol,atenolol)	21(8.6)
	Digoxin	15(6.1)
	Angiotensin converting enzyme inhibitors (enalapril/lisinopril)	48(19.6)
	Calcium channel blockers (nifedipine, amlodipine)	34(13.9)
	Hydrochlorothiazide	11(4.5)

Table 4Continued.....

Table 4 continued.....

Drugs class	Specific drugs	n (%)
Drugs act on the respiratory system	Long-acting beta blockers	15(6.1)
	bronchodilator	10(4.1)
Central nervous system drugs	Antiepileptics	5(2)
	antipsychotic	5(2)
	Amitriptylin	2(0.8)
Antimicrobial drugs	Antibiotics (piperacillin/tazobactam, meropenem, amoxicillin, amoxicillin /clavunicacid ,ceftriaxone, benzathine penicillin)	25(10.2)
	Combination antiretroviral therapy	15(6.1)
	Anti-tuberculosis	13(5.3)
Antineoplastic agents	Cyclophosphamide, imatinib, methotrexate, doxorubicin	23(9.4)
Immuno-suppressants	Mycophenolate	1(.4)
	corticosteroids (prednisolone, budesonide)	9(3.7)
Endocrine drugs	Oral hypoglycemic drugs (metformin, glibenclamide)	37(15.1)
	Insulin	24(9.8)
	Propylthiouracil	4(1.6)
Gastrointestinal drug	Proton pump inhibitors	7(2.9)
Others	Potassium chloride	1(0.4)
	Non-steroidal anti-inflammatory drugs	3(1.2)
	Opioid	1(0.4)

Table 4 Continued

Drugs class	Specific drugs	n (%)
Others		
	Ferrous sulphate	1(0.4)
Total number of medications involved in DRHs		497
Total number of participants with DRHs		245(57.9)
Average number medications per patients with DRHs		2.03

Factors associated with the occurrence of drug related hospitalizations

According to the multivariate logistic regression analysis, five variables such as age, employment, presence of co morbid diseases, length of hospital stay and education level were significantly associated with the occurrence of DRHs (See in Table5). Age > 64 years (Adjusted Odds Ratio [AOR] = 7.451, 95%CI: 1.889-29.397), tertiary educational level (AOR=0.360, 95%CI: 0.141-0.923), participants who did not have any occupation (AOR=3.409, 95%CI: 1.120-10.374), students (AOR=6.331,95%CI:1.375-29.153) presence of co-morbid diseases (AOR=2.004,95%CI: 1.095-3.668), and hospital stay > seven days (AOR=2.186, 95%CI: 1.412-3.382) were predictors of DRHs.

Table 5: Predictors that involved in drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Variables	Predictors of Patients hospitalization			Odds Ratios	
	⁵ DRH(245) n (%)	Non- DRH(178) n (%)	Total(423) n (%)	AOR(95% CI)	P- value
Age (Years)					
Mean±SD	48.24±17.86		47.50±17.21		
14 - 24	24(9.8)	14(7.9)	38(8.98)	1.000	0.006
25- 39	51(20.8)	59(33.1)	110(26)	1.55(0.51-4.66)	0.435
40 - 64	100(40.8)	74(41.6)	174(41.1)	2.567(0.82-8.06)	0.106
>64	70(28.6)	31(17.4)	101(23.9)	7.45(1.89-29.40)	0.004
Marital status					
Single	64(26.1)	34(19.1)	98(23.2)	1.00	0.300
Married	129(48.6)	105(59)	234(55.3)	0.60(0.29-1.23)	0.160
Widowed	20(8.2)	9(5.1)	29(6.7)	0.49(0.20-1.18)	0.109
Divorced	42(17.1)	31(16.9)	73(17.3)	0.35(0.19-0.75)	0.983
Education level					
No formal education	116(47.3)	72(40.4)	188(44.4)	1.00	0.183
Elementary	66(26.9)	47(26.4)	113(26.7)	0.57(0.23-1.43)	0.229
Secondary	31(12.7)	35(19.7)	66(15.6)	0.57(0.23-1.39)	0.215
Tertiary	32(13.1)	24(13.5)	56(13.2)	0.36(0.14-0.92)	0.033

¹⁰DRH, drug related hospitalization; non-DRH, non-drug related hospitalization; AOR, adjusted odds ratio; CI, confidence interval

Table 5 Continued

Variables	Predictors of Patients hospitalization			Odds Ratios	
	DRH(245) n (%)	Non-DRH(178) n (%)	Total(423) n (%)	AOR(95% CI)	P-value
Employment status					
Salaried worker	111(45.3)	83(46.6)	194(45.9)	1.00	0.156
Unemployed	87(35.5)	74(41.6)	161(38.1)	0.29(0.09-0.89)	1.000
Student	18(7.3)	7(3.9)	25(5.9)	6.33(1.38-29.15)	0.018
Others*	29(11.8)	14(7.9)	43(10.2)	3.41(1.12-10.37)	0.031
Polypharmacy					
Yes	84(34.3)	43(24.2)	127(30)	1.48(0.72-3.04)	0.284
No	161(65.7)	135(75.8)	296(70)	1.00	
Co morbid condition					
Yes	137(55.9)	76(42.7)	213(50.4)	2.00(1.09-3.67)	0.024
No	108(44.1)	102(57.3)	210(49.6)	1.00	
Hospital stays (days)					
1–7	101(41.2)	112(62.9)	213(50.4)	1.00	
>7	144(58.8)	66(37.1)	210(49.6)	2.19(1.41-3.38)	0.000

*Others: participants who did not have any occupation

DISCUSSION

The aim of optimizing pharmacotherapy is to achieve the desired therapeutic outcomes in the absence of morbidity and mortality associated with a drug. To the best of our knowledge, this study is the first to explore the prevalence, categories and rate of preventability of DRHs in the ED of three selected hospitals that are responsible for the provision of medical and surgical care to patients in need of immediate care.

1
2
3 The occurrence of DRHs reported in this study (245,57.9%) is substantially higher than studies
4 conducted elsewhere, including America (16.2%), Brasil (31.6%), Denmark (10.8%),
5 Norway(38%), Sweden_(41.3%), India (17.2 %), and Malaysia (39%).^{3 6 7 18-20 26 27}The high
6
7
8 prevalence in the current study could be explained by a number of reasons: (i) The categories of
9
10 DRPs causing DRHs in this study were comprehensive, whilst other studies investigated particular
11
12 types of DRPs resulted DRHs such as therapeutic failure²⁷ and ADR ^{2 26 28 29}; (ii) The prospective
13
14 design of this study helps to ensure the gathering all information required to accurately classify
15
16 the events; (iii) Detailed histories of drug therapy obtained by clinical pharmacists might have
17
18 improved detection of DRHs ; and (iv) use of the Helper's and Strand's comprehensive
19
20 classification system has likely boosted the probability that all possible drug-related causes of
21
22 hospitalization to be identified. In addition, the wide variability in the rate of DRHs could also be
23
24 attributed to the variations in the extent of study population, inclusion criteria, study settings,
25
26 participant's level of education and awareness, level of health professional expertise, methods of
27
28 evaluating DRHs attributed to DRPs, study designs (prospective vs. retrospective) and the study
29
30 duration. These variations are also reported by other studies.^{2 10 11 28 29}

31
32
33
34
35
36
37
38 In this study, 87.8 % of DRHs were deemed to be preventable and this is in line with other
39
40 international studies in which preventability of DRHs has been by far greater than fifty percent.¹⁰⁻¹²
41
42
43 ^{18 21 22 29 30} The reasons why DRHs preventability was high could be attributed to failure to taking
44
45 appropriate measurements before drug related diseases were apparent. For instance, the principal
46
47 categories of DRHs in our study were failure to receive drugs (130,53.5%) and untreated indication
48
49 (94, 38.5%). Hence, both DRHs attributed to DRPs could be avoided by providing awareness for
50
51 patients about their drugs use, applying good prescribing and dispensing practice, and providing
52
53 appropriate pharmaceutical care plan.
54
55
56
57
58
59

1
2
3 The majority of DRHs were most commonly seen among female patients, which is concordant
4 with a previous study.³¹ However, in a study done in Saudi Arabia, DRHs were largely found in
5 male patients.^{2 22} Elderly patients developed more DRPs leading to DRHs than patients in other
6 age groups which is also in line with other studies.^{6 16 27} The main reasons could be that increased
7 deterioration of physiologic functions and likelihood of co-morbid conditions with age. These
8 conditions may warrant taking of multiple drugs, which ultimately serve as basis for contracting
9 medication side effects and interactions (drug-drug or drug-food). This could possibly lead to
10 failure to receive drugs owing to patients' non-adherence to regimens, fear of drugs side effect,
11 unavailability and expensiveness of the drugs.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 In this study, patients whose education level being elementary and below were more prone to
26 develop DRHs than having high school education or above, which was consistent with studies
27 done previously.^{3 18} This could be related to high level education is useful to understand about
28 appropriate medications use.
29
30
31
32
33
34

35 Out of a total of 245 patients with DRHs, the foremost categories of DRHs were failure to receive
36 drugs (130,53.5%) followed by untreated indication (94,38.5%), adverse drug reactions
37 (38,15.5%) and sub therapeutic dosage (30,12.2%). Similar findings were reported by other
38 studies.^{5 12 18 20-22 25 27 30} The major reasons for failure to receive drugs in this study were preference
39 to cultural and religious therapies over conventional medicines, drug products were not available,
40 cost of medications was too expensive, fear of adverse events, failure to follow-up due to Covid-
41 19, felt better and illiteracy (near to half of patients with DRHs were illiterate). Thus, inability to
42 recall regimens is another important reason associated with increased risk of hospitalization related
43 to failure to receive drugs, as reported elsewhere.^{3 11 21}
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The second frequent category of DRHs was untreated indication (94, 38.5%) as reported in other
4 studies.^{9 22} Reasons were patients remained untreated; prophylaxis and synergistic medications
5 were not indicated. This might be due to incorrect diagnosis; patients didn't come to health setting
6 timely and treating physicians did not follow the management guidelines/protocols. For example,
7 patients having moderate persistent asthma were being treated with albuterol inhalation alone.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statins have not also been prescribed for patients with atherosclerotic cardiovascular disease (ASCVDs) like peripheral arterial disease, stroke, ischemic heart disease and whose age ≥ 40 years with diabetes mellitus and high low density lipoprotein level. In addition, some compelling indication like hypertension remains untreated and subsequently results in DRHs owing to stroke and others cardiovascular diseases. Furthermore, since only cancer diagnosis and management are carried out in one of this research setting hospital, which is TASH, patients coming from different corners of the country remained untreated and/or treated with various empirical therapies that also lead to improper drug selection until they start anti-cancer drugs in TASH.

ADRs (38, 15.5%) were also commonly reported as the common classifications of DRHs, which is also mentioned with other studies.^{11 19-21 29 30 32} This might be associated with numerous number of cardiac and diabetic patients in our study population and poor awareness of patients with regard to cardiac medications untoward effects such as diuretics induced electrolytes disturbance and hypoglycemic symptoms of antidiabetics. Some ADRs could be resulted from failure to follow direction for use of the medications. For example, diabetes mellitus patient who was on metformin experienced epigastric burning sensation pain and vomiting after taking metformin without meal. Overall, the plausible explanations for DRHs might be the absence of pharmaceutical care services in many health institutions including emergency wards of the study settings, which is very important for optimizing drug therapy and patient safety. There was also poor collaboration among patients, clinical pharmacists and physicians about patient's medications use process involving

1
2
3 medications use, their side effects, adherence issue and consequences if they will not take their
4 medication properly. Therefore, the better opportunity for clinical pharmacists to add value in
5 patient care roles is through ensuring medication management services according to evidence-
6 based guidelines. In the present study, both failure to receive drugs and untreated indication were
7 reported under the DRPs category of need additional drug therapy that resulted in DRHs, which is
8 supported by other studies.^{7 9 18}

9
10
11
12
13
14
15
16
17
18 In this study, medication classes frequently observed to cause DRHs were cardiovascular
19 medicines, antimicrobial, antineoplastic, endocrine drugs, respiratory medicines and central
20 nervous system drugs. Among these classes of drugs, cardiovascular drug were predominantly
21 involved in DRHs which was in line with other studies.^{3 5 6 21 25 27} Cardiovascular drugs,
22 antidiabetics, and antiasthmatics were most commonly associated with DRHs was supported in
23 the previous studies.^{2 24 26 27} The most common drugs associated with DRHs mentioned in this
24 study finding were furosemide, ACEIs, insulins, oral hypoglycemic agents, warfarin,
25 spironolactone, aspirin and central nervous system agent and these are also implicated in several
26 other studies.^{5 7 10 21 22 24 29} The main reason might be connected with the common diseases of the
27 study area which were heart failure, diabetes mellitus, stroke, human immunodeficiency virus and
28 asthma.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 Moreover, the most common organ system involved in DRHs was the cardiovascular system (80,
45 32.6%), with the most common specific disease of heart failure (55, 22.5%) which is consistent
46 with previous studies.^{6 25} Moreover, hypertension was mentioned for DRHs which was implicated
47 in the previous study.^{5 22 27} This is due to the fact that cardiovascular diseases require multiple
48 medicine regimens and this contributed to DRPs. Among hospitalized patients attributed to
49 endocrine systems were due to hypoglycemia, hyperglycemia and diabetic ketoacidosis, which
50 are also cited in other studies.^{22 27} It might be due to the patients poor awareness about the

1
2
3 hypoglycemic symptoms of anti-hypoglycemic agents , poor monitoring control and patients
4
5 prefer not to take the medications.
6
7

8
9 In this study, age, educational level, length of hospital stays and presence of comorbid diseases
10
11 had statistically significant correlation with the occurrence of DRHs. The findings are consistent
12
13 with other studies.^{18 20 30 33}
14
15

16
17 In multiple binary logistic regression analysis, patients with ≥ 65 years of age were 7.45 times
18
19 more likely to be hospitalized due to drug related morbidity than non-drug related as compared to
20
21 age between 14 and 24 years. This might be owing to age-related physiological changes, larger
22
23 number of coexisting disease conditions, which require multiple medications and this in turn is
24
25 associated with an increased risk of DRHs.
26
27

28
29 From employment factor, students were 6.3 folds high likely exposed to DRHs than non-drug
30
31 related as compared to the employed. This might be explained by the nature of the disease they
32
33 had which means students in this finding have majorly contracted heart failure disease secondary
34
35 to chronic rheumatoid valvular heart disease. Out of a total 16 students, 9 (56.3%) of them had
36
37 heart failure owing to valvular heart diseases. Consequently, it needs lifelong and multiple
38
39 medications treatment and then they faced various DRPs leading hospitalizations. Moreover,
40
41 participants who did not have any occupation were 3.4 times high likely to be hospitalized owing
42
43 to drug related diseases than non-drug related as compared to employed.
44
45
46
47
48

49 The other factor was education level in which patients with tertiary education level were 64% less
50
51 likely to be hospitalized with drug related hospitalizations as compared to participants who did not
52
53 have formal education. This could be related to high level education might be useful to understand
54
55 about appropriate medications use. This was supported by the studies conducted at Brasil.^{3 11 18}
56
57

58 Patients with co-morbid disease were also 2 folds high likely to be drug related hospitalized than
59
60

1
2
3 non-drug related as compared to patients without co morbid disease. As implicated in the previous
4 studies,^{18 30 33} co- morbidity increases the vulnerability towards DRPs. These results clearly
5 indicate the necessity of managing DRHs in multimorbid patients.
6
7
8

9
10 Patients with DRHs were 2.2 times more likely to stay for > 7 days after they were hospitalized
11 than patients with non-drug related hospitalization with estimated to < 7 days of the length of
12 hospital stay. In terms of drug related hospital stay, the overall length of the hospital stay in the
13 present study was 2788 days with the average length of hospital stay 11.4±9.27 days, which is
14 longer than what has been reported in other study.¹² This was might be owing to the data in the
15 previous study is in a single hospital and for a relatively short period of time (28 days) while in
16 this finding, the study was carried out at three tertiary care hospitals for the periods of 60 days.
17 Therefore, avoiding preventable DRHs is also a very cost-effective tool for health care systems
18 and could reduce the problem of bed crisis in hospitals.
19
20
21
22
23
24
25
26
27
28
29
30

31
32 Among factors which have not demonstrated an association in multivariate analysis, polypharmacy
33 was mentioned. This agree with what have been reported in other studies.^{21 25} In contrast,
34 polypharmacy has been reported having positive association with the occurrence of DRHs in
35 previous studies.^{3 6 11 21 22 30} This lack of significance could be resulted from variations in number
36 of used medications and identified DRPs for causing DRHs. In this study, around two third of the
37 patients with DRHs used from none to four drugs per patient. Accordingly, to say polypharmacy;
38 \geq five drugs should be concomitantly taken. Furthermore, the identified DRPs causing DRHs were
39 failure to receive drugs and untreated indication. So, both categories reveal not taking medications
40 and the patients might not use polypharmacy. Additionally; marital status did not illustrate
41 significant association with DRHs.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

The prevalence of DRHs was higher than studies conducted elsewhere among emergency ward patients in the study settings. Failure to receive drugs and untreated indication were the most frequently reported categories of DRHs. Cardiovascular drugs and drugs acting on the endocrine system have been the most frequently implicated drugs in patients with DRHs. Age, educational level, participants who did not have any occupation, presence of co-morbid condition and hospital stay have had significant association with DRHs. Hence, researches regarding DRHs should be conducted in different Ethiopian hospitals to demonstrate its impact.

Author affiliations

¹Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia

Acknowledgment

We would like to thank the study participants who gave their time and provided the necessary information. We also express our gratitude for data collectors and staffs who were assigned in ED of study settings for their cooperation.

Contributors

ABB and MBD contributed to conceptualization, design, analysis and write up. MBD organized the collection of data for analysis and write up the draft manuscript. ABB and MBD supervised the collection data and overall research work including interpretation of results, reviewed and revised critically the manuscript. Both authors approved the final version to be submitted for publication.

Funding

This study was done with the financial support of Addis Ababa University. The funder had no role in the study design, data collection, analysis, preparation of the manuscript, or decision to publish.

Competing interests

There are no conflicts of interest.

Patient consent for publication

Not required

Ethics approval

Prior to study initiation, letter of ethical approval (Ref No;ERB/SOP/172/08/2020) was obtained from ethical review committee, School of Pharmacy, College of Health Sciences, Addis Ababa University. Verbal consent from patients was obtained after the provision of information regarding the purpose of the study and its risk for the interviewed which could be time to be spent during the interview (maximum of 30 minutes). Names were not used rather codes to maintain confidentiality of the information throughout the study period. Patients were told the reasons of being selected to be included in the study and assured that waning participation would not have any influence on the right to get treatment. Patients were also told about their rights to withdraw from the study at any time.

Data availability statement

Data are accessed upon reasonable request of the corresponding author. All relevant data are within the manuscript and Supporting Information files.

Provenance and peer review

Not commissioned; externally peer reviewed.

ORCID iDs

Mulate Belete Demessie: <https://orcid.org/0000-0002-1517-7293>

Alemseged Beyene Berha: <https://orcid.org/0000-0003-3825-2863>

REFERENCES

- [dataset] 1. Al Hamid A, Ghaleb M, Aljadhey H, et al. A systematic review of hospitalization resulting from medicine-related problems in adult patients. *British journal of clinical pharmacology* 2014;78(2):202-17. doi: 10.1111/bcp.12293
- [dataset] 2. Alayed N, Alkhalifah B, Alharbi M, et al. Adverse Drug Reaction (ADR) as a Cause of Hospitalization at a Government Hospital in Saudi Arabia: A Prospective Observational Study. *Current drug safety* 2019;14(3):192-98. doi: 10.2174/1574886314666190520105330
- [dataset] 3. Andrezza RS, Silveira De Castro M, Sippel Koche P, et al. Causes of drug-related problems in the emergency room of a hospital in southern Brazil. *Gaceta sanitaria* 2011;25(6):501-6. doi: 10.1016/j.gaceta.2011.05.016
- [dataset] 4. STRAND HA. Opportunities and responsibilities in pharmaceutical care. *American journal of hospital pharmacy* 1990;47:533-43.
- [dataset] 5. Ayalew MB, HGT, OAA. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures. *Bulletin of emergency and trauma* 2019;7(4):339-46.
- [dataset] 6. Gustafsson M, Sjolander M, Pfister B, et al. Drug-related hospital admissions among old people with dementia. *European journal of clinical pharmacology* 2016;72(9):1143-53. doi: 10.1007/s00228-016-2084-3
- [dataset] 7. Lea M, Mowe M, Mathiesen L, et al. Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. *PloS one* 2019;14(7):e0220071. doi: 10.1371/journal.pone.0220071
- [dataset] 8. Pattanaik S, Dhamija P, Malhotra S, et al. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. *British journal of clinical pharmacology* 2009;67(3):363-9. doi: 10.1111/j.1365-2125.2008.03346.x
- [dataset] 9. Pellegrin KL, Lee E, Uyeno R, et al. Potentially preventable medication-related hospitalizations: A clinical pharmacist approach to assessment, categorization, and quality improvement. *Journal of the American Pharmacists Association : JAPhA* 2017;57(6):711-16. doi: 10.1016/j.japh.2017.06.019
- [dataset] 10. R L Howard AJA, P D Howard, M Partridge. Investigation into the reasons for preventable drug related admissions to a medical admissions unit:observational study *Qual Saf Health Care* 2003;125:280–85.
- [dataset] 11. Singh H, Kumar BN, Sinha T, et al. The incidence and nature of drug-related hospital admission: A 6-month observational study in a tertiary health care hospital. *Journal of pharmacology & pharmacotherapeutics* 2011;2(1):17-20. doi: 10.4103/0976-500X.77095
- [dataset] 12. Yosef H. Al-Olah KMAT. Admissions through the emergency department due to drug-related problems. *Ann Saudi Med* 2008;28 (6):426-29.
- [dataset] 13. Centre WMR. Medicines-related admissions. *WeMeReC Bulletin* February,2015
- [dataset] 14. Robert J. Cipolle LS, Peter Morley Pharmaceutical Care Practice: The PatientCentered Approach to Medication Management Services, 3e >. *McGraw-Hill Medical* 2012

- [dataset] 15. WHO. International drug monitoring. 1969(425)
- [dataset] 16. Linkens AEMJH, Milosevic V, van der Kuy PHM, et al. Medication-related hospital admissions and readmissions in older patients: an overview of literature. *International Journal of Clinical Pharmacy* 2020;42(5):1243-51. doi: 10.1007/s11096-020-01040-1
- [dataset] 17. Johnson JA, Boatman LI. Drug-Related Morbidity and Mortality: A Cost-of-Illness Model. *Journal of Managed Care Pharmacy* 1996;2(1):39-45.
- [dataset] 18. Dammalapati SG, Challa SR, Challa P, et al. Incidence and Factors Associated with Drug Related Hospital Admissions in a South Indian Tertiary Care Hospital. *Indian Journal of Pharmacy Practice* 2018;11(1):37-43. doi: 10.5530/ijopp.11.1.7
- [dataset] 19. J. HALLAS BH, L. F. GRAM, E. GRODUM, K. BRBSEN, T. HAGHFELT & N. DAMSBOS. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. *Journal of Internal Medicine* 1990; 2280: 83-90.
- [dataset] 20. Kent M. Nelson aRLT. Drug-Related Hospital Admissions. *Pharmacotherapy* 1996;16(4): 70 1-707.
- [dataset] 21. Leslie Jo Samoy PJZ, Robert M. Balen, Riyad B. Abu-Laban, and Mark Roberts. Drug-Related Hospitalizations in a Tertiary Care Internal Medicine Service of a Canadian Hospital: A Prospective Study. *Pharmacotherapy* 2006;26(11):1578–86.
- [dataset] 22. Mohamed Al-Arifi HA-H, Mohamed Al-Meziny , Ragab Said ,, Aljadhey H. Emergency department visits and admissions due to drug related problems at Riyadh military hospital (RMH), Saudi Arabia. *Saudi Pharmaceutical Journal* 2013(22):17–25. doi: 10.1016/j.jsps.2013.01.001
- [dataset] 23. Almut G Winterstein BCS, Charles D Hepler, and Charles Poole. Preventable Drug-Related Hospital Admissions. *Ann Pharmacother* 2002;36:1238-48. doi: 10.1345/aph.1A225
- [dataset] 24. Daniel S. Budnitz MCL, Nadine Shehab, and Chesley L. Richards. Emergency Hospitalizations for Adverse Drug Events in Older Americans. *The new england journal of medicine* 2011;365:2002-12.
- [dataset] 25. Marcum ZA, Pugh MJ, Amuan ME, et al. Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. *The journals of gerontology Series A, Biological sciences and medical sciences* 2012;67(8):867-74. doi: 10.1093/gerona/gls001
- [dataset] 26. Alexopoulou A, Dourakis SP, Mantzoukis D, et al. Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. *European journal of internal medicine* 2008;19(7):505-10. doi: 10.1016/j.ejim.2007.06.030
- [dataset] 27. Karuppannan M, Nee T, Thong W, et al. The prevalence of adverse drug event-related admissions at a local hospital in Malaysia. *Archives of Pharmacy Practice* 2013;4(4):160. doi: 10.4103/2045-080x.123224
- [dataset] 28. Geer MI, Koul PA, Tanki SA, et al. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. *Journal of pharmacological and toxicological methods* 2016;81:323-34. doi: 10.1016/j.vascn.2016.04.011
- [dataset] 29. Parameswaran Nair N, Chalmers L, Connolly M, et al. Prediction of Hospitalization due to Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC Score). *PloS one* 2016;11(10):e0165757. doi: 10.1371/journal.pone.0165757
- [dataset] 30. Peter J. Zed EAF, Stacy Ackroyd-Stolarz, Nancy G. Murphy, Neil J. MacKinnon, Doug Sinclair. Medication-Related Emergency Department Visits in Pediatrics: a Prospective Observational Study. *American Academy of Pediatrics* 2015;135(3) doi: DOI: 10.1542/peds.2014-1827
- [dataset] 31. Ayalew MB, Tegegn HG, Abdela OA. Drug related hospital admissions; a systematic review of the recent literatures. *Bulletin of Emergency & Trauma* 2019;7(4):339.

- 1
2
3 [dataset] 32. Hohl CM, Nosyk B, Kuramoto L, et al. Outcomes of emergency department patients
4 presenting with adverse drug events. *Annals of emergency medicine* 2011;58(3):270-79 e4.
5 doi: 10.1016/j.annemergmed.2011.01.003
6
7 [dataset] 33. Nivya K, Sri Sai Kiran V, Ragoo N, et al. Systemic review on drug related hospital
8 admissions - A pubmed based search. *Saudi pharmaceutical journal : SPJ : the official*
9 *publication of the Saudi Pharmaceutical Society* 2015;23(1):1-8. doi:
10.1016/j.jsps.2013.05.006
11
12
13
14
15
16

17 **Figure 1:** Patient's inclusion information flow chart in emergency ward at TASH, ZMH and
18 Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)
19
20
21
22
23
24

25 **Figure 2:** Numbers of drug related problems occurrence per patient leading hospitalization in
26 emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September,
27 2020 (n= 245)
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1




Figure 2

review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Editors' and Reviewers' Comments and Authors Response

Manuscript ID: bmjopen-2021-054778

Manuscript Title: Prevalence and Its Predictors of Drug-Related Hospitalizations among Patients Visited Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

We sincerely thank the reviewers for their significant comments and constructive suggestions which contributed to the quality of the manuscript. We have revised the manuscript as advised and changes made are highlighted in yellow at manuscript. Point-by-point response for the editor(s)' reviewers' comment is given below. We hope the revision undertaken has improved the manuscript to a level of your satisfaction and we request your editorial hand.

Editor(s)' Comments to Author (if any):

Comment1: - Please revise the 'Strengths and limitations' section of your manuscript (after the abstract). This section should contain up to five short bullet points, no longer than one sentence each, that relate specifically to the methods. The results of the study should not be summarized here.

Response 1: - We have made a correction as per comments

Comment 2: - Please complete a thorough proofread of the text and correct any spelling and grammar errors that you identify.

Response 2: - Accommodated

Reviewers' Comments to Author

Reviewer: 1 Dr. Jesus Ruiz Ramos, Hospital de la Santa Creu i Sant Pau

Comment 1: - The redaction of the manuscript must be reviewed. There are multiple typographical errors in the text. The punctuation and the number of decimals used are not adequate or homogeneous.

Response 1: - We have made the correction accordingly

1
2
3 Comment 2: - The Tables are too extensive. The authors could include the information of the three
4 hospitals in a single table, it does not seem necessary to differentiate the information between the
5 different hospitals
6

7
8 Response 2: - Dear reviewer, from the beginning the three-hospital results merge and present in a
9 single table.
10

11 INTRODUCTION

12
13 Comment 3: - The authors may include the following reference in the manuscript, as it shows
14 relevant information in this field.
15

16
17 Response 3: - Dear reviewer thank you for your concern, we already used in reference 31.

18
19 Comment 4: Page 8, line 32. The sentence is incorrectly worded. It is not well understood why of
20 the 2,655 enrolled patients we only assessed 426.
21

22 Response 4: First we determined a total sample size which is 423. Then put an exclusion criterion
23 to select the patients. Here are the exclusion criteria that wrote in the text. "Patients having a
24 medical history with completed data and ≥ 14 years old were included. Patients with incomplete
25 or no medical records, refused to participate, presented with trauma and injuries associated with
26 accidents (e.g. road traffic accidents, beaten by stick, stabbing and bulleting) and
27 poisoned/intoxicated (for instance snake bite, alcohol intoxication or use of pesticide) were
28 excluded." However, until to get the expected samples size, we enrolled all patients attending to
29 the emergency department. During the study period, about 2655 were admitted to the emergency
30 ward, and of those only 423 participants were fulfilled the inclusion criteria. One thing we want to
31 inform you that we assessed all admitted patients not only 426. The reasons behind the higher
32 number of patients enrollments to get the calculated sample size was due to many exclusion criteria
33 and being in an emergency ward (high patient flow with multiple diagnoses) would be the two
34 main reasons.
35

36
37 Comment 5: The revenue figure for DRPs is certainly misleading. Many patients, mainly surgical,
38 were excluded from the study. The authors must make it clear in the abstract are during the text
39 that this is a study in medical patients (Is not a real prevalence or all patients attended in the
40 hospital). This concept should also be repeated in the discussion
41

42
43 Response 5: Dear reviewer, in our study setting almost all patients (medical case, surgical case,
44 and others) were attending to the emergency ward as a triage then if the patients were candite for
45 further admission, they went to surgical and medical wards. However, other cold cases or
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ambulated patients directly go to the various clinics for follow-up, in case some patients still there
4 will be a probability of admission to different wards. Therefore, we missed those patients who
5 came from other than an emergency ward, because of this we put a limitation on this study next to
6 an abstract section under the title of ‘Strength and limitations of the study and also in the title of
7 ‘limitation of the study.
8
9

10
11
12 Comment 6: Consider change “chemotherpautic drugs” for “chemotherapy drugs” or
13 “antineoplastic drugs” (ATC / WHO definition)
14

15 Response 6: Dear reviewer, as per the comments we put the name of ‘antineoplastic drugs’ for list
16 of anticancer drugs and ‘antimicrobial drugs’ for the lists that comprise antibiotics, antifungals,
17 antiprotozoals, and antivirals.
18

19 "Antimicrobial" is a general term that refers to a group of drugs that includes antibiotics,
20 antifungals, antiprotozoals, and antivirals.
21
22

23
24 Comment 7: Page 23, line 23. Regarding risk factors implicated in DRH admission, the approach
25 used by the authors doesn’t seem correct. The authors found differences between patients
26 hospitalized by DRPs and for other causes, buy these variables cannot be considered as risk factors.
27 In order to study risk factors, a study including patients that are not hospitalized and patients
28 hospitalized is needed. In very opinion, the authors should change the concept “risk factors” for
29 differences between patients hospitalized by DRPs or others causes.
30
31

32
33
34 Response 7: Dear reviewer, as you have seen the exclusion criteria, we recruited only patients
35 who were taking drugs upon admission to the emergency ward. Then, we evaluated the patients
36 by multi-disciplinary team whether they have drug-related problems or not. Here again, we
37 classified those patients who have DRPs that lead to DRH or not to determine the possible risk
38 factors (these risk factors putting as independent variables after reviewing various literatus that
39 cause DRH). One thing to remind you that the other causes of hospitalization without taking
40 medication upon admission were excluded from the beginning. OR
41

42
43 Moreover, Factors associated with drug-related hospitalization were determined in accordance
44 with variables that were described as independent variables and evidence that was extracted from
45 the literature. Accordingly, we identified that which factors were having a significant association
46 with hospitalization owing to drugs-related.
47
48

49
50 Comment 8: Page 23, line 28-60. The paragraph must be redrafted. It is not necessary to explain
51 what an OR means (it is known by the readers; it is enough to indicate the OR value
52
53
54
55
56
57
58
59

1
2
3 Response 8: Accommodated

4
5 Comment 9: On page 16, line 23 there is a citation not properly included. Also, unify the names
6 of the authors in the bibliography (Some names are in Capital letters)

7
8 Response 9: This paragraph comprised the findings of the present study that didn't require the
9 insertion of references. Regards to the bibliography we have made a correction.

10
11 Comment 10: Discussion: Page 35 line 42. Please, define EW

12
13 Response10: We have made the correction as per the comment. We used the word 'emergency
14 department' (ED) in the whole document for consistency

15
16 Comment 11: Conclusion: Page 35, line 55: Consider modifying the expression. "Relatively High"
17 for "Higher than in studies published in other countries." It is undoubtedly the most relevant
18 conclusion of this study

19
20 Response11 Accommodated.

21
22 Comment 12. Page 36, LINE 14-27: Consider deleting lines 14 to 26. These sentences are
23 statements that do not correspond to the results of the study.

24
25 Response12 Accommodated

26
27 **Reviewer 2: General Comments to the Author:**

28
29 Dr. Aisha Vadhariya, Eli Lilly and Company

30
31
32
33
34 Comment 1: - My first comment is about the general flow, grammar and interpretability of the
35 manuscript. I suggest revision in the writing and review of the grammar and review the content in
36 tables/ figures. There seem to be missing values in the tables.

37
38 Response 1: - We have a correction as per the comment.

39
40
41 Comment 2: - My second comment is regarding the methods. There is very little emphasis on the
42 actual content of the data collection sheet which determines the main outcome of the study i.e.
43 DRH. There should be transparency for the readers to understand the definition used to categorize
44 a certain case as a DRH vs not.

45
46 Response 2: - Accommodated.

47
48
49
50
51 Comment 3: - The results tables have some categorizations that need to be collapsed to be made
52 more meaningful. I suggest limiting the content of the tables to the one's pertinent to the study.
53 There is point-by-point discussion for each major finding however, the assumptions/extrapolations

1
2
3 from the results may not be valid/accurate. This is a point in time data collection and causality
4 should not be so easily inferred. This is a major concern I have from this study.

5
6 Response 3: - Dear review, thank you for your comment. One thing we want to inform you that
7 most of our results emanated from the data collecting tools. The data collection tools were prepared
8 after extensively revising many published articles to capture the important variables that could be
9 affected/ determined DRHs across the globe. And also, we tried to contextualize based on our
10 setting.

11
12 Reviewer 2: Specific Comments to the Authors

13
14 Comment 1: Pg. 1 line 56 (Abstract): from failure to receive drugs followed by untreated
15 indications (awkward –start a new sentence. Also (and independent of phrasing), these two
16 categories would appear to overlap a good deal (if not be exactly the same. How are they
17 different?).

18
19 Response 1: We have made a correction as follows. The cause for hospitalization for more than
20 half (130, 53%) of them was failure to receive drugs and 37.85 (94) patients were categorized as
21 untreated indications.

22
23 For further clarification, even though, the two terms it seems similar, however, they are quite
24 different, you can see the difference here is below.

25
26 Failure to receive drugs: diseases that resulted from not receiving a drug due to unavailability or
27 unaffordability drugs, patients no need to take drugs or stop taking medications upon they felt
28 better e.t.c. In failure to receive drugs, the patients have information about the drugs that are being
29 taken.

30
31 Untreated indication: medical condition needing new drug therapy, or preventive therapy is needed
32 to reduce the risk of developing a new condition, or a medical condition requires combination
33 therapy for better efficacy (STRAND, 1990). Here, patients did not know the drugs they should
34 take.

35
36 Comment 2: Pg. 4 lines 18-23: In the globe, medications use has becoming increased because of
37 the presence of large number of diseases (which are treatable by such medication use??), and thus
38 contribute

39
40 Response2: We have been accommodated in the revised version.

41
42 Comment 3: Pg. 4 line 49: Over the past decades, DRHs have been stated as prevailing (??).

1
2
3 Response 3: Dear review thank you for your comment. We have made a correction as per the
4 comments and also cited accordingly by inserted reference.
5

6 Comment 4: Pg. 4 lines 49-54:17 million emergency department (ED) visits and 8.7 hospital
7 admissions accounted from DRPs annually (probably trying to say: DRPs accounted for 17 million
8 ED visits and 8.7 hospitalizations annually).
9

10
11 Response 4: We rewrite as per the comment.
12

13 Comment 5: Pg. 5 lines 25-27:financial difficulties whilst if there was no reasonable actions
14 to prevent DRPs which is termed as non-preventable (difficult phrasing - consider starting a new
15 sentence).
16
17

18 Response 5: Accommodated
19

20 Comment 6: Pg. 6 lines 48-51: Patients played the central role in this study in determining the
21 level of medication use, adherence, and medical history (don't know what is really meant here, but
22 it is probably different from what is stated).
23
24

25 Response 6: Dear reviewer thank you for your comment. The point what we want to inform you/the
26 reader/ that during the data collection of periods, patients alone or patients with the help of their
27 family were actively participated in determining the medication use, level of adherence, and
28 medical history. For the sake of clarification, I rewrite the statement with slight modification.
29 'Patients who participated actively in this study determine the medication use, level of adherence
30 and medical history.
31
32
33
34
35

36 Comment 7: Pg. 8 lines 53-57: data abstraction formats (?) were reviewed and checked (sp!)
37 for their completeness every day to assure its quality. Urgent correction was made, if any errors
38 were identified.
39
40

41 Response 7: We modified the statement as follows. 'The data collection process was supervised,
42 and the information gathered via data abstraction formats were reviewed and checked for their
43 completeness every day to ensure its quality. An urgent correction was made, if any errors were
44 identified'
45
46
47

48 Comment 8: Pg. 16 lines 11-13:245 patients, representing 1.31 DRPs per patient, since 55
49 (22.4%) patients presented two DRPs (figure 2). (Just drop this last clause. Misleading, as only '2'
50 is mentioned when '2', '3', and '4' were observed).
51
52

53 Response 8: Accommodated
54
55
56
57
58
59
60

1
2
3 Comment 9: Pg. 18 lines 40-47:nearly one thirdwhich was stroke (26,10.6%)
4 (Run-on sentence rephrase to split into two sentences).
5

6 Response 9: We shortened the statement to accommodate reviewer 2 comment
7
8
9

10 Comment 10: Pg. 21 lines 6-8: A total of 497 drugsinvolved in DRHs. (Unusual wording,
11 including use of ‘pertained to’ and ‘entails’, change in tenses, change from passive to active verb.
12 Consider rephrasing).
13
14

15 Response 10: Accommodated
16

17 Comment 11: Inclusion/exclusion criteria (pg 7): Explain more in the text how your original group
18 of 2,655 eligible patients led to 423 study participants (as described in top of figure 1).
19

20 Response 11: First we determined a total sample size which is 423. Then put an exclusion criterion
21 to select the patients. Here are the exclusion criteria that wrote in the text. “Patients who had
22 incomplete or no medical records, patients who refused to participate, patients presented with
23 trauma and injuries associated with accidents (e.g. road traffic accidents, beaten by stick, stabbing
24 and bulleting) and who was poisoned/intoxicated (for instance snake bite, alcohol intoxication or
25 use of pesticide) were excluded”. However, until to get the expected samples size, we enrolled all
26 patients attending the emergency department. During the study period, about 2655 were admitted
27 to the emergency ward, and of those only 423 participants were fulfilled the inclusion criteria. One
28 thing we want to inform you that we assessed all admitted patients not only 426. The reasons
29 behind the higher number of patients enrollments to get the calculated sample size was due to
30 many exclusion criteria and being an emergency ward (high patient flow with multiple diagnoses)
31 would be the two main reasons.
32
33

34 During data collection periods, about 2655 patients were being admitted and assessed whether they
35 fulfilled the inclusion criteria or not. Of those, 423 participants only fulfilled the inclusion criteria.
36

37 Comment 12: Analyses (pg 9): The descriptors ‘univariate’ and ‘multiple binary logistic
38 regressions’ are not always correctly used. The models you referred to as multiple binary logistic
39 regressions are really multivariate logistic regressions. Table 1 does provide real univariates (albeit
40 overall and stratified by DPH status), but when you go on to test whether percentages are different
41 between DPH and non-DPH groups, then you are performing bivariate (two-variable) analyses.
42 Thus, your sentence should read ‘....variables whose p-values<.2 in the bivariate analyses were
43 included in the multivariate logistic regressions’. In line with this, it would make sense to indicate
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in Table 1 all the factors which were significant (or highly significant) in these binary analyses.
4 This can be done with asterisks (* for significant or ** for highly significant). Table 5 should only
5 show the AOR (95% CI) and p-values from the multivariate logistic regressions. The n (%) results
6 just repeat values in Table 1. If you really need to present CORs, they should be in Table 1 as well
7 (but asterisks for significant bivariate associations are probably sufficient).
8
9

10
11
12 Response12: We have made a correction as per the comments.

13
14 Comment 13: Analysis Variables:

15 -The logistic models should not include the length of stay variable (greater than 7 days). This
16 variable becomes known after admission, not at the start, and thus is really an outcome of DPH,
17 not a predictor.
18

19
20 -Change the descriptor 'Causes' in the table header. Cross-sectional, observational models cannot
21 demonstrate causality.
22

23
24 -relabel 'Employed' as an employment status (consider instead 'wage or salaried worker'). The
25 term
26

27 Employed could be interpreted more broadly than intended (and thus overlap with merchant, day
28 laborer, and farmer).
29

30
31 - I approve that only indicator for polypharmacy (5+) is in the regression model, but for consistency
32 (and
33

34 to be less confusing) consider using categories 0, 1, 2, 3-4, and polypharmacy for number of drugs
35 in
36

37 Table 1. Don't need 3-5, more than 5, and polypharmacy as separate indicators in this table.

38
39 Response 13: Dear reviewer, the intention is to demonstrate that patients with DRHs were 2.2
40 times more likely to stay for > 7 days after they were hospitalized than patients with non-drug
41 related hospitalization with an estimated to < 7 days of the length of hospital stay. Moreover,
42 "Length of stay" can be a predictor or outcome of DRHs. Once the patients were admitted to the
43 emergency ward and who fulfilled the inclusion criteria, we followed those patients until to
44 discharge from the hospital. At that moment some patients might be developed drug-related
45 problems rendering to DRHs or not. During follow up those admitted patients to the emergency
46 ward who fulfilled the inclusion criteria at the beginning didn't have any drug-related problems,
47 however, due to staying a longer period of time (patients might be exposed to hospital-acquired
48 infection which leads to receiving multiple medications), they develop drug-related problems that
49
50
51
52
53
54
55
56
57
58
59
60

would result in DRHs outcomes. Patients who had DRHs stayed more time in the emergency ward than patients with non-DRHs.

We have made a correction by considering using categories 0, 1, 2, 3-4 of the number of medications taken per patient. About polypharmacy, I understand your concern, however, according to standard definition for those patients who took more than or equal to five drugs considered as polypharmacy. “Yes” or “No” polypharmacy classification is useful to interpret its association with the clinical outcomes.

We have accommodated all the remaining comments in the text.

Comment 14: Shortening some Tables (pgs. 17-23): Tables 2, 3, and 4 are probably too detailed to include in the paper. Consider shortening these tables by using only the broader categories - with a note that further breakdowns are available from the author upon request. Also, Table 1 is included twice in the paper (this could be an editing issue at the journal’s end).

Response 14: Dear reviewer as per the comment, we shortened table 3. Whereas the table 2 & 4 we believed that the main objective of this research work. So, the findings presented in the broader categories in Tables 2 & 4 will have paramount importance for the readers.

Comment 15: Comparison of DRH rates (pg. 26): Some of the DRH rates from other countries (other referenced studies) are so different, that they can’t possibly be measuring the same thing. Consider comparing current results with a smaller set of previous ones, dropping those which are not nearly as comprehensive (e.g., America, Denmark, Greece, India).

Response 15: A study done in India assessed the prevalence of DRH in a similar way in the present study. On the other hand, studies conducted in America and Denmark also assessed DRPs and subsequently determine the prevalence of DRH (the methods are somehow different from our study). In effect, all of the studies determined the prevalence of DRHs in one or the another way. That way we compared the findings of this study with those lists of studies.

Response to Reviewer’s 3 comments

Page 3 line 34

Comment 1: Since the study was based of patients only in the emergency ward, did it capture patients through other channels? IF not, then the number identified cannot be true incidence

1
2
3 Response 1: Dear reviewer, this study was carried out in the emergency ward of three hospitals,
4 patients who required admission through various channels such as ambulatory and different
5 specialty clinics were sent back again to the emergency department triage before admission to
6 various wards. Therefore, in our study settings, the admission procedure is less likely for patients
7 admitted without passing the triage of emergency wards. Being a sufficient samples size and
8 multicenter study, this study can be showing us the true incidence.
9

10
11
12
13 Comment 2: Page 6 line 14, I am not sure how the information about the year they are founded has
14 relevance to the methods.
15

16
17 Response 2: We have made a correction as per the comments/ deleted the founding years/
18

19
20 Comment 3: Page 7 line 11, rigorous evaluation is a subjective term. What was extracted from the
21 literature? Need more clarity on the development of the questionnaires/tool
22

23
24 Response 3: We change the word 'rigorously' by 'carefully'. However, the statement tales about
25 the instrument I should go to the 'Data Collection' section. For your information: "A structured
26 questionnaire was developed from carefully **evaluated** published articles in the literature. For
27 instance, categories of DRPs that leads to hospitalization and factors having association with DRH
28 (e.g. socio-demographic and clinical characteristics) were extracted from literatures".
29

30
31 Comment 4: ED vs EW?
32

33
34 Response 4: We use those terms interchangeably in various guidelines/ protocols and published
35 articles. ED: Emergency department; or EW: Emergency ward. However, to make consistency
36 afterward we used the Emergency department (ED) in this manuscript.
37

38
39 Page 7 line 16
40

41
42 Comment 5: Please mention if there was any ethics approval required for the study
43

44
45 Response 5: we have made a correction as per the comment. However, the content move to the
46 'Ethical Approval' section to end of Manuscript before the "Reference section" . For your
47 information see the following paragraph.
48

49
50 Patients' names were not used rather codes to maintain the confidentiality of the information
51 throughout the study period. Verbal consent from patients was obtained after the provision of
52 information regarding the purpose of the study and its risk for the interviewee which could be time
53 to be spent during the interview (maximum of 30 minutes). Patients were told the reasons for being
54 selected to be included in the study and assured that waning participation would not have any
55 influence on the right to get treatment. Patients were also told about their rights to withdraw from
56
57
58
59

1
2
3 the study at any time. Moreover, as per BMJ open journal outline, we mentioned Ethical Approval
4 on page 38 lines 19-25. “Ethics approval prior to study initiation, letter of ethical approval (Ref
5 No; ERB/SOP/172/08/2020) was obtained from the ethical review committee, School of
6 Pharmacy, College of Health Sciences, Addis Ababa University”.

7
8
9
10 Comment 6: Page7 line 22 edit: 'who refused to participate'

11 Response 6: Accommodated

12
13 Comment 7: Page 7 line 47, why has P been selected as 0.5?

14
15 Response 7: Since there was no study done on DRHs in Ethiopia, the sample size was estimated
16 using the general formula for single population proportion and P has been taken as 0.5 to simply
17 increase the sample size.
18
19
20
21

22 Comment 8: Page 7 line 52, can the authors please clarify more what this 10% contingency is for?

23
24 Response 8: It is significant to compensate participants who were refusing to participate and
25 thereby sufficient sample size was found.
26
27
28

29 Comment 9: Page 8 line 10, is this one pharmacist per hospital?

30
31 Response 9: Yes, all three pharmacists were independently collecting the data from respective
32 hospitals, but they have been discussing and deciding together on hospitalization attributed to
33 drugs-related problems. This is paramount to minimize self-selection bias.
34
35
36
37

38 Comment 9: Page 8 line 18, were there missing values? Were any imputation techniques used?

39
40 Response 9: As it is expressed under inclusion and exclusion criteria, patients who had incomplete
41 or no medical records were excluded because of their missing values.
42
43
44

45 Comment 10: Page 8 line 19. More information about the questionnaire should be added and the
46 variables that were collected to provide transparency to the readers about how was a determination
47 made whether a hospitalization was drug-related.
48

49 The definitions from literature are mentioned in the background, but the definition that was used
50 for this particular study should be provided.
51
52
53
54
55
56
57
58
59
60

1
2
3 Response 10: Data were collected by three pharmacists having Master of Science degrees in
4 Clinical Pharmacy. They had basic knowledge and skill in pharmaceutical care services and also
5 received training on how to obtain data from patients' medication charts and approach the patients
6 and health care professionals. Updated Ethiopian Standard Treatment Guidelines for Hospitals,
7 third edition, 2014, Ethiopian Antiretroviral Therapy and Tuberculosis Guidelines, Cancer
8 Treatment Protocols prepared by TASH Oncologists, Pharmacotherapy textbooks, Medscape,
9 UpToDate were used as a guide for diseases management, and also Micromedex online database
10 was used to check the drug interaction. Furthermore, updated guidelines released from American
11 Cardiology Center, American Heart Association, European Cardiology Society, American
12 Diabetic Association were used as a guide to treat different diseases. Clinical pharmacists along
13 with physicians were determined subtherapeutic and supratherapeutic dosage outcomes using the
14 medical charts, laboratory tests, clinical outcomes, medication dose, and frequency. Participants
15 hospitalized attributed to failure to receive drugs were decided via using physician's recording
16 documentation, clinical pharmacists' knowledge, and patients reporting evidence. And also,
17 untreated indications and improper drug selection were being evaluated and interpreted by using
18 treatment guidelines. For instance, if patients presented with cardiac diseases which were untreated
19 or improperly treated identified using the American Heart Association guidelines, and UpToDate
20 latest version. To minimize bias, the three pharmacists at each hospital were evaluated
21 independently following the identified DRPs rendered hospitalizations. Consequently, they were
22 meeting and discussing their judgment to DRPs resulting DRHs. Accordingly, DRPs rendering
23 DRHs were determined after they have been reaching on concord. Moreover, Physicians and
24 residents were involved in interpreting DRPs causing hospitalizations. Once DRPs resulting DRHs
25 were identified, they were recorded and classified using DRPs registration format according to
26 Helper's and Strand's classification.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Comment 11: Page 9 line14. Is there a need for univariate logistic regression? The results are going
47 to be unadjusted for confounders anyway with this technique.

48 Response 11: Yes, I agreed on it. Certainly; univariate logistic regression does not limit/control
49 confounders. However, in this study, we tried to control the confounding factors by doing further
50 analysis using multiple logistic regression.
51
52
53
54

55 Comment 12: Need to explain what variables were adjusted for in multiple binary regressions
56
57
58
59
60

1
2
3 Response 12: As it is already mentioned, Variables with P-values < 0.2 in the binary logistic
4 regression analysis were included in the multiple binary logistic regressions to control the effect
5 of confounders.
6
7

8 We put asterisks for those variables having significant bivariate associations in Table 1. For further
9 information see the below paragraph.
10

11 Univariate analysis showed that age, educational level, marital status, employment, number of
12 medications taken, presence of co-morbid diseases and length of hospital stay have been revealed
13 p-value which was less than 0.2 and they were incorporated for multivariate binary logistic
14 regressions. According to the multivariate analysis, five variables were significantly associated
15 with the occurrence of DRHs. Those statistically significant correlations with the occurrence of
16 DRHs were found in age, employment, presence of co-morbid diseases, length of hospital stay and
17 education level.
18
19
20
21
22
23

24
25
26 Comment 12: Suggest the use of chi-square tests and t-tests to capture differences in baseline
27 demographic and clinical characteristics between these two groups.
28

29 Response 12: We have done by using chi square tests and t-tests.
30

31 Comment 13: Page 9 line 54 and 57. Is the age missing here?
32

33 Response 13: Accommodated
34

35 Comment 14: Page 10 line 46. Suggest breaking employment into 2-3 meaningful groups. Collapse
36 these categories into small groups.
37

38 Response 14: We have done as per the comment.
39

40 Comment 15: Page 14 line 13. Typo
41

42 Response 15: Accommodated
43

44 Comment 16: Page 14 line 24. Would recommend collapsing the two physical activity variables
45 into one category- any physical activity vs not
46

47 Response 16: We have made a correction as per the comments.
48

49 Comment 17: Page 14 line 41. Some of these variables are confusing and should be explained
50 better in the methods section. The methods section does not have sufficient information about the
51 questionnaire. What does other drugs indicate?
52

53 Response 17: We rewrite the statement; other drugs indicate that traditional home remedies
54 (herbals) were being used.
55
56
57
58
59
60

1
2
3 Comment 18: Is there some missing information in these tables?
4

5 Response18: No missing information. This is similar to what is corrected in comment 13.

6 The number of medications taken per patient serves as an umbrella for both continuous and
7
8 categorical variables.
9

10 Comment 19: Page 15 line 31. Missing information here as well

11 Response 19: We deleted the content due to Reviewer 1 raised concerns about its importance

12 Comment 20: Page 16 line 23. Referencing error

13 Response 20: This wasn't a reference error, by default computer-related typographic error. We
14 wrote the word 'Table 2' instead of inserting the reference.
15

16 Comment 21: Page 16 line 38. Untreated indication would mean that a condition exists that
17 receives no therapy at all. Improper management i.e. need of a potentiating drug may not fall into
18 lack of treatment
19

20 Response 21:Untreated indication includes medical condition needing new drug therapy, or
21 preventive therapy is needed to reduce the risk of developing a condition, or a medical condition
22 requires combination therapy for better efficacy (STRAND, 1990).
23

24 Comment 22: Page 18 line 10 Does this categorization refer to patients not using drugs as
25 instructed i.e. adherence and compliance issues?
26

27 Response 22: Failure to receive drugs encompasses not only using drugs as directed. And also
28 diseases that resulted from not receiving a drug for unavailability or unaffordability of drugs. For
29 more, you can see causes of failure to receive drugs with their respective proportions as you
30 mentioned in comment 22.
31

32 Comment 23: Page 19 line 10. Can you indicate in the table or text that the DRH was related to
33 this particular disease. E.g. lack of treatment with hypertensives of hypertension was the reason
34 for the hospitalization? This part is not clear in the manuscript
35

36 Response 23: Dear reviewer, in addition to your comment, Reviewer 2 also raised concern about
37 the size of the Tables. So, we made a correction by congesting Table 2 in short form by listing
38 only the 'major classification of drugs'.
39

40 Comment 24: Page 24 line 24. It is incorrect to list these as causes of hospitalization - these as
41 mentioned above are merely predictors. This study is not determined to establish causality
42

43 Response 24: We have made a correction as per the comments.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Comment 25: Page 25 line 27. Same comment as above to collapse employment and education
4 categories
5

6 Response 25: Accommodated.
7

8 Comment 26: This statement is confusing. The proportion of females in the DRH and non-DRH
9 group is very similar. What is the basis of this?
10

11 Response 26: Among the total of 216 included female patients, 126 of them were hospitalized due
12 to drugs-related as it is specified in Table 1 .in percent it comprises 51.4%.
13

14 Comment 27; Page 31 line 37. Examples are helpful
15

16 Response 27: Dear reviewer, we already included the example next to this statement.
17

18 Comment 28: Page 34 line 5&7. This finding surprises me because students tend to be younger in
19 age and CV diseases increase with increasing age.
20

21 Response 28: Even though it is known that as age increased cardiovascular diseases prevalence is
22 also increased, individuals in younger age may encounter significant cardiovascular diseases
23 attributed to rheumatic heart disease/ valvular heart diseases. As we know the rheumatic heart
24 disease mainly affected the younger age group of the population and is common in developing
25 nations like in Ethiopia. In sub-Saharan Africa, studies from multiple countries report that
26 approximately 0.5–3% of school-age children have echocardiographic signs of definite or
27 borderline disease according to World Heart Federation (WHF) criteria.
28

29 Comment 29: Was a subgroup analysis performed in the student group to make this statement?
30

31 Response 29: Yes, it was performed. Of the total of 16 students, 9 (56.3%) of them had heart failure
32 owing to valvular heart diseases.
33

34 Comment 30: Page 34-line 42. The outcome of the model is DRH - so the assumption is the reason
35 for H was drug-related. This says patients developed DRH after staying in the hospital which does
36 not align conceptually.
37

38 Response 30: Dear reviewer, the intention is to demonstrate that patients with DRHs were 2.2
39 times more likely to stay for > 7 days after they were hospitalized than patients with non-drug
40 related hospitalization with an estimated to < 7 days of the length of hospital stay.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Prevalence and Predictors of Drug-Related Hospitalizations among Patients Visiting Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054778.R2
Article Type:	Original research
Date Submitted by the Author:	27-Dec-2021
Complete List of Authors:	Demessie, Mulate ; Addis Ababa University Berha, Alemseged; Addis Ababa University, Pharmacology and Clinical Pharmacy
Primary Subject Heading:	Emergency medicine
Secondary Subject Heading:	Patient-centred medicine, Pharmacology and therapeutics, Health services research
Keywords:	Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Prevalence and Predictors of Drug-Related Hospitalizations among Patients Visiting Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

Mulate Belete Demessie¹, Alemseged Beyene Berha^{1*}

*Corresponding author: alembeyene98@gmail.com

ABSTRACT

Objectives: This study aimed to determine the prevalence, categories, and predictors of drug-related hospitalizations (DRHs) among patients visiting emergency departments of Addis Ababa city hospitals, Ethiopia.

Design: A multicenter prospective observational study was conducted through patients interview and chart review.

Settings: The study was undertaken in three tertiary care hospitals, Addis Ababa, Ethiopia.

Participants: A total of 423 patients fulfilling the inclusion criteria were included.

Outcome measures: Prevalence and preventability of DRHs, categories of drug-related problems causing DRHs, medications, and diseases involved in DRHs, and factors significantly associated with DRHs.

Result: More than half of the patients (216, 51.1%) were females. The mean age (SD) was 47.50 (± 17.21) years. The mean length of hospital stay (SD) was 10.29 (± 8.99) days. Nearly, 60% (249) of them were hospitalized due to drug-related problems, of which 87.8% were preventable. The cause for hospitalization for more than half (130, 53%) of them was a failure to receive drugs, and 37.85 (94) patients were categorized as untreated indications. Age ≥ 65 years (Adjusted Odds Ratio [AOR]=7.451, 95%CI: 1.889-29.397), tertiary educational level (AOR=0.360, 95%CI: 0.141-

0.923), participants who did not have any occupation (AOR=3.409, 95%CI: 1.120-10.374) and presence of co-morbid conditions (AOR=2.004, 95%CI: 1.095-3.668) were predictors of DRHs.

Conclusion: Nearly 90% of DRHs were deemed to be preventable in the study settings. Older age, lower educational level, unemployment, and presence of the co-morbid condition in hospital as an inpatient were predictors of DRHs.

Strength and limitations of the study

- The strength of this study is the study design which is a prospective observational study.
- This is a multicenter study with sufficient sample size, increasing representativeness the findings.
- The main limitation of this study is lack of standardized procedures for immediate recording and reporting of DRHs.
- Patients who visited other than the emergency ward were excluded from participation can also be considered as a limitation of the study.

INTRODUCTION

Though drugs can be ordered for the intention of achieving desired health outcomes that improve patients quality of life, symptoms and signs of diseases causing drug related hospitalizations (DRHs) as a result of drug related problems (DRPs) could be apparent.¹⁻³ DRP is defined according to Helper and strand as ‘an undesired event or circumstance due to drug therapy that actually or potentially interferes with desired health outcomes’.⁴

Medication’s use has been increasing across the globe due to the presence of large number of treatable diseases and this has contributed to production of more advanced medications by the pharmaceutical industries. Therefore, advances in drug therapies could lead to an apparent increase in the incidence of DRPs, which in turn lead to hospitalization⁵. Hospitalization can be defined as drug related if it is straightforwardly linked to one of the eight predefined Helper’s and Strand’s classifications of DRPs: adverse drug reaction (ADR), drug interaction, improper drug selection, untreated indication, sub-therapeutic dosage, supra-therapeutic dosage, failure to receive drugs, and drug use without indication.⁶⁻¹² Those DRPs can arise when a medicine is prescribed aptly and used correctly (e.g., ADR), due to errors involving prescribing (including inappropriate or over-treatment, and failure to prescribe the indicated treatment or under-treatment), dispensing, administering, reconciling, or monitoring of medicines as well as from poor patient adherence.^{2 13}

¹⁴ According to the World Health Organization (WHO), an ADR is any harmful, undesired and inadvertent drug effect that occurs at doses used in human for therapy, diagnosis or prophylaxis.¹⁵

Over the past decades, DRHs have been considered as wide spreading¹⁶. In the United States, DRPs accounted for 17 million emergency department (ED) visits and 8.7 hospitalizations annually.¹⁷ It increases morbidity and mortality rates, health care cost, decreases income and household productivity and reduced quality of life.^{2 18 19}

1
2
3 Studies carried out in different areas of the globe estimated the extent of DRHs to be between 16%
4 to 41.3%. Of these, 50% to 95% were preventable. Supratherapeutic dosage (10.3%-12.7%), non-
5 compliance (10.6%-65.8%), ADRs (10.7%-45.5%) and untreated indications (10.7-13.3%) were
6 frequently identified as the causes of DRHs.^{6 9 18 20-22}

7
8
9
10
11
12
13 DRPs resulting DRHs were defined as preventable if the patient failed to take a drug that is known
14 to reduce or prevent symptoms according to the prescribed directions, took a drug for which a
15 patient had a known allergy, drug treatment was obviously improper, dosage differed from
16 accepted recommendations, took a drug that was not indicated, and if there was a failure to monitor
17 by a physician at reasonable time intervals due to financial difficulty. If there was, however, no
18 reasonable actions to prevent DRPs, it is then termed as non-preventable.^{20 23}

19
20
21
22
23
24
25
26
27
28 In many studies, patients with DRHs had mainly cardiovascular diseases and diabetes, suggesting
29 that cardiovascular and hypoglycemic medications were involved in DRHs.^{6 10 11 18 20 21 24 25}

30
31
32
33 Previous studies also identified polypharmacy, advanced age and comorbid conditions as factors
34 that favor the occurrence of DRHs.^{3 6 20 21}

35
36
37
38
39 It is thus important to determine DRHs prevalence to improve treatment outcomes and prevent
40 unnecessary admissions. To the best of our knowledge, there are no studies conducted about DRHs
41 in Ethiopia. The present study therefore aimed to determine the prevalence, categories and
42 predictors of DRHs among patients admitted to an ED of three selected hospitals in Addis Ababa,
43 the capital of Ethiopia.

METHODS

Study Settings

The study was carried out in the ED of Tikur Anbessa Specialized Hospital (TASH), Zewditu Memorial Hospital (ZMH), and Yekatit 12 Hospital Medical College (Y12HMC), Addis Ababa, Ethiopia. TASH has 700 beds and it is a tertiary care teaching hospital affiliated with Addis Ababa University. In TASH, outpatient, inpatient, and emergency services are delivered. The ED provides services for about 13,920 patients per year. Y12HMC is also a tertiary care level referral and teaching hospital that provides both inpatient and outpatient treatment for a large number of people coming from Addis Ababa as well as other places of the country. The hospital has a total of three ED rooms. The adult medical ED is collocated with adult surgical ED. It serves around 10,560 patients per year. The third hospital is ZMH, which is one of the teaching and general referral hospitals in Ethiopia and the ED serves about 10,560 patients per year.

Patient involvement

Patients did not participate in the initial conception and design of the study. However, based on the participating patients' comments during the pretest (5% of the sample size), we made a correction on the patient approach and timing for an interview at ED during data collection. Patients who participated actively in this study determined the medication use, level of adherence, and medical history.

Study design and population

A prospective observational study design was used to collect data from August to September, 2020. All patients admitted to the ED of the three selected hospitals during the study period and fulfilled the inclusion criteria were included.

Inclusion and exclusion criteria

Patients having a medical history with completed data and ≥ 14 years old were included. Patients with incomplete or no medical records, refused to participate, presented with trauma and injuries associated with accidents (e.g. road traffic accidents, beaten by stick, stabbing and bulleting) and poisoned/intoxicated (for instance snake bite, alcohol intoxication or use of pesticide) were excluded. During data collection periods, about 2655 patients were being admitted to the ED, out of which 423 participants fulfilled the inclusion criteria

Sample size determination and techniques

Since there was no study done on DRHs in Ethiopia, the sample size was estimated using the general formula for single population proportion.

$$n = [(Z \alpha/2)^2 \times p (1-p)] \div d^2 = [(1.96)^2 \times 0.5 \times 0.5] \div 0.05^2 = 384$$

(Hence; n = required sample size, $Z_{\alpha/2}$ = critical value for normal distribution at 95% confidence interval, which equals 1.96 (Z value at $\alpha = 0.05$), P = Proportion of DRH = 0.5, d = margin of error of 5% = 0.05. The calculated sample size using this formula was 384. Adding 10% contingency (for non-response rate) to compensate participants who could refuse to participate, brought the final sample size to 423. The sample size was distributed to the three hospitals based on the patient load of hospital's ED per annum as mentioned in the Study settings. Accordingly, 169 participants were included from TASH, 127 participants from ZMH and 127 participants from Y12MHC.

Data collection procedures

A structured questionnaire was developed from carefully evaluated published articles in the literature. For instance, categories of DRPs that leads to hospitalization and factors having association with DRH (e.g. socio-demographic and clinical characteristics) were extracted from

1
2
3 literatures. All the necessary data including patients' demographic details (age, sex, marital status,
4 education level, employment), and clinical information like the number of medications being taken
5 prior to admission were collected and documented using a data collection tools through
6 interviewing the patients/family members. Furthermore, patient's medical records were reviewed
7 by data collectors to obtain clinical information (disease history, allergic status, admission
8 diagnosis, length of hospital stay during admission, number of medications being taken prior to
9 admission, data on laboratory investigations). Supplementary information and clarifications on
10 some patient's medical information were obtained through discussion with the treating physicians
11 and residents. By applying those data gathering approach, different categories of DRPs resulting
12 hospitalization with their possible causes were determined.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 Data were collected by three pharmacists having Master of Science degrees in Clinical Pharmacy.
29 They had basic knowledge and skill in pharmaceutical care services and also received training on
30 how to obtain data from patients' medication charts and approach the patients and health care
31 professionals. Updated Ethiopian Standard Treatment Guidelines for Hospitals, third edition,
32 2014, Ethiopian Antiretroviral Therapy and Tuberculosis Guidelines, Cancer Treatment Protocols
33 prepared by TASH Oncologists, Pharmacotherapy textbooks, Medscape, UpToDate were used as
34 a guide for diseases management. Micromedex online database was used to check drug
35 interactions. Furthermore, updated guidelines released from American Cardiology Center,
36 American Heart Association, European Cardiology Society, American Diabetic Association were
37 used as a guide to treat different diseases. Clinical pharmacists along with physicians determined
38 subtherapeutic and suprathereapeutic dosage outcomes using medical charts, laboratory tests,
39 clinical outcomes, medication dose and frequency. Participant's hospitalization attributed to
40 failure to receive drugs was decided using physician's recording documentation, clinical
41 pharmacists' knowledge and patients reporting evidence. Untreated indications and improper drug
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 selection were evaluated and interpreted using treatment guidelines. For instance, if patients
4 presented with untreated or improperly treated cardiac diseases, treatment was initiated and
5 optimized using the American Heart Association guidelines, and UpToDate latest version. To
6 minimize bias, the three pharmacists at each hospital independently evaluated the identified DRPs
7 resulted hospitalizations. Decision was then reached by reaching consensus after a series of
8 meetings and discussions as well consultations with physicians and residents. Once DRPs resulting
9 DRHs were identified, they were recorded and classified using DRPs registration format according
10 to Helper's and Strand's classification.
11
12
13
14
15
16
17
18
19
20
21

22 **Data collection management**

23
24 Pretest was performed on 5% patients in TASH prior to the actual data collection period and
25 amendment was made accordingly. The data collection process was supervised, and the
26 information gathered via data abstraction formats were reviewed and checked for their
27 completeness every day to ensure quality. Urgent correction was made, if any errors were
28 identified.
29
30
31
32
33
34
35
36

37 **Data analysis**

38
39 The data were entered and analyzed using Statistical Package for Social Sciences (SPSS) version
40 26. Mean and standard deviation for continuous variables and frequency and percentage for
41 categorical variables were computed by using descriptive statistics in SPSS to summarize socio-
42 demographic and relevant clinical characteristics of the study participants. Tables and charts were
43 used to present the results. Furthermore, univariate and multiple binary logistic regressions were
44 performed to analyze factors that predict DRHs. Variables with p-values < 0.2 in the binary
45 univariate analysis were included in the multiple binary logistic regressions to control the effect of
46 confounders. The level of significance was set at p-value ≤ 0.05 and results were reported as odds
47 ratios (OR) with 95% confidence intervals.
48
49
50
51
52
53
54
55
56
57
58
59

RESULTS

Socio-demographic and clinical characteristics

From 2655 participants enrolled in the study, a total of 423 study participants were included for analysis. Of them, 169 participants from TASH, 127 from ZMH and another 127 from Y12HMC were included (*Figure 1*).

Socio-demographic and clinical characteristics of the participants is depicted in Table 1. More than half of the participants (216, 51.1%) were females. The mean (SD) age of the participants was 47.5 (± 17.21) years and nearly two third (275, 65%) were ≥ 40 years of age. More than 70 % (301, 71.1%) of the total participants' level of education was below secondary school. Nearly three-quarter of them (304, 71.9%) resided in Addis Ababa city. Out of the total study participants, 58% (245) of them were taking ≥ 3 and 30% (127) \geq five drugs prior to admission, which is termed as polypharmacy. Above half of the participants (213, 50.4%) had co-morbid diseases, including hypertension (108, 22.5%), cardiac diseases (59, 13.5%) and diabetes mellitus (53, 12.5%). The mean (SD) length of hospital stay was 10.28 ± 8.99 days and ranges from 2 to 96 days.

Table 1: Socio-demographic and clinical characteristics of the participants in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)

Variables	¹ DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Gender			
Male	119(48.6)	88(49.4)	207(48.9)
Female	126(51.4)	90(50.6)	216(51.1)
Age* (in years)			
Mean± SD	48.23±17.85	46.5±16.3	47.5±17.2
14 - 24	24(9.8)	14(7.9)	38(8.98)
25- 39	51(20.8)	59(33.1)	110(26)
40 - 64	100(40.8)	74(41.6)	174(41.1)
>64	70(28.6)	31(17.4)	101(23.9)
Marital status*			
Single	64(26.1)	34(19.1)	98(23.2)
Married	129(48.6)	105(59)	234(55.3)
widowed	20(8.2)	9(5.1)	29(6.7)
Divorced	42(17.1)	31(16.9)	73(17.3)
Education level*			
No formal education	116(47.3)	72(40.4)	188(44.4)
Elementary	66(26.9)	47(26.4)	113(26.7)
Secondary	31(12.7)	35(19.7)	66(15.6)
Tertiary	32(13.1)	24(13.5)	56(13.2)
Residence			
Addis Ababa	177(72.2)	127(71.3)	304(71.9)
Out of Addis Ababa	68(27.8)	51(28.7)	119(28.1)
Religion			
Orthodox	186(76)	136(76)	322(76.1)
Muslim	42(17.1)	31(17.4)	73(17.3)
Catholic	1(0.4)	1(0.6)	2(0.5)
Protestant	16(6.5)	10(6)	26(6.1)

DRHs, drug related hospitalizations; non-DRHs, non-drug related hospitalizations; SD, standard deviation;

* Represent variables having significant bivariate associations.

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Employment status*			
Salaried worker	111(45.3)	83(46.6)	194(45.9)
Unemployed	87(35.5)	74(41.6)	161(38.1)
Student	18(7.3)	7(3.9)	25(5.9)
Other ²	29(11.8)	14(7.9)	43(10.2)
Social habit (smoking cigarette)			
Yes	29(11.8)	15(8.4)	44(10.4)
No	216(88.2)	163(91.6)	379(89.6)
Social habit (drinking alcohol)			
Yes	71(29)	57(32)	128(30.3)
No	174(71)	121(68)	295(69.7)
Any physical activity			
Yes	170(69.4)	132(74.1)	302(71.4)
No	70(30.6)	46(25.9)	106(28.6)

² Others: participants who did not have any occupation rather they were lived as dependent with other people. DRH, drug related hospitalization; Non-DRH, Non-drug related hospitalization; n, number; SD, standard deviation

Table 1 Continued

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Home remedies (herbals)			
Yes	3(1.2)	0(0)	3(0.7)
No	242(98.8)	178(100)	420(99.3)
Number of medications taken per patient *			
Mean± SD	3.4±2.4	3.2±2.1	3.3±2.3
0	24(9.8)	12(6.7)	36(8.5)
1	41(16.7)	26(14.6)	67(15.8)
2	35(14.3)	40(22.5)	75(17.7)
3-4	61(24.9)	57(32)	118(27.9)
≥5	84(34.3)	43(24.2)	127(30)
Polypharmacy			
Yes	84(34.3)	43(24.2)	127(30)
No	161(65.7)	135(75.8)	296(70)
Co morbid condition*			
Yes	137(55.9)	76(42.7)	213(50.4)
No	108(44.1)	102(57.3)	210(49.6)
Co morbid condition (Hypertension)			
Yes	68(27.8)	40(22.5)	108(25.5)
Co morbid condition (Diabetes mellitus)			
Yes	31(12.7)	22(12.4)	53(12.5)
Co morbid condition (Cardiac diseases)			
Yes	38(15.5)	21(11.8)	59(13.9)

* Represent variables having significant bivariate associations.

Prevalence and categories of drug related hospitalizations

From a total of 423 enrolled patients, DRHs were identified in 245 (57.9%) participants, of which 87.8% were deemed preventable. A total of 322 DRPs rendering DRHs were observed in 245 participants, representing 1.31 DRPs per patient (**Figure 2**). Out of 245 drug related hospitalized patients, more than half (130, 53%) of them were due to failure to receive drugs followed by untreated indication (94, 37.8%) and sub-therapeutic dosage (30, 12.2%). The main reasons for failure to receive drugs included patients preferred not to take the medication (43, 33.1%); feared adverse events (18, 13.8%); and drug products were not available (17, 13.1%)**Error! Reference source not found.**

Table 2: Categories of drugs related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Untreated indications	Untreated medical condition is existed	34(36.2)
	Synergistic/ potentiating drug needed	42(44.7)
	Preventive/ prophylactic drug needed	18(19%)
	Improper Drug Selection	16(6.5)
Improper Drug Selection	More effective alternative drug is available	6(37.5)
	Condition is already refractory to drug	2(12.5)
	The drug is not effective for condition	6(37.5)
	Others ⁴	2(12.5)

⁴ Others; patients who were using expired drugs like insulin and albuterol.

Table 2Continued.....

Error! Reference source not found. Continued.....

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Sub therapeutic Dosage		30(12.2)
	Wrong dose (too small) of the drug	24(80)
	Frequency is inappropriate (long)	5(16.7)
	Duration of drug use is too short	1(3.3)
Supra therapeutic Dosage		13(5.3)
	Wrong dose (too high) of the drug	11(84.6)
	Frequency is inappropriate (short)	2(15.4)
Adverse drug reaction		38(15.5)
	Undesired effect from the drug is found	34(89.5)
	Unsafe drug for patient is existed	1(2.6)
	Dosage is administered too rapidly	1(2.6)
	Allergic reactions is found/reported	2(5.3)
Drug Interactions		1(0.4)
	There is (are) major drug interaction	1(100)

⁵Others; patients who were using expired drugs like insulin and albuterol.

Table 2 Continued....

Error! Reference source not found. Continued.....

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Failure to receive drugs.		130(53.5)
	Does not understand instructions	6(4.6)
	Patients prefer not to take	43(33.1)
	Patients forget to take	3(2.3)
	Drug product not available	17(13.1)
	Cost of medication too expensive	16(12.3)
	Disbelieves on the drug effectiveness	1(0.8)
	Patients felt better	17(13.1)
	Patients felt worse	1(0.8)
	Fear of adverse events	18(13.8)
	Failure to follow-up due to Covid-19	8(6.2)

Total number of DRPs leading DRHs	322
Total number of participants with DRHs	245
Average number DRPs per patients with DRHs	1.31
Preventability of DRHs	215(87.8)

Medications and diseases involved in drug related hospitalizations

Out of a total of 245 drug related hospitalized patients, nearly one -third of them had cardiovascular diseases (80, 32.6%) followed by endocrine disorders (47, 19.2%) and cerebrovascular disease (26, 10.6%).

Table 3: Diseases that associated with drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Diseasecategories	n(%)
Cardiovascular diseases	80 (32.6%)
CNS diseases	8 (3.2%)
Cerebrovascular disease	26(10.6%)
Infectious diseases	21 (8.5%)
Endocrine system diseases	47 (19.2%)
Diseases of cancer	25 (10.1%)
Diseases of the respiratory system	21 (8.5%)
GI diseases	10 (4%)
Others*	7 (2.8%)

*Includes anemia, chronic kidney disease, systemic lupus erythematosus and hemophilia

Medication classes and specific drugs implicated in DRHs are depicted in Table 4.

A total of 497 drugs were implicated in 245 drug-related hospitalized patients, providing an encounter of 2.03 drugs per drug-related hospitalized patient. Cardiovascular, antimicrobial, antineoplastic and endocrine drug classes were the most frequently involved drugs in the hospital admissions. Among cardiovascular drugs; furosemide (59,24.1%), angiotensin converting enzyme inhibitors (ACEIs) (48,19.1%), and antiplatelets & anticoagulants (44,18%) were the most frequently mentioned followed by drugs acting on the endocrine system like oral hypoglycemic

agents (37, 15.1%) and insulin (24, 9.8%). Antibiotics (25, 10%), anticancer drugs (23, 9%), and combination antiretroviral therapy (15, 6.1%) had also contributed to admission to varied extent.

Table 4: Medication classes and specific drugs implicated in drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Drugs class	Specific drugs	n (%)
Cardiovascular drugs		
	Atorvastatin	31(12.7)
	Antiplatelets(aspirin,clopidogril)	24(9.8)
	Furosemide	59(24.1)
	Spironolactone	33(13.5)
	Anticoagulants (Warfarin, heparin)	20(8.2)
	Beta blockers (metoprolol,atenolol)	21(8.6)
	Digoxin	15(6.1)
	Angiotensin converting enzyme inhibitors (enalapril/lisinopril)	48(19.6)
	Calcium channel blockers (nifedipine, amlodipine)	34(13.9)
	Hydrochlorothiazide	11(4.5)

Table 4Continued.....

Table 4 continued.....

Drugs class	Specific drugs	n (%)
Drugs act on the respiratory system		
	Long-acting beta blockers	15(6.1)
	bronchodilator	10(4.1)
Central nervous system drugs		
	Antiepileptics	5(2)

	antipsychotic	5(2)
	Amitriptylin	2(0.8)
Antimicrobial drugs		
	Antibiotics (piperacillin/tazobactam, meropenem, amoxicillin, amoxicillin /clavunicacid ,ceftriaxone, benzathine penicillin)	25(10.2)
	Combination antiretroviral therapy	15(6.1)
	Anti-tuberculosis	13(5.3)
Antineoplastic agents		
Immuno-suppressants	Cyclophosphamide, imatinib, methotrexate, doxorubicin	23(9.4)
	Mycophenolate	1(.4)
	corticosteroids (prednisolone, budesonide)	9(3.7)
Endocrine drugs		
	Oral hypoglycemic drugs (metformin, glibenclamide)	37(15.1)
	Insulin	24(9.8)
	Propylthiouracil	4(1.6)
Gastrointestinal drug	Proton pump inhibitors	7(2.9)
Others	Potassium chloride	1(0.4)
	Non-steroidal anti-inflammatory drugs	3(1.2)
	Opioid	1(0.4)

Table 4 Continued

Drugs class	Specific drugs	n (%)
Others		
	Ferrous sulphate	1(0.4)
Total number of medications involved in DRHs		497
Total number of participants with DRHs		245(57.9)
Average number medications per patients with DRHs		2.03

Factors associated with the occurrence of drug related hospitalizations

According to the multivariate logistic regression analysis the variables age, employment, presence of co morbid diseases and education level were significantly associated with the occurrence of DRHs (See in Table5). Age > 64 years (Adjusted Odds Ratio [AOR] = 7.451, 95%CI: 1.889-29.397), tertiary educational level (AOR=0.360, 95%CI: 0.141-0.923), participants who did not have any occupation (AOR=3.409, 95%CI: 1.120-10.374), students (AOR=6.331,95%CI:1.375-29.153) and presence of co-morbid diseases (AOR=2.004,95%CI: 1.095-3.668) were predictors of DRHs.

Table 5: Predictors that involved in drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Variables	Predictors of Patients hospitalization			Odds Ratios	
	³ DRH(245) n (%)	Non- DRH(178) n (%)	Total(423) n (%)	AOR(95% CI)	P- value
Age (Years)					
Mean±SD	48.24±17.86		47.50±17.21		
14 - 24	24(9.8)	14(7.9)	38(8.98)	1.000	
25- 39	51(20.8)	59(33.1)	110(26)	1.55(0.51-4.66)	0.435
40 - 64	100(40.8)	74(41.6)	174(41.1)	2.567(0.82-8.06)	0.106
>64	70(28.6)	31(17.4)	101(23.9)	7.45(1.89-29.40)	0.004
Marital status					
Single	64(26.1)	34(19.1)	98(23.2)	1.00	
Married	129(48.6)	105(59)	234(55.3)	0.60(0.29-1.23)	0.160
Widowed	20(8.2)	9(5.1)	29(6.7)	0.49(0.20-1.18)	0.109
Divorced	42(17.1)	31(16.9)	73(17.3)	0.35(0.19-0.75)	0.983
Education level					
No formal education	116(47.3)	72(40.4)	188(44.4)	1.00	
Elementary	66(26.9)	47(26.4)	113(26.7)	0.57(0.23-1.43)	0.229
Secondary	31(12.7)	35(19.7)	66(15.6)	0.57(0.23-1.39)	0.215
Tertiary	32(13.1)	24(13.5)	56(13.2)	0.36(0.14-0.92)	0.033

¹⁰DRH, drug related hospitalization; non-DRH, non-drug related hospitalization; AOR, adjusted odds ratio; CI, confidence interval

Table 5 Continued

Variables	Predictors of Patients hospitalization			Odds Ratios	
	DRH(245) n (%)	Non-DRH(178) n (%)	Total(423) n (%)	AOR(95% CI)	P-value
Employment status					
Salaried worker	111(45.3)	83(46.6)	194(45.9)	1.00	
Unemployed	87(35.5)	74(41.6)	161(38.1)	0.29(0.09-0.89)	1.000
Student	18(7.3)	7(3.9)	25(5.9)	6.33(1.38-29.15)	0.018
Others*	29(11.8)	14(7.9)	43(10.2)	3.41(1.12-10.37)	0.031
Polypharmacy					
Yes	84(34.3)	43(24.2)	127(30)	1.48(0.72-3.04)	0.284
No	161(65.7)	135(75.8)	296(70)	1.00	
Co morbid condition					
Yes	137(55.9)	76(42.7)	213(50.4)	2.00(1.09-3.67)	0.024
No	108(44.1)	102(57.3)	210(49.6)	1.00	

*Others: participants who did not have any occupation

DISCUSSION

The aim of optimizing pharmacotherapy is to achieve the desired therapeutic outcomes in the absence of morbidity and mortality associated with a drug. To the best of our knowledge, this study is the first to explore the prevalence, categories and rate of preventability of DRHs in the ED of three selected hospitals that are responsible for the provision of medical and surgical care to patients in need of immediate care.

The occurrence of DRHs reported in this study (245,57.9%) is substantially higher than studies conducted elsewhere, including America (16.2%), Brasil (31.6%), Denmark (10.8%), Norway(38%), Sweden_(41.3%), India (17.2 %), and Malaysia (39%).^{3 6 7 18-20 26 27}The high prevalence in the current study could be explained by a number of reasons: (i) The categories of DRPs causing DRHs in this study were comprehensive, whilst other studies investigated particular types of DRPs resulted DRHs such as therapeutic failure²⁷ and ADR ^{2 26 28 29}; (ii) The prospective design of this study helps to ensure the gathering all information required to accurately classify the events; (iii) Detailed histories of drug therapy obtained by clinical pharmacists might have improved detection of DRHs ; and (iv) use of the Helper's and Strand's comprehensive classification system has likely boosted the probability that all possible drug-related causes of hospitalization to be identified. In addition, the wide variability in the rate of DRHs could also be attributed to the variations in the extent of study population, inclusion criteria, study settings, participant's level of education and awareness, level of health professional expertise, methods of evaluating DRHs attributed to DRPs, study designs (prospective vs. retrospective) and the study duration. These variations are also reported by other studies.^{2 10 11 28 29}

In this study, 87.8 % of DRHs were deemed to be preventable and this is in line with other international studies in which preventability of DRHs has been by far greater than fifty percent.¹⁰⁻¹²

^{18 21 22 29 30} The reasons why DRHs preventability was high could be attributed to failure to taking

1
2
3 appropriate measurements before drug related diseases were apparent. For instance, the principal
4 categories of DRHs in our study were failure to receive drugs (130,53.5%) and untreated indication
5 (94, 38.5%). Hence, both DRHs attributed to DRPs could be avoided by providing awareness for
6 patients about their drugs use, applying good prescribing and dispensing practice, and providing
7 appropriate pharmaceutical care plan.
8
9

10
11
12 The majority of DRHs were most commonly seen among female patients, which is concordant
13 with a previous study.³¹ However, in a study done in Saudi Arabia, DRHs were largely found in
14 male patients.^{2 22} Elderly patients developed more DRPs leading to DRHs than patients in other
15 age groups which is also in line with other studies.^{6 16 27} The main reasons could be that increased
16 deterioration of physiologic functions and likelihood of co-morbid conditions with age. These
17 conditions may warrant taking of multiple drugs, which ultimately serve as basis for contracting
18 medication side effects and interactions (drug-drug or drug-food).
19
20
21
22
23
24
25
26
27
28
29
30

31
32
33 In this study, patients whose education level being elementary and below were more prone to
34 develop DRHs than having high school education or above, which was consistent with studies
35 done previously.^{3 18} This could be related to high level education is useful for better socioeconomic
36 status and to understand about appropriate medications use
37
38
39
40
41
42

43
44 Out of a total of 245 patients with DRHs, the foremost categories of DRHs were failure to receive
45 drugs (130,53.5%) followed by untreated indication (94,38.5%), adverse drug reactions
46 (38,15.5%) and sub therapeutic dosage (30,12.2%). Similar findings were reported by other
47 studies.^{5 12 18 20-22 25 27 30} The major reasons for failure to receive drugs in this study were preference
48 to cultural and religious therapies over conventional medicines, drug products were not available,
49 cost of medications was too expensive, fear of adverse events, failure to follow-up due to Covid-
50 19, felt better and illiteracy (near to half of patients with DRHs were illiterate). Thus, inability to
51
52
53
54
55
56
57
58
59
60

1
2
3 recall regimens is another important reason associated with increased risk of hospitalization related
4
5 to failure to receive drugs, as reported elsewhere.^{3 11 21}
6
7

8
9 The second frequent category of DRHs was untreated indication (94, 38.5%) as reported in other
10
11 studies.^{9 22} Reasons were patients remained untreated; prophylaxis and synergistic medications
12
13 were not indicated. This might be due to incorrect diagnosis; patients didn't come to health setting
14
15 timely and treating physicians did not follow the management guidelines/protocols. For example,
16
17 patients having moderate persistent asthma were being treated with albuterol inhalation alone.
18
19 Statins have not also been prescribed for patients with atherosclerotic cardiovascular disease
20
21 (ASCVDs) like peripheral arterial disease, stroke, ischemic heart disease and whose age ≥ 40 years
22
23 with diabetes mellitus and high low density lipoprotein level as per the guidelines. In addition,
24
25 some compelling indication like hypertension remains untreated and subsequently results in DRHs
26
27 owing to stroke and others cardiovascular diseases. Furthermore, since only cancer diagnosis and
28
29 management are carried out in one of this research setting hospital, which is TASH, patients
30
31 coming from different corners of the country remained untreated and/or treated with various
32
33 empirical therapies that also lead to improper drug selection until they start anti-cancer drugs in
34
35 TASH.
36
37
38
39
40

41
42 ADRs (38, 15.5%) were also commonly reported as the common classifications of DRHs, which
43
44 is also mentioned with other studies.^{11 19-21 29 30 32} This might be associated with numerous number
45
46 of cardiac and diabetic patients in our study population and poor awareness of patients with regard
47
48 to cardiac medications untoward effects such as diuretics induced electrolytes disturbance and
49
50 hypoglycemic symptoms of antidiabetics. Some ADRs could be resulted from failure to follow
51
52 direction for use of the medications. For example, diabetes mellitus patient who was on metformin
53
54 experienced epigastric burning sensation pain and vomiting after taking metformin without meal.
55
56
57
58 Overall, the plausible explanations for DRHs might be the absence of pharmaceutical care services
59
60

1
2
3 in many health institutions including emergency wards of the study settings, which is very
4 important for optimizing drug therapy and patient safety. There was also poor collaboration among
5 patients, clinical pharmacists and physicians about patient's medications use process involving
6 medications use, their side effects, adherence issue and consequences of not taking their
7 medication properly. Therefore, the better opportunity for clinical pharmacists to add value in
8 patient care roles is through ensuring medication management services according to evidence-
9 based guidelines. In the present study, both failure to receive drugs and untreated indication were
10 reported under the DRPs category of need additional drug therapy that resulted in DRHs, which is
11 supported by other studies.^{7 9 18}

12
13
14 In this study, medication classes frequently observed to cause DRHs were cardiovascular
15 medicines, antimicrobial, antineoplastic, endocrine drugs, respiratory medicines and central
16 nervous system drugs. Among these classes of drugs, cardiovascular drug were predominantly
17 involved in DRHs which was in line with other studies.^{3 5 6 21 25 27} Cardiovascular drugs,
18 antidiabetics, and antiasthmatics were most commonly associated with DRHs was supported in
19 the previous studies.^{2 24 26 27} The most common drugs associated with DRHs mentioned in this
20 study finding were furosemide, ACEIs, insulins, oral hypoglycemic agents, warfarin,
21 spironolactone, aspirin and central nervous system agent and these are also implicated in several
22 other studies.^{5 7 10 21 22 24 29} The main reason might be connected with the common diseases of the
23 study area which were heart failure, diabetes mellitus, stroke, human immunodeficiency virus and
24 asthma.

25
26
27 Moreover, the most common organ system involved in DRHs was the cardiovascular system (80,
28 32.6%), with the most common specific disease of heart failure (55, 22.5%) which is consistent
29 with previous studies.^{6 25} Moreover, hypertension was mentioned for DRHs which was implicated
30 in the previous study.^{5 22 27} This is due to the fact that cardiovascular diseases require multiple

1
2
3 medicine regimens and this contributed to DRPs. Among hospitalized patients attributed to
4 endocrine systems were due to hypoglycemia, hyperglycemia and diabetic ketoacidosis, which
5 are also cited in other studies.^{22 27}It might be due to the patients poor awareness about the
6 hypoglycemic symptoms of anti-hypoglycemic agents , poor monitoring control and patients
7 prefer not to take the medications.
8
9

10
11
12 In this study, age, educational level and presence of comorbid diseases had statistically significant
13 correlation with the occurrence of DRHs. The findings are consistent with other studies.^{18 20 30 33}
14
15

16
17
18 In multiple binary logistic regression analysis, patients with ≥ 65 years of age were 7.45 times
19 more likely to be hospitalized due to drug related morbidity than non-drug related as compared to
20 age between 14 and 24 years. This might be owing to age-related physiological changes, larger
21 number of coexisting disease conditions, which require multiple medications and this in turn is
22 associated with an increased risk of DRHs.
23
24
25
26
27
28
29
30
31

32
33
34 From employment factor, students were 6.3 folds high likely exposed to DRHs than non-drug
35 related as compared to the employed. This might be explained by the nature of the disease they
36 had which means students in this finding have majorly contracted heart failure disease secondary
37 to chronic rheumatoid valvular heart disease. Out of a total 16 students, 9 (56.3%) of them had
38 heart failure owing to valvular heart diseases. Consequently, it needs lifelong and multiple
39 medications treatment and then they faced various DRPs leading hospitalizations. Moreover,
40 participants who did not have any occupation were 3.4 times high likely to be hospitalized owing
41 to drug related diseases than non-drug related as compared to employed.
42
43
44
45
46
47
48
49
50
51

52
53 The other factor was education level in which patients with tertiary education level were 64% less
54 likely to be hospitalized with drug related hospitalizations as compared to participants who did not
55 have formal education. This could be related to high level education might be useful to understand
56
57
58
59

1
2
3 about appropriate medications use. This was supported by the studies conducted at Brasil.^{3 11 18}
4
5 Patients with co-morbid disease were also 2 folds high likely to be drug related hospitalized than
6
7 non-drug related as compared to patients without co morbid disease. As implicated in the previous
8
9 studies,^{18 30 33} co- morbidity increases the vulnerability towards DRPs. These results clearly
10
11 indicate the necessity of managing DRHs in multimorbid patients.
12
13

14
15 In terms of drug related hospital stay, the overall length of the hospital stay in the present study
16
17 was 4352 days with the average length of hospital stay 10.28 ± 8.99 days, which is longer than what
18
19 has been reported in other study.¹² This was might be owing to the data in the previous study is in
20
21 a single hospital and for a relatively short period of time (28 days) while in this finding, the study
22
23 was carried out at three tertiary care hospitals for the periods of 60 days. Therefore, avoiding
24
25 preventable DRHs is also a very cost-effective tool for health care systems and could reduce the
26
27 problem of bed crisis in hospitals.
28
29
30

31
32 Among factors which have not demonstrated an association in multivariate analysis, polypharmacy
33
34 was mentioned. This agree with what have been reported in other studies.^{21 25} In contrast,
35
36 polypharmacy has been reported having positive association with the occurrence of DRHs in
37
38 previous studies.^{3 6 11 21 22 30} This lack of significance could be resulted from variations in number
39
40 of used medications and identified DRPs for causing DRHs. In this study, around two third of the
41
42 patients with DRHs used from none to four drugs per patient. Accordingly, to say polypharmacy;
43
44 \geq five drugs should be concomitantly taken. Furthermore, the identified DRPs causing DRHs were
45
46 failure to receive drugs and untreated indication. So, both categories reveal not taking medications
47
48 and the patients might not use polypharmacy. Additionally; marital status did not illustrate
49
50 significant association with DRHs.
51
52
53
54
55
56
57
58
59
60

Conclusion

The prevalence of DRHs was higher than studies conducted elsewhere among emergency ward patients in the study settings. Among those, majority of DRHs were deemed to be preventable. These findings provide valuable insight about category of DRPs and class of drugs that causes DRHs. Age, educational level, participants who did not have any occupation and presence of co-morbid condition have had significant association with DRHs. Hence, researches regarding DRHs should be conducted in different Ethiopian hospitals to demonstrate its impact.

Author affiliations

¹Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia

Acknowledgment

We would like to thank the study participants who gave their time and provided the necessary information. We also express our gratitude for data collectors and staffs who were assigned in ED of study settings for their cooperation.

Contributors

ABB and MBD contributed to conceptualization, design, analysis and write up. MBD organized the collection of data for analysis and write up the draft manuscript. ABB and MBD supervised the collection data and overall research work including interpretation of results, reviewed and revised critically the manuscript. Both authors approved the final version to be submitted for publication.

Funding

This study was done with the financial support of Addis Ababa University. The funder had no role in the study design, data collection, analysis, preparation of the manuscript, or decision to publish.

Competing interests

There are no conflicts of interest.

Patient consent for publication

 Not required

Ethics approval

Prior to study initiation, letter of ethical approval (Ref No;ERB/SOP/172/08/2020) was obtained from ethical review committee, School of Pharmacy, College of Health Sciences, Addis Ababa University. Verbal consent from patients was obtained after the provision of information regarding the purpose of the study and its risk for the interviewed which could be time to be spent during the interview (maximum of 30 minutes). Names were not used rather codes to maintain confidentiality of the information throughout the study period. Patients were told the reasons of being selected to be included in the study and assured that waning participation would not have any influence on the right to get treatment. Patients were also told about their rights to withdraw from the study at any time.

Data availability statement

Data are accessed upon reasonable request of the corresponding author. All relevant data are within the manuscript and Supporting Information files.

Provenance and peer review

Not commissioned; externally peer reviewed.

ORCID iDs

Mulate Belete Demessie: <https://orcid.org/0000-0002-1517-7293>

Alemseged Beyene Berha: <https://orcid.org/0000-0003-3825-2863>

REFERENCES

- [dataset] 1. Al Hamid A, Ghaleb M, Aljadhey H, et al. A systematic review of hospitalization resulting from medicine-related problems in adult patients. *British journal of clinical pharmacology* 2014;78(2):202-17. doi: 10.1111/bcp.12293
- [dataset] 2. Alayed N, Alkhalifah B, Alharbi M, et al. Adverse Drug Reaction (ADR) as a Cause of Hospitalization at a Government Hospital in Saudi Arabia: A Prospective Observational Study. *Current drug safety* 2019;14(3):192-98. doi: 10.2174/1574886314666190520105330
- [dataset] 3. Andreazza RS, Silveira De Castro M, Sippel Koche P, et al. Causes of drug-related problems in the emergency room of a hospital in southern Brazil. *Gaceta sanitaria* 2011;25(6):501-6. doi: 10.1016/j.gaceta.2011.05.016
- [dataset] 4. STRAND HA. Opportunities and responsibilities in pharmaceutical care. *American journal of hospital pharmacy* 1990;47:533-43.
- [dataset] 5. Ayalew MB, HGT, OAA. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures. *Bulletin of emergency and trauma* 2019;7(4):339-46.
- [dataset] 6. Gustafsson M, Sjolander M, Pfister B, et al. Drug-related hospital admissions among old people with dementia. *European journal of clinical pharmacology* 2016;72(9):1143-53. doi: 10.1007/s00228-016-2084-3
- [dataset] 7. Lea M, Mowe M, Mathiesen L, et al. Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. *PloS one* 2019;14(7):e0220071. doi: 10.1371/journal.pone.0220071
- [dataset] 8. Pattanaik S, Dhamija P, Malhotra S, et al. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. *British journal of clinical pharmacology* 2009;67(3):363-9. doi: 10.1111/j.1365-2125.2008.03346.x
- [dataset] 9. Pellegrin KL, Lee E, Uyeno R, et al. Potentially preventable medication-related hospitalizations: A clinical pharmacist approach to assessment, categorization, and quality improvement. *Journal of the American Pharmacists Association : JAPhA* 2017;57(6):711-16. doi: 10.1016/j.japh.2017.06.019
- [dataset] 10. R L Howard AJA, P D Howard, M Partridge. Investigation into the reasons for preventable drug related admissions to a medical admissions unit:observational study *Qual Saf Health Care* 2003;125:280–85.
- [dataset] 11. Singh H, Kumar BN, Sinha T, et al. The incidence and nature of drug-related hospital admission: A 6-month observational study in a tertiary health care hospital. *Journal of pharmacology & therapeutics* 2011;2(1):17-20. doi: 10.4103/0976-500X.77095
- [dataset] 12. Yosef H. Al-Olah KMAT. Admissions through the emergency department due to drug-related problems. *Ann Saudi Med* 2008;28 (6):426-29.
- [dataset] 13. Centre WMR. Medicines-related admissions. *WeMeReC Bulletin* February,2015
- [dataset] 14. Robert J. Cipolle LS, Peter Morley Pharmaceutical Care Practice: The PatientCentered Approach to Medication Management Services, 3e >. *McGraw-Hill Medical* 2012
- [dataset] 15. WHO. International drug monitoring. 1969(425)
- [dataset] 16. Linkens AEMJH, Milosevic V, van der Kuy PHM, et al. Medication-related hospital admissions and readmissions in older patients: an overview of literature. *International Journal of Clinical Pharmacy* 2020;42(5):1243-51. doi: 10.1007/s11096-020-01040-1
- [dataset] 17. Johnson JA, Boatman LI. Drug-Related Morbidity and Mortality: A Cost-of-Illness Model. *Journal of Managed Care Pharmacy* 1996;2(1):39-45.
- [dataset] 18. Dammalapati SG, Challa SR, Challa P, et al. Incidence and Factors Associated with Drug Related Hospital Admissions in a South Indian Tertiary Care Hospital. *Indian Journal of Pharmacy Practice* 2018;11(1):37-43. doi: 10.5530/ijopp.11.1.7

- 1
2
3 [dataset] 19. J. HALLAS BH, L. F. GRAM, E. GRODUM, K. BRBSEN, T. HAGHFELT & N.
4 DAMSBOS. Drug related hospital admissions: the role of definitions and intensity of data
5 collection, and the possibility of prevention. *Journal of Internal Medicine* 1990; 2280: 83-90.
6 [dataset] 20. Kent M. Nelson aRLT. Drug-Related Hospital Admissions. *Pharmacotherapy*
7 1996;16(4): 70 1-707.
8 [dataset] 21. Leslie Jo Samoy PJZ, Robert M. Balen, Riyad B. Abu-Laban, and Mark Roberts. Drug-
9 Related Hospitalizations in a Tertiary Care Internal Medicine Service of a Canadian Hospital:
10 A Prospective Study. *Pharmacotherapy* 2006;26(11):1578–86.
11
12 [dataset] 22. Mohamed Al-Arifi HA-H, Mohamed Al-Meziny , Ragab Said ,, Aljadhey H.
13 Emergency department visits and admissions due to drug related problems at Riyadh military
14 hospital (RMH), Saudi Arabia. *Saudi Pharmaceutical Journal* 2013(22):17–25. doi:
15 10.1016/j.jsps.2013.01.001
16 [dataset] 23. Almut G Winterstein BCS, Charles D Hepler, and Charles Poole. Preventable Drug-
17 Related Hospital Admissions. *Ann Pharmacother* 2002;36:1238-48. doi: 10.1345/aph.1A225
18 [dataset] 24. Daniel S. Budnitz MCL, Nadine Shehab, and Chesley L. Richards. Emergency
19 Hospitalizations for Adverse Drug Events in Older Americans. *The new england journal of*
20 *medicine* 2011;365:2002-12.
21 [dataset] 25. Marcum ZA, Pugh MJ, Amuan ME, et al. Prevalence of potentially preventable
22 unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events
23 among older veterans. *The journals of gerontology Series A, Biological sciences and medical*
24 *sciences* 2012;67(8):867-74. doi: 10.1093/gerona/gls001
25 [dataset] 26. Alexopoulou A, Dourakis SP, Mantzoukis D, et al. Adverse drug reactions as a cause
26 of hospital admissions: a 6-month experience in a single center in Greece. *European journal*
27 *of internal medicine* 2008;19(7):505-10. doi: 10.1016/j.ejim.2007.06.030
28 [dataset] 27. Karuppanan M, Nee T, Thong W, et al. The prevalence of adverse drug event-related
29 admissions at a local hospital in Malaysia. *Archives of Pharmacy Practice* 2013;4(4):160. doi:
30 10.4103/2045-080x.123224
31 [dataset] 28. Geer MI, Koul PA, Tanki SA, et al. Frequency, types, severity, preventability and
32 costs of Adverse Drug Reactions at a tertiary care hospital. *Journal of pharmacological and*
33 *toxicological methods* 2016;81:323-34. doi: 10.1016/j.vascn.2016.04.011
34 [dataset] 29. Parameswaran Nair N, Chalmers L, Connolly M, et al. Prediction of Hospitalization
35 due to Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC
36 Score). *PloS one* 2016;11(10):e0165757. doi: 10.1371/journal.pone.0165757
37 [dataset] 30. Peter J. Zed EAF, Stacy Ackroyd-Stolarz, Nancy G. Murphy, Neil J. MacKinnon,
38 Doug Sinclair. Medication-Related Emergency Department Visits in Pediatrics: a Prospective
39 Observational Study. *American Academy of Pediatrics* 2015;135(3) doi: DOI:
40 10.1542/peds.2014-1827
41 [dataset] 31. Ayalew MB, Tegegn HG, Abdela OA. Drug related hospital admissions; a systematic
42 review of the recent literatures. *Bulletin of Emergency & Trauma* 2019;7(4):339.
43 [dataset] 32. Hohl CM, Nosyk B, Kuramoto L, et al. Outcomes of emergency department patients
44 presenting with adverse drug events. *Annals of emergency medicine* 2011;58(3):270-79 e4.
45 doi: 10.1016/j.annemergmed.2011.01.003
46 [dataset] 33. Nivya K, Sri Sai Kiran V, Ragoo N, et al. Systemic review on drug related hospital
47 admissions - A pubmed based search. *Saudi pharmaceutical journal : SPJ : the official*
48 *publication of the Saudi Pharmaceutical Society* 2015;23(1):1-8. doi:
49 10.1016/j.jsps.2013.05.006
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 **Figure 1:** Patient's inclusion information flow chart in emergency ward at TASH, ZMH and
6 Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)
7
8
9
10
11
12

13 **Figure 2:** Numbers of drug related problems occurrence per patient leading hospitalization in
14 emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September,
15 2020 (n= 245)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1




Figure 2

BMJ Open

Prevalence and Predictors of Drug-Related Hospitalizations among Patients Visiting Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054778.R3
Article Type:	Original research
Date Submitted by the Author:	26-Jan-2022
Complete List of Authors:	Demessie, Mulate ; Addis Ababa University Berha, Alemseged; Addis Ababa University, Pharmacology and Clinical Pharmacy
Primary Subject Heading:	Emergency medicine
Secondary Subject Heading:	Patient-centred medicine, Pharmacology and therapeutics, Health services research
Keywords:	Health & safety < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Prevalence and Predictors of Drug-Related Hospitalizations among Patients Visiting Emergency Departments of Addis Ababa City Hospitals in Ethiopia: A Multicenter Prospective Observational Study

Mulate Belete Demessie¹, Alemseged Beyene Berha^{1*}

*Corresponding author: alembeyene98@gmail.com

ABSTRACT

Objectives: This study aimed to determine the prevalence, categories, and predictors of drug-related hospitalizations (DRHs) among patients visiting emergency departments of Addis Ababa city hospitals, Ethiopia.

Design: A multicenter prospective observational study was conducted through patients interview and chart review.

Settings: The study was undertaken in three tertiary care hospitals, Addis Ababa, Ethiopia.

Participants: A total of 423 patients fulfilling the inclusion criteria were included.

Outcome measures: Prevalence and preventability of DRHs, categories of drug-related problems causing DRHs, medications, and diseases involved in DRHs, and factors significantly associated with DRHs.

Result: More than half of the patients (216, 51.1%) were females. The mean age (SD) was 47.50 (± 17.21) years. The mean length of hospital stay (SD) was 10.29 (± 8.99) days. Nearly, 60% (249) of them were hospitalized due to drug-related problems, of which 87.8% were preventable. The cause for hospitalization for more than half (130, 53%) of them was a failure to receive drugs, and 37.85 (94) patients were categorized as untreated indications. Age ≥ 65 years (Adjusted Odds Ratio [AOR]=7.451, 95%CI: 1.889-29.397), tertiary educational level (AOR=0.360, 95%CI: 0.141-

0.923), participants who did not have any occupation (AOR=3.409, 95%CI: 1.120-10.374) and presence of co-morbid conditions (AOR=2.004, 95%CI: 1.095-3.668) were predictors of DRHs.

Conclusion: Nearly 90% of DRHs were deemed to be preventable in the study settings. Older age, lower educational level, unemployment, and presence of the co-morbid condition in hospital as an inpatient were predictors of DRHs.

Strength and limitations of the study

- The strength of this study is the study design which is a prospective observational study.
- This is a multicenter study with sufficient sample size, increasing representativeness the findings.
- The main limitation of this study is lack of standardized procedures for immediate recording and reporting of DRHs.
- Patients who visited other than the emergency ward were excluded from participation can also be considered as a limitation of the study.

INTRODUCTION

Though drugs can be ordered for the intention of achieving desired health outcomes that improve patients quality of life, symptoms and signs of diseases causing drug related hospitalizations (DRHs) as a result of drug related problems (DRPs) could be apparent.¹⁻³ DRP is defined according to Helper and strand as ‘an undesired event or circumstance due to drug therapy that actually or potentially interferes with desired health outcomes’.⁴

Medication’s use has been increasing across the globe due to the presence of large number of treatable diseases and this has contributed to production of more advanced medications by the pharmaceutical industries. Therefore, advances in drug therapies could lead to an apparent increase in the incidence of DRPs, which in turn lead to hospitalization⁵. Hospitalization can be defined as drug related if it is straightforwardly linked to one of the eight predefined Helper’s and Strand’s classifications of DRPs: adverse drug reaction (ADR), drug interaction, improper drug selection, untreated indication, sub-therapeutic dosage, supra-therapeutic dosage, failure to receive drugs, and drug use without indication.⁶⁻¹² Those DRPs can arise when a medicine is prescribed aptly and used correctly (e.g., ADR), due to errors involving prescribing (including inappropriate or over-treatment, and failure to prescribe the indicated treatment or under-treatment), dispensing, administering, reconciling, or monitoring of medicines as well as from poor patient adherence.^{2 13}

¹⁴ According to the World Health Organization (WHO), an ADR is any harmful, undesired and inadvertent drug effect that occurs at doses used in human for therapy, diagnosis or prophylaxis.¹⁵

Over the past decades, DRHs have been considered as wide spreading¹⁶. In the United States, DRPs accounted for 17 million emergency department (ED) visits and 8.7 hospitalizations annually.¹⁷ It increases morbidity and mortality rates, health care cost, decreases income and household productivity and reduced quality of life.^{2 18 19}

1
2
3 Studies carried out in different areas of the globe estimated the extent of DRHs to be between 16%
4 to 41.3%. Of these, 50% to 95% were preventable. Supratherapeutic dosage (10.3%-12.7%), non-
5 compliance (10.6%-65.8%), ADRs (10.7%-45.5%) and untreated indications (10.7-13.3%) were
6 frequently identified as the causes of DRHs.^{6 9 18 20-22}
7
8
9

10
11
12
13 DRPs resulting DRHs were defined as preventable if the patient failed to take a drug that is known
14 to reduce or prevent symptoms according to the prescribed directions, took a drug for which a
15 patient had a known allergy, drug treatment was obviously improper, dosage differed from
16 accepted recommendations, took a drug that was not indicated, and if there was a failure to monitor
17 by a physician at reasonable time intervals due to financial difficulty. If there was, however, no
18 reasonable actions to prevent DRPs, it is then termed as non-preventable.^{20 23}
19
20
21
22
23
24
25
26
27

28 In many studies, patients with DRHs had mainly cardiovascular diseases and diabetes, suggesting
29 that cardiovascular and hypoglycemic medications were involved in DRHs.^{6 10 11 18 20 21 24 25}
30
31

32 Previous studies also identified polypharmacy, advanced age and comorbid conditions as factors
33 that favor the occurrence of DRHs.^{3 6 20 21}
34
35
36
37

38 It is thus important to determine DRHs prevalence to improve treatment outcomes and prevent
39 unnecessary admissions. To the best of our knowledge, there are no studies conducted about DRHs
40 in Ethiopia. The present study therefore aimed to determine the prevalence, categories and
41 predictors of DRHs among patients admitted to an ED of three selected hospitals in Addis Ababa,
42 the capital of Ethiopia.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Study Settings

The study was carried out in the ED of Tikur Anbessa Specialized Hospital (TASH), Zewditu Memorial Hospital (ZMH), and Yekatit 12 Hospital Medical College (Y12HMC), Addis Ababa, Ethiopia. TASH has 700 beds and it is a tertiary care teaching hospital affiliated with Addis Ababa University. In TASH, outpatient, inpatient, and emergency services are delivered. The ED provides services for about 13,920 patients per year. Y12HMC is also a tertiary care level referral and teaching hospital that provides both inpatient and outpatient treatment for a large number of people coming from Addis Ababa as well as other places of the country. The hospital has a total of three ED rooms. The adult medical ED is collocated with adult surgical ED. It serves around 10,560 patients per year. The third hospital is ZMH, which is one of the teaching and general referral hospitals in Ethiopia and the ED serves about 10,560 patients per year.

Patient involvement

Patients did not participate in the initial conception and design of the study. However, based on the participating patients' comments during the pretest (5% of the sample size), we made a correction on the patient approach and timing for an interview at ED during data collection. Patients who participated actively in this study determined the medication use, level of adherence, and medical history.

Study design and population

A prospective observational study design was used to collect data from August to September, 2020. All patients admitted to the ED of the three selected hospitals during the study period and fulfilled the inclusion criteria were included.

Inclusion and exclusion criteria

Patients having a medical history with completed data and ≥ 14 years old were included. Patients with incomplete or no medical records, refused to participate, presented with trauma and injuries associated with accidents (e.g. road traffic accidents, beaten by stick, stabbing and bulleting) and poisoned/intoxicated (for instance snake bite, alcohol intoxication or use of pesticide) were excluded. During data collection periods, about 2655 patients were being admitted to the ED, out of which 423 participants fulfilled the inclusion criteria

Sample size determination and techniques

Since there was no study done on DRHs in Ethiopia, the sample size was estimated using the general formula for single population proportion.

$$n = [(Z \alpha/2)^2 \times p (1-p)] \div d^2 = [(1.96)^2 \times 0.5 \times 0.5] \div 0.05^2 = 384$$

(Hence; n = required sample size, $Z_{\alpha/2}$ = critical value for normal distribution at 95% confidence interval, which equals 1.96 (Z value at $\alpha = 0.05$), P = Proportion of DRH = 0.5, d = margin of error of 5% = 0.05. The calculated sample size using this formula was 384. Adding 10% contingency (for non-response rate) to compensate participants who could refuse to participate, brought the final sample size to 423. The sample size was distributed to the three hospitals based on the patient load of hospital's ED per annum as mentioned in the Study settings. Accordingly, 169 participants were included from TASH, 127 participants from ZMH and 127 participants from Y12MHC.

Data collection procedures

A structured questionnaire was developed from carefully evaluated published articles in the literature. For instance, categories of DRPs that leads to hospitalization and factors having association with DRH (e.g. socio-demographic and clinical characteristics) were extracted from

1
2
3 literatures. All the necessary data including patients' demographic details (age, sex, marital status,
4 education level, employment), and clinical information like the number of medications being taken
5 prior to admission were collected and documented using a data collection tools through
6 interviewing the patients/family members. Furthermore, patient's medical records were reviewed
7 by data collectors to obtain clinical information (disease history, allergic status, admission
8 diagnosis, length of hospital stay during admission, number of medications being taken prior to
9 admission, data on laboratory investigations). Supplementary information and clarifications on
10 some patient's medical information were obtained through discussion with the treating physicians
11 and residents. By applying those data gathering approach, different categories of DRPs resulting
12 hospitalization with their possible causes were determined.
13
14
15
16
17
18
19
20
21
22
23
24

25
26
27 Data were collected by three pharmacists having Master of Science degrees in Clinical Pharmacy.
28 They had basic knowledge and skill in pharmaceutical care services and also received training on
29 how to obtain data from patients' medication charts and approach the patients and health care
30 professionals. Updated Ethiopian Standard Treatment Guidelines for Hospitals, third edition,
31 2014, Ethiopian Antiretroviral Therapy and Tuberculosis Guidelines, Cancer Treatment Protocols
32 prepared by TASH Oncologists, Pharmacotherapy textbooks, Medscape, UpToDate were used as
33 a guide for diseases management. Micromedex online database was used to check drug
34 interactions. Furthermore, updated guidelines released from American Cardiology Center,
35 American Heart Association, European Cardiology Society, American Diabetic Association were
36 used as a guide to treat different diseases. Clinical pharmacists along with physicians determined
37 subtherapeutic and suprathereapeutic dosage outcomes using medical charts, laboratory tests,
38 clinical outcomes, medication dose and frequency. Participant's hospitalization attributed to
39 failure to receive drugs was decided using physician's recording documentation, clinical
40 pharmacists' knowledge and patients reporting evidence. Untreated indications and improper drug
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 selection were evaluated and interpreted using treatment guidelines. For instance, if patients
4 presented with untreated or improperly treated cardiac diseases, treatment was initiated and
5 optimized using the American Heart Association guidelines, and UpToDate latest version. To
6 minimize bias, the three pharmacists at each hospital independently evaluated the identified DRPs
7 resulted hospitalizations. Decision was then reached by reaching consensus after a series of
8 meetings and discussions as well consultations with physicians and residents. Once DRPs resulting
9 DRHs were identified, they were recorded and classified using DRPs registration format according
10 to Helper's and Strand's classification.
11
12
13
14
15
16
17
18
19
20
21

22 **Data collection management**

23
24 Pretest was performed on 5% patients in TASH prior to the actual data collection period and
25 amendment was made accordingly. The data collection process was supervised, and the
26 information gathered via data abstraction formats were reviewed and checked for their
27 completeness every day to ensure quality. Urgent correction was made, if any errors were
28 identified.
29
30
31
32
33
34
35
36

37 **Data analysis**

38
39 The data were entered and analyzed using Statistical Package for Social Sciences (SPSS) version
40 26. Mean and standard deviation for continuous variables and frequency and percentage for
41 categorical variables were computed by using descriptive statistics in SPSS to summarize socio-
42 demographic and relevant clinical characteristics of the study participants. Tables and charts were
43 used to present the results. Furthermore, univariate and multiple binary logistic regressions were
44 performed to analyze factors that predict DRHs. Variables with p-values < 0.2 in the binary
45 univariate analysis were included in the multiple binary logistic regressions to control the effect of
46 confounders. The level of significance was set at p-value ≤ 0.05 and results were reported as odds
47 ratios (OR) with 95% confidence intervals.
48
49
50
51
52
53
54
55
56
57
58
59

RESULTS

Socio-demographic and clinical characteristics

From 2655 participants enrolled in the study, a total of 423 study participants were included for analysis. Of them, 169 participants from TASH, 127 from ZMH and another 127 from Y12HMC were included (*Figure 1*).

Socio-demographic and clinical characteristics of the participants is depicted in Table 1. More than half of the participants (216, 51.1%) were females. The mean (SD) age of the participants was 47.5 (± 17.21) years and nearly two third (275, 65%) were ≥ 40 years of age. More than 70 % (301, 71.1%) of the total participants' level of education was below secondary school. Nearly three-quarter of them (304, 71.9%) resided in Addis Ababa city. Out of the total study participants, 58% (245) of them were taking ≥ 3 and 30% (127) \geq five drugs prior to admission, which is termed as polypharmacy. Above half of the participants (213, 50.4%) had co-morbid diseases, including hypertension (108, 22.5%), cardiac diseases (59, 13.5%) and diabetes mellitus (53, 12.5%). The mean (SD) length of hospital stay was 10.28 ± 8.99 days and ranges from 2 to 96 days.

Table 1: Socio-demographic and clinical characteristics of the participants in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)

Variables	¹ DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Gender			
Male	119(48.6)	88(49.4)	207(48.9)
Female	126(51.4)	90(50.6)	216(51.1)
Age* (in years)			
Mean± SD	48.23±17.85	46.5±16.3	47.5±17.2
14 - 24	24(9.8)	14(7.9)	38(8.98)
25- 39	51(20.8)	59(33.1)	110(26)
40 - 64	100(40.8)	74(41.6)	174(41.1)
>64	70(28.6)	31(17.4)	101(23.9)
Marital status*			
Single	64(26.1)	34(19.1)	98(23.2)
Married	129(48.6)	105(59)	234(55.3)
widowed	20(8.2)	9(5.1)	29(6.7)
Divorced	42(17.1)	31(16.9)	73(17.3)
Education level*			
No formal education	116(47.3)	72(40.4)	188(44.4)
Elementary	66(26.9)	47(26.4)	113(26.7)
Secondary	31(12.7)	35(19.7)	66(15.6)
Tertiary	32(13.1)	24(13.5)	56(13.2)
Residence			
Addis Ababa	177(72.2)	127(71.3)	304(71.9)
Out of Addis Ababa	68(27.8)	51(28.7)	119(28.1)
Religion			
Orthodox	186(76)	136(76)	322(76.1)
Muslim	42(17.1)	31(17.4)	73(17.3)
Catholic	1(0.4)	1(0.6)	2(0.5)
Protestant	16(6.5)	10(6)	26(6.1)

DRHs, drug related hospitalizations; non-DRHs, non-drug related hospitalizations; SD, standard deviation;

* Represent variables having significant bivariate associations.

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Employment status*			
Salaried worker	111(45.3)	83(46.6)	194(45.9)
Unemployed	87(35.5)	74(41.6)	161(38.1)
Student	18(7.3)	7(3.9)	25(5.9)
Other ²	29(11.8)	14(7.9)	43(10.2)
Social habit (smoking cigarette)			
Yes	29(11.8)	15(8.4)	44(10.4)
No	216(88.2)	163(91.6)	379(89.6)
Social habit (drinking alcohol)			
Yes	71(29)	57(32)	128(30.3)
No	174(71)	121(68)	295(69.7)
Any physical activity			
Yes	170(69.4)	132(74.1)	302(71.4)
No	70(30.6)	46(25.9)	106(28.6)

² Others: participants who did not have any occupation rather they were lived as dependent with other people. DRH, drug related hospitalization; Non-DRH, Non-drug related hospitalization; n, number; SD, standard deviation

Table 1 Continued

Table 1 continued

Variables	DRHs (245), n (%)	Non-DRHs (178), n (%)	Total (423), n (%)
Home remedies (herbals)			
Yes	3(1.2)	0(0)	3(0.7)
No	242(98.8)	178(100)	420(99.3)
Number of medications taken per patient *			
Mean± SD	3.4±2.4	3.2±2.1	3.3±2.3
0	24(9.8)	12(6.7)	36(8.5)
1	41(16.7)	26(14.6)	67(15.8)
2	35(14.3)	40(22.5)	75(17.7)
3-4	61(24.9)	57(32)	118(27.9)
≥5	84(34.3)	43(24.2)	127(30)
Polypharmacy			
Yes	84(34.3)	43(24.2)	127(30)
No	161(65.7)	135(75.8)	296(70)
Co morbid condition*			
Yes	137(55.9)	76(42.7)	213(50.4)
No	108(44.1)	102(57.3)	210(49.6)
Co morbid condition (Hypertension)			
Yes	68(27.8)	40(22.5)	108(25.5)
Co morbid condition (Diabetes mellitus)			
Yes	31(12.7)	22(12.4)	53(12.5)
Co morbid condition (Cardiac diseases)			
Yes	38(15.5)	21(11.8)	59(13.9)

* Represent variables having significant bivariate associations.

Prevalence and categories of drug related hospitalizations

From a total of 423 enrolled patients, DRHs were identified in 245 (57.9%) participants, of which 87.8% were deemed preventable. A total of 322 DRPs rendering DRHs were observed in 245 participants, representing 1.31 DRPs per patient (**Figure 2**). Out of 245 drug related hospitalized patients, more than half (130, 53%) of them were due to failure to receive drugs followed by untreated indication (94, 37.8%) and sub-therapeutic dosage (30, 12.2%). The main reasons for failure to receive drugs included patients preferred not to take the medication (43, 33.1%); feared adverse events (18, 13.8%); and drug products were not available (17, 13.1%)**Error! Reference source not found.**

Table 2: Categories of drugs related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Untreated indications	Untreated medical condition is existed	34(36.2)
	Synergistic/ potentiating drug needed	42(44.7)
	Preventive/ prophylactic drug needed	18(19%)
	Improper Drug Selection	16(6.5)
	More effective alternative drug is available	6(37.5)
	Condition is already refractory to drug	2(12.5)
	The drug is not effective for condition	6(37.5)
	Others ⁴	2(12.5)

⁴ Others; patients who were using expired drugs like insulin and albuterol.

Table 2Continued.....

Error! Reference source not found. Continued.....

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Sub therapeutic Dosage		30(12.2)
	Wrong dose (too small) of the drug	24(80)
	Frequency is inappropriate (long)	5(16.7)
	Duration of drug use is too short	1(3.3)
Supra therapeutic Dosage		13(5.3)
	Wrong dose (too high) of the drug	11(84.6)
	Frequency is inappropriate (short)	2(15.4)
Adverse drug reaction		38(15.5)
	Undesired effect from the drug is found	34(89.5)
	Unsafe drug for patient is existed	1(2.6)
	Dosage is administered too rapidly	1(2.6)
	Allergic reactions is found/reported	2(5.3)
Drug Interactions		1(0.4)
	There is (are) major drug interaction	1(100)

⁵Others; patients who were using expired drugs like insulin and albuterol.

Table 2 Continued....

Error! Reference source not found. Continued.....

Categories of DRHs	Causes of drug related hospitalizations	Frequency (%)
Failure to receive drugs.		130(53.5)
	Does not understand instructions	6(4.6)
	Patients prefer not to take	43(33.1)
	Patients forget to take	3(2.3)
	Drug product not available	17(13.1)
	Cost of medication too expensive	16(12.3)
	Disbelieves on the drug effectiveness	1(0.8)
	Patients felt better	17(13.1)
	Patients felt worse	1(0.8)
	Fear of adverse events	18(13.8)
	Failure to follow-up due to Covid-19	8(6.2)

Total number of DRPs leading DRHs	322
Total number of participants with DRHs	245
Average number DRPs per patients with DRHs	1.31
Preventability of DRHs	215(87.8)

Medications and diseases involved in drug related hospitalizations

Out of a total of 245 drug related hospitalized patients, nearly one -third of them had cardiovascular diseases (80, 32.6%) followed by endocrine disorders (47, 19.2%) and cerebrovascular disease (26, 10.6%). (See in Table 3)

Table 3: Diseases that associated with drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Diseasecategories	n(%)
Cardiovascular diseases	80 (32.6%)
CNS diseases	8 (3.2%)
Cerebrovascular disease	26(10.6%)
Infectious diseases	21 (8.5%)
Endocrine system diseases	47 (19.2%)
Diseases of cancer	25 (10.1%)
Diseases of the respiratory system	21 (8.5%)
GI diseases	10 (4%)
Others*	7 (2.8%)

*Includes anemia, chronic kidney disease, systemic lupus erythematosus and hemophilia

Medication classes and specific drugs implicated in DRHs are depicted in Table 4.

A total of 497 drugs were implicated in 245 drug-related hospitalized patients, providing an encounter of 2.03 drugs per drug-related hospitalized patient. Cardiovascular, antimicrobial, antineoplastic and endocrine drug classes were the most frequently involved drugs in the hospital admissions. Among cardiovascular drugs; furosemide (59,24.1%), angiotensin converting enzyme inhibitors (ACEIs) (48,19.1%), and antiplatelets & anticoagulants (44,18%) were the most frequently mentioned followed by drugs acting on the endocrine system like oral hypoglycemic

agents (37, 15.1%) and insulin (24, 9.8%). Antibiotics (25, 10%), anticancer drugs (23, 9%), and combination antiretroviral therapy (15, 6.1%) had also contributed to admission to varied extent.

Table 4: Medication classes and specific drugs implicated in drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Drugs class	Specific drugs	n (%)
Cardiovascular drugs		
	Atorvastatin	31(12.7)
	Antiplatelets(aspirin,clopidogril)	24(9.8)
	Furosemide	59(24.1)
	Spironolactone	33(13.5)
	Anticoagulants (Warfarin, heparin)	20(8.2)
	Beta blockers (metoprolol,atenolol)	21(8.6)
	Digoxin	15(6.1)
	Angiotensin converting enzyme inhibitors (enalapril/lisinopril)	48(19.6)
	Calcium channel blockers (nifedipine, amlodipine)	34(13.9)
	Hydrochlorothiazide	11(4.5)

Table 4Continued.....

Table 4 continued.

Drugs class	Specific drugs	n (%)
Drugs act on the respiratory system		
	Long-acting beta blockers	15(6.1)
	bronchodilator	10(4.1)
Central nervous system drugs		
	Antiepileptics	5(2)
	antipsychotic	5(2)

	Amitriptylin	2(0.8)
Antimicrobial drugs		
	Antibiotics (piperacillin/tazobactam, meropenem, amoxicillin, amoxicillin /clavunicacid, ceftriaxone, benzathine penicillin)	25(10.2)
	Combination antiretroviral therapy	15(6.1)
	Anti-tuberculosis	13(5.3)
Antineoplastic agents	Cyclophosphamide, imatinib, methotrexate, doxorubicin	23(9.4)
Immuno-suppressants		
	Mycophenolate	1(.4)
	corticosteroids (prednisolone, budesonide)	9(3.7)
Endocrine drugs		
	Oral hypoglycemic drugs (metformin, glibenclamide)	37(15.1)
	Insulin	24(9.8)
	Propylthiouracil	4(1.6)
Gastrointestinal drug	Proton pump inhibitors	7(2.9)
Others	Potassium chloride	1(0.4)
	Non-steroidal anti-inflammatory drugs	3(1.2)
	Opioid	1(0.4)

Table 4 Continued

Drugs class	Specific drugs	n (%)
Others		
	Ferrous sulphate	1(0.4)
Total number of medications involved in DRHs		497
Total number of participants with DRHs		245(57.9)
Average number medications per patients with DRHs		2.03

Factors associated with the occurrence of drug related hospitalizations

According to the multivariate logistic regression analysis the variables age, employment, presence of co morbid diseases and education level were significantly associated with the occurrence of DRHs (See in Table5). Age > 64 years (Adjusted Odds Ratio [AOR] = 7.451, 95%CI: 1.889-29.397), tertiary educational level (AOR=0.360, 95%CI: 0.141-0.923), participants who did not have any occupation (AOR=3.409, 95%CI: 1.120-10.374), students (AOR=6.331,95%CI:1.375-29.153) and presence of co-morbid diseases (AOR=2.004,95%CI: 1.095-3.668) were predictors of DRHs.

Table 5: Predictors that involved in drug related hospitalizations in emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 245)

Variables	Predictors of Patients hospitalization			Odds Ratios	
	³ DRH(245) n (%)	Non- DRH(178) n (%)	Total(423) n (%)	AOR(95% CI)	P- value
Age (Years)					
Mean±SD	48.24±17.86		47.50±17.21		
14 - 24	24(9.8)	14(7.9)	38(8.98)	1.000	
25- 39	51(20.8)	59(33.1)	110(26)	1.55(0.51-4.66)	0.435
40 - 64	100(40.8)	74(41.6)	174(41.1)	2.567(0.82-8.06)	0.106
>64	70(28.6)	31(17.4)	101(23.9)	7.45(1.89-29.40)	0.004
Marital status					
Single	64(26.1)	34(19.1)	98(23.2)	1.00	
Married	129(48.6)	105(59)	234(55.3)	0.60(0.29-1.23)	0.160
Widowed	20(8.2)	9(5.1)	29(6.7)	0.49(0.20-1.18)	0.109
Divorced	42(17.1)	31(16.9)	73(17.3)	0.35(0.19-0.75)	0.983
Education level					
No formal education	116(47.3)	72(40.4)	188(44.4)	1.00	
Elementary	66(26.9)	47(26.4)	113(26.7)	0.57(0.23-1.43)	0.229
Secondary	31(12.7)	35(19.7)	66(15.6)	0.57(0.23-1.39)	0.215
Tertiary	32(13.1)	24(13.5)	56(13.2)	0.36(0.14-0.92)	0.033

¹⁰DRH, drug related hospitalization; non-DRH, non-drug related hospitalization; AOR, adjusted odds ratio; CI, confidence interval

Table 5 Continued

Variables	Predictors of Patients hospitalization			Odds Ratios	
	DRH(245) n (%)	Non-DRH(178) n (%)	Total(423) n (%)	AOR(95% CI)	P-value
Employment status					
Salaried worker	111(45.3)	83(46.6)	194(45.9)	1.00	
Unemployed	87(35.5)	74(41.6)	161(38.1)	0.29(0.09-0.89)	1.000
Student	18(7.3)	7(3.9)	25(5.9)	6.33(1.38-29.15)	0.018
Others*	29(11.8)	14(7.9)	43(10.2)	3.41(1.12-10.37)	0.031
Polypharmacy					
Yes	84(34.3)	43(24.2)	127(30)	1.48(0.72-3.04)	0.284
No	161(65.7)	135(75.8)	296(70)	1.00	
Co morbid condition					
Yes	137(55.9)	76(42.7)	213(50.4)	2.00(1.09-3.67)	0.024
No	108(44.1)	102(57.3)	210(49.6)	1.00	

*Others: participants who did not have any occupation

DISCUSSION

The aim of optimizing pharmacotherapy is to achieve the desired therapeutic outcomes in the absence of morbidity and mortality associated with a drug. To the best of our knowledge, this study is the first to explore the prevalence, categories and rate of preventability of DRHs in the ED of three selected hospitals that are responsible for the provision of medical and surgical care to patients in need of immediate care.

The occurrence of DRHs reported in this study (245,57.9%) is substantially higher than studies conducted elsewhere, including America (16.2%), Brasil (31.6%), Denmark (10.8%), Norway(38%), Sweden_(41.3%), India (17.2 %), and Malaysia (39%).^{3 6 7 18-20 26 27}The high prevalence in the current study could be explained by a number of reasons: (i) The categories of DRPs causing DRHs in this study were comprehensive, whilst other studies investigated particular types of DRPs resulted DRHs such as therapeutic failure²⁷ and ADR ^{2 26 28 29}; (ii) The prospective design of this study helps to ensure the gathering all information required to accurately classify the events; (iii) Detailed histories of drug therapy obtained by clinical pharmacists might have improved detection of DRHs ; and (iv) use of the Helper's and Strand's comprehensive classification system has likely boosted the probability that all possible drug-related causes of hospitalization to be identified. In addition, the wide variability in the rate of DRHs could also be attributed to the variations in the extent of study population, inclusion criteria, study settings, participant's level of education and awareness, level of health professional expertise, methods of evaluating DRHs attributed to DRPs, study designs (prospective vs. retrospective) and the study duration. These variations are also reported by other studies.^{2 10 11 28 29}

In this study, 87.8 % of DRHs were deemed to be preventable and this is in line with other international studies in which preventability of DRHs has been by far greater than fifty percent.¹⁰⁻¹²

^{18 21 22 29 30} The reasons why DRHs preventability was high could be attributed to failure to taking

1
2
3 appropriate measurements before drug related diseases were apparent. For instance, the principal
4 categories of DRHs in our study were failure to receive drugs (130,53.5%) and untreated indication
5 (94, 38.5%). Hence, both DRHs attributed to DRPs could be avoided by providing awareness for
6 patients about their drugs use, applying good prescribing and dispensing practice, and providing
7 appropriate pharmaceutical care plan.
8
9
10
11
12
13

14
15 The majority of DRHs were most commonly seen among female patients, which is concordant
16 with a previous study.³¹ However, in a study done in Saudi Arabia, DRHs were largely found in
17 male patients.^{2 22} Elderly patients developed more DRPs leading to DRHs than patients in other
18 age groups which is also in line with other studies.^{6 16 27} The main reasons could be that increased
19 deterioration of physiologic functions and likelihood of co-morbid conditions with age. These
20 conditions may warrant taking of multiple drugs, which ultimately serve as basis for contracting
21 medication side effects and interactions (drug-drug or drug-food).
22
23
24
25
26
27
28
29
30

31
32 In this study, patients whose education level being elementary and below were more prone to
33 develop DRHs than having high school education or above, which was consistent with studies
34 done previously.^{3 18} This could be related to high level education is useful for better socioeconomic
35 status and to understand about appropriate medications use
36
37
38
39
40
41
42

43 Out of a total of 245 patients with DRHs, the foremost categories of DRHs were failure to receive
44 drugs (130,53.5%) followed by untreated indication (94,38.5%), adverse drug reactions
45 (38,15.5%) and sub therapeutic dosage (30,12.2%). Similar findings were reported by other
46 studies.^{5 12 18 20-22 25 27 30} The major reasons for failure to receive drugs in this study were preference
47 to cultural and religious therapies over conventional medicines, drug products were not available,
48 cost of medications was too expensive, fear of adverse events, failure to follow-up due to Covid-
49 19, felt better and illiteracy (near to half of patients with DRHs were illiterate). Thus, inability to
50
51
52
53
54
55
56
57
58
59

1
2
3 recall regimens is another important reason associated with increased risk of hospitalization related
4
5 to failure to receive drugs, as reported elsewhere.^{3 11 21}
6
7

8
9 The second frequent category of DRHs was untreated indication (94, 38.5%) as reported in other
10
11 studies.^{9 22} Reasons were patients remained untreated; prophylaxis and synergistic medications
12
13 were not indicated. This might be due to incorrect diagnosis; patients didn't come to health setting
14
15 timely and treating physicians did not follow the management guidelines/protocols. For example,
16
17 patients having moderate persistent asthma were being treated with albuterol inhalation alone.
18
19 Statins have not also been prescribed for patients with atherosclerotic cardiovascular disease
20
21 (ASCVDs) like peripheral arterial disease, stroke, ischemic heart disease and whose age ≥ 40 years
22
23 with diabetes mellitus and high low density lipoprotein level as per the guidelines. In addition,
24
25 some compelling indication like hypertension remains untreated and subsequently results in DRHs
26
27 owing to stroke and others cardiovascular diseases. Furthermore, since only cancer diagnosis and
28
29 management are carried out in one of this research setting hospital, which is TASH, patients
30
31 coming from different corners of the country remained untreated and/or treated with various
32
33 empirical therapies that also lead to improper drug selection until they start anti-cancer drugs in
34
35 TASH.
36
37
38
39
40

41
42 ADRs (38, 15.5%) were also commonly reported as the common classifications of DRHs, which
43
44 is also mentioned with other studies.^{11 19-21 29 30 32} This might be associated with numerous number
45
46 of cardiac and diabetic patients in our study population and poor awareness of patients with regard
47
48 to cardiac medications untoward effects such as diuretics induced electrolytes disturbance and
49
50 hypoglycemic symptoms of antidiabetics. Some ADRs could be resulted from failure to follow
51
52 direction for use of the medications. For example, diabetes mellitus patient who was on metformin
53
54 experienced epigastric burning sensation pain and vomiting after taking metformin without meal.
55
56
57
58 Overall, the plausible explanations for DRHs might be the absence of pharmaceutical care services
59
60

1
2
3 in many health institutions including emergency wards of the study settings, which is very
4 important for optimizing drug therapy and patient safety. There was also poor collaboration among
5 patients, clinical pharmacists and physicians about patient's medications use process involving
6 medications use, their side effects, adherence issue and consequences of not taking their
7 medication properly. Therefore, the better opportunity for clinical pharmacists to add value in
8 patient care roles is through ensuring medication management services according to evidence-
9 based guidelines. In the present study, both failure to receive drugs and untreated indication were
10 reported under the DRPs category of need additional drug therapy that resulted in DRHs, which is
11 supported by other studies.^{7 9 18}

12
13
14 In this study, medication classes frequently observed to cause DRHs were cardiovascular
15 medicines, antimicrobial, antineoplastic, endocrine drugs, respiratory medicines and central
16 nervous system drugs. Among these classes of drugs, cardiovascular drug were predominantly
17 involved in DRHs which was in line with other studies.^{3 5 6 21 25 27} Cardiovascular drugs,
18 antidiabetics, and antiasthmatics were most commonly associated with DRHs was supported in
19 the previous studies.^{2 24 26 27} The most common drugs associated with DRHs mentioned in this
20 study finding were furosemide, ACEIs, insulins, oral hypoglycemic agents, warfarin,
21 spironolactone, aspirin and central nervous system agent and these are also implicated in several
22 other studies.^{5 7 10 21 22 24 29} The main reason might be connected with the common diseases of the
23 study area which were heart failure, diabetes mellitus, stroke, human immunodeficiency virus and
24 asthma.

25
26
27 Moreover, the most common organ system involved in DRHs was the cardiovascular system (80,
28 32.6%), with the most common specific disease of heart failure (55, 22.5%) which is consistent
29 with previous studies.^{6 25} Moreover, hypertension was mentioned for DRHs which was implicated
30 in the previous study.^{5 22 27} This is due to the fact that cardiovascular diseases require multiple

1
2
3 medicine regimens and this contributed to DRPs. Among hospitalized patients attributed to
4 endocrine systems were due to hypoglycemia, hyperglycemia and diabetic ketoacidosis, which
5 are also cited in other studies.^{22 27}It might be due to the patients poor awareness about the
6 hypoglycemic symptoms of anti-hypoglycemic agents , poor monitoring control and patients
7 prefer not to take the medications.
8
9

10
11
12 In this study, age, educational level and presence of comorbid diseases had statistically significant
13 correlation with the occurrence of DRHs. The findings are consistent with other studies.^{18 20 30 33}
14
15

16
17
18 In multiple binary logistic regression analysis, patients with ≥ 65 years of age were 7.45 times
19 more likely to be hospitalized due to drug related morbidity than non-drug related as compared to
20 age between 14 and 24 years. This might be owing to age-related physiological changes, larger
21 number of coexisting disease conditions, which require multiple medications and this in turn is
22 associated with an increased risk of DRHs.
23
24
25
26
27
28
29
30
31

32
33
34 From employment factor, students were 6.3 folds high likely exposed to DRHs than non-drug
35 related as compared to the employed. This might be explained by the nature of the disease they
36 had which means students in this finding have majorly contracted heart failure disease secondary
37 to chronic rheumatoid valvular heart disease. Out of a total 16 students, 9 (56.3%) of them had
38 heart failure owing to valvular heart diseases. Consequently, it needs lifelong and multiple
39 medications treatment and then they faced various DRPs leading hospitalizations. Moreover,
40 participants who did not have any occupation were 3.4 times high likely to be hospitalized owing
41 to drug related diseases than non-drug related as compared to employed.
42
43
44
45
46
47
48
49
50
51

52
53 The other factor was education level in which patients with tertiary education level were 64% less
54 likely to be hospitalized with drug related hospitalizations as compared to participants who did not
55 have formal education. This could be related to high level education might be useful to understand
56
57
58
59

1
2
3 about appropriate medications use. This was supported by the studies conducted at Brasil.^{3 11 18}
4
5 Patients with co-morbid disease were also 2 folds high likely to be drug related hospitalized than
6
7 non-drug related as compared to patients without co morbid disease. As implicated in the previous
8
9 studies,^{18 30 33} co- morbidity increases the vulnerability towards DRPs. These results clearly
10
11 indicate the necessity of managing DRHs in multimorbid patients.
12
13

14
15 In terms of drug related hospital stay, the overall length of the hospital stay in the present study
16
17 was 4352 days with the average length of hospital stay 10.28 ± 8.99 days, which is longer than what
18
19 has been reported in other study.¹² This was might be owing to the data in the previous study is in
20
21 a single hospital and for a relatively short period of time (28 days) while in this finding, the study
22
23 was carried out at three tertiary care hospitals for the periods of 60 days. Therefore, avoiding
24
25 preventable DRHs is also a very cost-effective tool for health care systems and could reduce the
26
27 problem of bed crisis in hospitals.
28
29
30

31
32 Among factors which have not demonstrated an association in multivariate analysis, polypharmacy
33
34 was mentioned. This agree with what have been reported in other studies.^{21 25} In contrast,
35
36 polypharmacy has been reported having positive association with the occurrence of DRHs in
37
38 previous studies.^{3 6 11 21 22 30} This lack of significance could be resulted from variations in number
39
40 of used medications and identified DRPs for causing DRHs. In this study, around two third of the
41
42 patients with DRHs used from none to four drugs per patient. Accordingly, to say polypharmacy;
43
44 \geq five drugs should be concomitantly taken. Furthermore, the identified DRPs causing DRHs were
45
46 failure to receive drugs and untreated indication. So, both categories reveal not taking medications
47
48 and the patients might not use polypharmacy. Additionally; marital status did not illustrate
49
50 significant association with DRHs.
51
52
53
54
55
56
57
58
59
60

Conclusion

The prevalence of DRHs was higher than studies conducted elsewhere among emergency ward patients in the study settings. Among those, majority of DRHs were deemed to be preventable. These findings provide valuable insight about category of DRPs and class of drugs that causes DRHs. Age, educational level, participants who did not have any occupation and presence of co-morbid condition have had significant association with DRHs. Hence, researches regarding DRHs should be conducted in different Ethiopian hospitals to demonstrate its impact.

Author affiliations

¹Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia

Acknowledgment

We would like to thank the study participants who gave their time and provided the necessary information. We also express our gratitude for data collectors and staffs who were assigned in ED of study settings for their cooperation.

Contributors

ABB and MBD contributed to conceptualization, design, analysis, and write-up. MBD organized the collection of data for analysis and write up the draft manuscript. ABB and MBD supervised the collection of data and overall research work including interpretation of results, reviewed and revised critically the manuscript. Both authors approved the final version to be submitted for publication.

Funding

This study was done with the financial support of Addis Ababa University. The funder had no role in the study design, data collection, analysis, preparation of the manuscript, or decision to publish.

Competing interests

There are no conflicts of interest.

Patient consent for publication

 Not required

Ethics approval

Prior to study initiation, letter of ethical approval (Ref No;ERB/SOP/172/08/2020) was obtained from ethical review committee, School of Pharmacy, College of Health Sciences, Addis Ababa University. Verbal consent from patients was obtained after the provision of information regarding the purpose of the study and its risk for the interviewed which could be time to be spent during the interview (maximum of 30 minutes). Names were not used rather codes to maintain confidentiality of the information throughout the study period. Patients were told the reasons of being selected to be included in the study and assured that waning participation would not have any influence on the right to get treatment. Patients were also told about their rights to withdraw from the study at any time.

Data availability statement

All relevant data are included in the article and uploaded as supporting information files. Extra data are accessed upon reasonable request of the corresponding author.

Provenance and peer review

Not commissioned; externally peer reviewed.

ORCID iDs

Mulate Belete Demessie: <https://orcid.org/0000-0002-1517-7293>

Alemseged Beyene Berha: <https://orcid.org/0000-0003-3825-2863>

REFERENCES

- [dataset] 1. Al Hamid A, Ghaleb M, Aljadhey H, et al. A systematic review of hospitalization resulting from medicine-related problems in adult patients. *British journal of clinical pharmacology* 2014;78(2):202-17. doi: 10.1111/bcp.12293
- [dataset] 2. Alayed N, Alkhalifah B, Alharbi M, et al. Adverse Drug Reaction (ADR) as a Cause of Hospitalization at a Government Hospital in Saudi Arabia: A Prospective Observational Study. *Current drug safety* 2019;14(3):192-98. doi: 10.2174/1574886314666190520105330
- [dataset] 3. Andreazza RS, Silveira De Castro M, Sippel Koche P, et al. Causes of drug-related problems in the emergency room of a hospital in southern Brazil. *Gaceta sanitaria* 2011;25(6):501-6. doi: 10.1016/j.gaceta.2011.05.016
- [dataset] 4. STRAND HA. Opportunities and responsibilities in pharmaceutical care. *American journal of hospital pharmacy* 1990;47:533-43.
- [dataset] 5. Ayalew MB, HGT, OAA. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures. *Bulletin of emergency and trauma* 2019;7(4):339-46.
- [dataset] 6. Gustafsson M, Sjolander M, Pfister B, et al. Drug-related hospital admissions among old people with dementia. *European journal of clinical pharmacology* 2016;72(9):1143-53. doi: 10.1007/s00228-016-2084-3
- [dataset] 7. Lea M, Mowe M, Mathiesen L, et al. Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. *PloS one* 2019;14(7):e0220071. doi: 10.1371/journal.pone.0220071
- [dataset] 8. Pattanaik S, Dhamija P, Malhotra S, et al. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. *British journal of clinical pharmacology* 2009;67(3):363-9. doi: 10.1111/j.1365-2125.2008.03346.x
- [dataset] 9. Pellegrin KL, Lee E, Uyeno R, et al. Potentially preventable medication-related hospitalizations: A clinical pharmacist approach to assessment, categorization, and quality improvement. *Journal of the American Pharmacists Association : JAPhA* 2017;57(6):711-16. doi: 10.1016/j.japh.2017.06.019
- [dataset] 10. R L Howard AJA, P D Howard, M Partridge. Investigation into the reasons for preventable drug related admissions to a medical admissions unit:observational study *Qual Saf Health Care* 2003;125:280–85.
- [dataset] 11. Singh H, Kumar BN, Sinha T, et al. The incidence and nature of drug-related hospital admission: A 6-month observational study in a tertiary health care hospital. *Journal of pharmacology & therapeutics* 2011;2(1):17-20. doi: 10.4103/0976-500X.77095
- [dataset] 12. Yosef H. Al-Olah KMAT. Admissions through the emergency department due to drug-related problems. *Ann Saudi Med* 2008;28 (6):426-29.
- [dataset] 13. Centre WMR. Medicines-related admissions. *WeMeReC Bulletin* February,2015
- [dataset] 14. Robert J. Cipolle LS, Peter Morley Pharmaceutical Care Practice: The PatientCentered Approach to Medication Management Services, 3e >. *McGraw-Hill Medical* 2012
- [dataset] 15. WHO. International drug monitoring. 1969(425)
- [dataset] 16. Linkens AEMJH, Milosevic V, van der Kuy PHM, et al. Medication-related hospital admissions and readmissions in older patients: an overview of literature. *International Journal of Clinical Pharmacy* 2020;42(5):1243-51. doi: 10.1007/s11096-020-01040-1
- [dataset] 17. Johnson JA, Boatman LI. Drug-Related Morbidity and Mortality: A Cost-of-Illness Model. *Journal of Managed Care Pharmacy* 1996;2(1):39-45.
- [dataset] 18. Dammalapati SG, Challa SR, Challa P, et al. Incidence and Factors Associated with Drug Related Hospital Admissions in a South Indian Tertiary Care Hospital. *Indian Journal of Pharmacy Practice* 2018;11(1):37-43. doi: 10.5530/ijopp.11.1.7

- 1
2
3 [dataset] 19. J. HALLAS BH, L. F. GRAM, E. GRODUM, K. BRBSEN, T. HAGHFELT & N.
4 DAMSBOS. Drug related hospital admissions: the role of definitions and intensity of data
5 collection, and the possibility of prevention. *Journal of Internal Medicine* 1990; 2280: 83-90.
6 [dataset] 20. Kent M. Nelson aRLT. Drug-Related Hospital Admissions. *Pharmacotherapy*
7 1996;16(4): 70 1-707.
8 [dataset] 21. Leslie Jo Samoy PJZ, Robert M. Balen, Riyad B. Abu-Laban, and Mark Roberts. Drug-
9 Related Hospitalizations in a Tertiary Care Internal Medicine Service of a Canadian Hospital:
10 A Prospective Study. *Pharmacotherapy* 2006;26(11):1578–86.
11
12 [dataset] 22. Mohamed Al-Arifi HA-H, Mohamed Al-Meziny , Ragab Said ,, Aljadhey H.
13 Emergency department visits and admissions due to drug related problems at Riyadh military
14 hospital (RMH), Saudi Arabia. *Saudi Pharmaceutical Journal* 2013(22):17–25. doi:
15 10.1016/j.jsps.2013.01.001
16 [dataset] 23. Almut G Winterstein BCS, Charles D Hepler, and Charles Poole. Preventable Drug-
17 Related Hospital Admissions. *Ann Pharmacother* 2002;36:1238-48. doi: 10.1345/aph.1A225
18 [dataset] 24. Daniel S. Budnitz MCL, Nadine Shehab, and Chesley L. Richards. Emergency
19 Hospitalizations for Adverse Drug Events in Older Americans. *The new england journal of*
20 *medicine* 2011;365:2002-12.
21 [dataset] 25. Marcum ZA, Pugh MJ, Amuan ME, et al. Prevalence of potentially preventable
22 unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events
23 among older veterans. *The journals of gerontology Series A, Biological sciences and medical*
24 *sciences* 2012;67(8):867-74. doi: 10.1093/gerona/gls001
25 [dataset] 26. Alexopoulou A, Dourakis SP, Mantzoukis D, et al. Adverse drug reactions as a cause
26 of hospital admissions: a 6-month experience in a single center in Greece. *European journal*
27 *of internal medicine* 2008;19(7):505-10. doi: 10.1016/j.ejim.2007.06.030
28 [dataset] 27. Karuppanan M, Nee T, Thong W, et al. The prevalence of adverse drug event-related
29 admissions at a local hospital in Malaysia. *Archives of Pharmacy Practice* 2013;4(4):160. doi:
30 10.4103/2045-080x.123224
31 [dataset] 28. Geer MI, Koul PA, Tanki SA, et al. Frequency, types, severity, preventability and
32 costs of Adverse Drug Reactions at a tertiary care hospital. *Journal of pharmacological and*
33 *toxicological methods* 2016;81:323-34. doi: 10.1016/j.vascn.2016.04.011
34 [dataset] 29. Parameswaran Nair N, Chalmers L, Connolly M, et al. Prediction of Hospitalization
35 due to Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC
36 Score). *PloS one* 2016;11(10):e0165757. doi: 10.1371/journal.pone.0165757
37 [dataset] 30. Peter J. Zed EAF, Stacy Ackroyd-Stolarz, Nancy G. Murphy, Neil J. MacKinnon,
38 Doug Sinclair. Medication-Related Emergency Department Visits in Pediatrics: a Prospective
39 Observational Study. *American Academy of Pediatrics* 2015;135(3) doi: DOI:
40 10.1542/peds.2014-1827
41 [dataset] 31. Ayalew MB, Tegegn HG, Abdela OA. Drug related hospital admissions; a systematic
42 review of the recent literatures. *Bulletin of Emergency & Trauma* 2019;7(4):339.
43 [dataset] 32. Hohl CM, Nosyk B, Kuramoto L, et al. Outcomes of emergency department patients
44 presenting with adverse drug events. *Annals of emergency medicine* 2011;58(3):270-79 e4.
45 doi: 10.1016/j.annemergmed.2011.01.003
46 [dataset] 33. Nivya K, Sri Sai Kiran V, Ragoo N, et al. Systemic review on drug related hospital
47 admissions - A pubmed based search. *Saudi pharmaceutical journal : SPJ : the official*
48 *publication of the Saudi Pharmaceutical Society* 2015;23(1):1-8. doi:
49 10.1016/j.jsps.2013.05.006
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 **Figure 1:** Patient's inclusion information flow chart in emergency ward at TASH, ZMH and
6 Y12HMC, Addis Ababa, Ethiopia, August to September, 2020 (n= 423)
7
8
9
10
11
12

13 **Figure 2:** Numbers of drug related problems occurrence per patient leading hospitalization in
14 emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August to September,
15 2020 (n= 245)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1




Figure 2